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Preface 
 
In this thesis I present a series of prospective studies to establish novel strategies 
using B mode ultrasound imaging and advanced three-dimensional 3D technology, 
alongside early pregnancy biochemical parameters to predict early pregnancy 
complications. These strategies can broadly be divided into pre-conception, 
implantation and early pregnancy phases. 
 
I hereby declare this research consists of work carried out on my own account, the 
greater proportion of which has been undertaken during the period of registration 
specified and under the direct supervision of my academic supervisors. I was 
responsible for securing the ethical approval, designing the study protocols, patient 
recruitment and writing up this document. The ultrasound scans referred to in this 
thesis were conducted mainly by myself with some examinations carried out jointly 
with a senior sonographer certified by my academic supervisors. All other work 
referred to in this thesis is appropriately referenced. 
 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers 
are free to copy, distribute or transmit the thesis on the condition that they attribute it, 
that they do not use it for commercial purposes and that they do not alter, transform 
or build upon it. For any reuse or redistribution, researchers must make clear to 
others the licence terms of this work.  
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Abbreviations!
!
3D: Three-dimension  
ACR: American College of Radiologist  
EMJ: Endometrial-myometrial junction 
EP: Ectopic pregnancy 
EPAGU:Early Pregnancy and Acute Gynae Unit 
ERPC: Evacuation of retained products of conception 
ET: Endometrial thickness 
FLDA: Functional longitudinal discriminant analysis  
hCG: Human chorionic gonadotrophin  
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IPUV: Intra-uterine pregnancy of uncertain viability 
IUGS: Intra-uterine gestational sac 
IUH: Intra-uterine haematoma  
IUP: Intra-uterine pregnancy 
IVF: In-vitro fertilisation  
JZ: Junctional zone 
LH: Luteinizing hormone 
MRI: Magnetic resonance imaging 
NPV: Negative predictive value 
PD: Power Doppler 
PI: Pulsatility index 
POC: Products of conception 
PPV: Positive predictive value 
PUL:  Pregnancy of unknown location  
QCCH: Queen Charlotte’s and Chelsea hospital 
RCOG: Royal College of Obstetricians and Gynaecologists  
RI: Resistance index 
RPL: Recurrent pregnancy loss 
SCH: Sub-chorionic Haematoma  
SMH: St Mary’s hospital 
TVS: Trans-vaginal sonography 
UPT: Urine pregnancy test 
VFI: Velocity / Flow index 
VI: Velocity index 
VOCAL:Virtual organ computer-aided analysis 
WOI: Window of implantation  
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Abstract 
  
Introduction: Conventional ultrasound has been used in the management of early 
pregnancy complications. Common clinical situations that are encountered include 
pregnancies of unknown location (PUL) defined as a woman with a positive 
pregnancy test, but when no intra or extra-uterine pregnancy is visualised on trans-
vaginal sonography (TVS); intra-uterine pregnancies of uncertain viability (IPUV) 
defines as when an intrauterine gestational sac (<20mm mean diameter) is seen on 
ultrasonography with no visible yolk sac or embryo, or an embryo of <7mm crown–
rump length with no visible heart activity; and recurrent pregnancy losses (RPL). 
Emerging evidence suggests that novel strategies may be developed to predict early 
pregnancy complications such as miscarriage using B mode ultrasound imaging and 
advanced three-dimensional 3D technology, alongside early pregnancy biochemical 
parameters. These strategies can be assessed prior to conception, at implantation 
and subsequently in the early stages of pregnancy. In this thesis we describe a 
series of studies to evaluate the role of ultrasound and biochemical markers for the 
prediction of early pregnancy complications in relation to these three time periods. 
  
Methods: Pre-conception, we used 3D ultrasound to study longitudinal changes in 
endometrial morphology and vascularity, the influence of physical injury to the 
endometrium on these parameters and their relationship with implantation success. 
We investigated the relationship between the ovulation-implantation (OI) time interval 
and subsequent implantation or early pregnancy failure. Post-conception, we studied 
PUL and IPUV. In the PUL group, ultrasonography in combination with serum 
biochemical markers were used to validate the role of mathematical logistic 
regression models for predicting pregnancy location and viability. We investigated 
the performance of biochemical markers in urine to assess whether measurements 
of urine markers can replace serum markers for the management of PUL. In the 
IPUV group, we established ultrasound criteria that can be used to definitively 
diagnose miscarriage. In addition, we studied the growth of these pregnancies and 
its relationship with pregnancy viability and the appearance of early embryonic 
structures in the gestational sac. 
  
5""
Results: We have provided evidence to support the view that endometrial biopsy 
enhances endometrial vascularity in women with a history of RPL. We have 
suggested a safe approach to characterise PUL and have shown that logistic 
regression-based prediction models can reliably be used and further developed to 
predict the outcome in PUL, independent of the timing of serum biochemistry. In 
addition, we have shown a potential role for urine pregnancy biochemistry in the 
management of PUL. We have developed new reliable definitions to diagnose 
miscarriage, which have now been adopted both in the UK and internationally. 
Furthermore, we found that, gestation sac growth is not a safe indicator of pregnancy 
viability, although cutoff values for embryo growth can be suggested below which a 
miscarriage can be predicted. 
  
Conclusion: The studies described in this thesis have introduced a number of novel 
findings in relation to the use of ultrasound and biochemistry for predicting, and 
optimising the management of, early pregnancy complications from the 
preconception phase, through early implantation, to the post conception phase. 
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1 Introduction 
 
Early pregnancy complications are one of the most common general medical 
complications associated with pregnancy. Most of these complications occur prior to 
12 weeks of gestation such as miscarriage, ectopic pregnancy, trophoblastic disease 
and hyperemesis gravidarum. During the work up to the diagnosis of these 
conditions, clinicians face several clinically challenging situations, which require 
careful management. Trans-vaginal sonography (TVS) has evolved over the last two 
decades as an indispensable tool in working up the diagnosis and the management 
of these complications (1, 2).  
 
1.1 Ultrasound assessment of the peri-implantation uterus "
1.1.1 Introduction: decidualisation and implantation 
 
Successful embryo implantation can only take place in a receptive uterus. In human 
beings, the uterus becomes receptive during the mid-secretory phase (days 19–23) 
of the menstrual cycle, a functional period widely referred to as the window of 
implantation (WOI) (3) (4) (5). During this transient WOI, the endometrium 
undergoes profound molecular changes that enable a developmentally competent 
blastocyst to contact the luminal epithelium and then invade of the underlying stroma 
(6). Importantly, the signals that induce this receptive phenotype in the luminal 
epithelium are derived from the underlying stromal cells (7). In fact, the WOI is 
characterised is by profound changes in this stromal compartment, which include 
recruitment of specialised natural killer cells, vascular remodelling, and – perhaps 
most strikingly – transformation of stromal fibroblasts into specialised rounded 
decidual cells (8) (9) (6). 
 
Decidual transformation of the stromal compartment only occurs in those mammalian 
species where implantation involves breaching of maternal tissues by the embryo 
(10) (11). Furthermore, a correlation exists between the extent of the decidual 
process and the depth of trophoblast invasion amongst various species (9). Human 
placenta formation, however, does not only involve trophoblast invasion of the 
maternal decidua but also of the inner layer of the myometrium, a highly specialised 
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uterine structure known as the ‘junctional zone’ (JZ). Importantly, trophoblast 
invasion of the decidua and JZ, which together forms the placental bed, is not only 
interstitial but also intravascular (11) (12) (13). In fact, this process of intravascular 
trophoblast invasion critically controls the transformation of high-resistant, low-
capacity spiral arteries into low-resistant, high-capacity vessels of pregnancy (14) 
(11). In other words, the decidua and JZ form a functional unit that largely 
determines the likelihood of successful pregnancy outcome. 
 
The current model of fetal-maternal interactions views the trophoblast as the active 
invader of the passive decidua. However, this paradigm has been challenged by 
recent observations demonstrating that decidual cells acquire an invasive phenotype 
upon contact with trophoblast (15). In other words, rather than being passively 
invaded, decidual cells may in fact actively encapsulate embryos that breach the 
luminal epithelium. Furthermore, emerging evidence suggests that decidual cells are 
programmed to respond to embryos of limited developmental potential, thus serving 
as biosensors that enable the mother to limit investment into failing pregnancies (16). 
Furthermore, it has been suggested that impaired decidualisation is associated with 
a prolonged WOI and lack of embryo quality control, thus facilitating implantation of 
developmentally compromised embryos (16). This concept is supported by the 
landmark study by Wilcox and colleagues, demonstrating that delayed implantation 
beyond the conventional WOI is strongly associated with early pregnancy loss (17).  
 
These observations suggest that prospective assessment of the quality of 
decidualisation response in the endometrium may be an important tool to predict the 
likelihood of successful implantation and pregnancy outcome.  From its introduction 
into the clinic, ultrasound has been widely used to assess uterine features, such as 
endometrial thickness, endometrial pattern and uterine blood flow, that may be 
predictive of pregnancy, especially in the context of assisted reproductive technology 
(ART). Furthermore, the development of 3D-ultrasound and 3D-Doppler studies now 
enable a much more detailed examination of uterine morphology, including 
visualisation of the JZ (18). 
 
In this background section, we also critically assess the role of various ultrasound 
techniques and markers in predicting the likelihood of conception and subsequent 
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pregnancy outcome. In addition, we will argue that, with the introduction of high-
resolution ultrasound technologies, imaging of extremely early implantation events 
may yield novel markers predictive of pregnancy outcome. 
 "
1.1.2 Endometrial thickness and pregnancy outcome 
 
Several early studies evaluated the value of endometrial thickness measurements by 
ultrasonography as a tool to predict the likelihood of pregnancy. The data were 
conflicting. While the endometrium was reported to be thicker in conception than in 
non-conception cycles (19), this was not confirmed by another study (20). In an IVF 
population, the endometrial thickness the day after embryo transfer was reported to 
be higher in those patients who subsequently conceived (21). In contrast, an review 
of the early literature concluded that endometrial thickness is comparable between 
successful and unsuccessful IVF treatment cycles (range: 8.6-11.8 mm and 8.6-11.9, 
respectively) (22). The concept that endometrium must measure at least 6 mm or 
thicker to sustain a pregnancy in natural cycles was first established two decades 
ago (23). This was subsequently refined by the recommendation that the endometrial 
thickness should be ≥ 7 mm on the day of hCG administration and ≥ 8 mm at the 
time of a day2 embryo transfer (24). These recommendations were supported by the 
observation that an endometrial thickness of < 6 mm has a high negative predictive 
value (NPV) for pregnancy (22). Thus, while a “normal” endometrial thickness does 
not necessarily predict pregnancy, a thin endometrium means that implantation is 
highly unlikely to occur.  
 "
1.1.3 Endometrial morphology and pregnancy outcome "
The appearance of the endometrium on ultrasound changes in a cycle-dependent 
manner. Consequently, ultrasound endometrial morphology at the time of embryo 
transfer has been widely studied in an attempt to predict the likelihood of pregnancy. 
The results are similar to endometrial thickness in so far that a normal tri-laminar 
appearance of the endometrium (multi-layered or the presence of midline echo) has 
a low positive predictive value (PPV) for pregnancy (33.1%), whereas the absence of 
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a multi-layered pattern does not exclude conception but renders it unlikely (NPV: 
85.7%) (22, 25). ""
1.1.4 Endometrial injury and “enhanced” implantation "
Several studies have reported improved implantation rates after physical injury to the 
endometrium suggesting that this results in enhanced decidualisation. It has been 
hypothesised that the inflammatory response associated with physical injury 
improves endometrial blood flow and increases the volume of the endometrium in 
the cycles following the injury. Data from 2003 demonstrated that endometrial 
biopsies taken during the spontaneous cycle preceding in vitro fertilisation (IVF) and 
embryo transfer (ET) more than doubled the implantation rate, the number of clinical 
pregnancies and live births" (26). This favourable influence of local injury was later 
confirmed in more recent studies with a significant increase in the success of either 
spontaneous conception or IVF in a population of patients with previous implantation 
failures (27) (28) (29). It has even been reported that performing serial endometrial 
biopsies can be a successful treatment following Asherman’s syndrome leading to 
successful implantation in the next IVF cycle (30). In keeping with this, a recent 
systematic review of the literature reported that hysteroscopy in the cycle preceding 
a subsequent IVF embryo transfer cycle nearly doubles the pregnancy rate in 
patients with at least two failed IVF attempts compared with control subjects starting 
IVF immediately and had no undergone uterine instrumentation (31). This could be 
explained by a mechanical effect of the procedure, as prior cervical dilatation might 
facilitate embryo transfer (32) (33). An immunological response arising from 
hysteroscopic manipulation or the effect of the distension medium on the 
endometrium may also be factors. Similar mechanisms have been thought to 
increase the rates of spontaneous pregnancy after HSG (31) (34). ""
1.1.5 Uterine blood flow and pregnancy outcome "
Uterine artery blood flow can usefully be expressed by the impedance indices – the 
pulsatility index (PI) and resistance index (RI) (Table 1).  Early studies in 1988 (35) 
reported that a poor uterine artery blood flow response to treatment with exogenous 
hormones(oestradiol and norgestrel) was associated with a low pregnancy rate in 
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IVF cycles. The authors hypothesised that a decreased uterine perfusion response is 
a contributing factor to infertility. In addition, they reported greater pregnancy rates 
achieved after hormone therapy and an improvement in uterine perfusion. This was 
in agreement with their previous study also in 1988, which showed increasing uterine 
perfusion with rising levels of plasma oestradiol and progesterone (36). Taking this 
work a step further, Steer et al. 1992 reported higher pregnancy rates (PR), 
implantation rates (IR) and multiple pregnancies with lower uterine blood flow 
impedance before embryo transfer (ET) (37). They concluded that uterine artery 
blood flow is a useful method for assessing uterine receptivity in assisted conception 
programs (38). In agreement with these findings, other reports demonstrated that low 
impedance uterine artery blood flow in the early and mid-luteal phase is associated 
with higher conception rates in assisted reproduction cycles (25), while high uterine 
artery impedance (PI of > 3.3) predicts treatment failure with relative high sensitivity 
but low specificity (88% and 26%, respectively) (39). In a review of the literature, 
Friedler et al. 1996 reported a high NPV and sensitivity (in the ranges 88–100 and 
96–100% respectively) and a relatively higher PPV and specificity (44–56 and 13–
35% respectively) for the use of the Doppler assessment of uterine artery blood flow 
using an upper limit for PI of 3 or 3.3, compared with the other ultrasonic parameters 
(22). These data suggest that uterine vascularity or the factors that affect it are 
important for implantation and subsequent pregnancy to be successful.  
 
A recent study examined the optimal timing of B mode and Doppler ultrasound 
evaluation of uterine receptivity in IVF populations. Different variables were studied 
including the endometrial thickness, endometrial morphology, uterine artery 
pulsatility index, the presence or absence of a protodiastolic notch, the presence of 
end-diastolic blood flow, and endometrial-subendometrial blood flow distribution 
patterns. The most effective combination for evaluating uterine receptivity was the 
presence or absence of end-diastolic blood flow in the uterine arteries, endometrial 
morphology and endometrial thickness. The best sensitivity and specificity were 
obtained on the day of HCG administration (81.1 and 81.3%) respectively (40). 
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Author Year Number  of 
patients 
Population studied Mode Variables  Findings  
Goswamy et al.  1988 16 Spontaneous ovarian 
cycles 
TA Uterine artery 
PI, RI 
Direct correlation with hormone assays 
Goswamy et al.  1988 153 Spontaneous ovarian 
cycles 
then IVF 
TA  Uterine artery 
Flow velocity wave 
forms 
Decreased uterine perfusion response may be a 
cause of infertility 
Steer et al.  
 
1992 82 IVF TV Uterine artery 
PI 
No implantation with PI>3 
Steer et al 1995 
 
86 GnRH cycle then 
Embryo transfer cycle 
TV Uterine artery PI PI lower in successful then unsuccessful cycles  
Serafini et al.  
 
1994 96 Ovulation induction 
for IVF, GIFT and 
intrafallopian transfer 
TV Uterine artery 
PI & RI 
Higher conception rate with low impendence 
Coulam et al 1994 
 
405 IVF natural and docor 
cycles and IUI 
TV Uterien artery PI PI of > 3.3 predicted 88% of non-conception 
cycles 
Friedler et al 1996 495 Review of 3 studies  TV Uterine arteryPI PI of 3 or 3.3 – high NPV (88-100%) and 
sensitivity (96-100%) for conception 
Habara et al.  2002 121 Recurrent pregnancy 
loss RPL and controls 
TV Uterine artery PI High impedance with RPL especially with 
antinuclear antibodies. 
Raine-Fenning 
et al 
2004 48 Normal cycles in 
subfertility and control 
TV Endometrial and 
subendometrial VI 
and VFI 
Vascularity indices are reduced in unexplained 
subfertility  
Alcázar 2006 725 Review (5 IVF 
studies)  
TV Endometrial and 
subendometrial VI 
and VFI 
conflicting results 
Ng EH et al.  2007 161 IVF  TV Endometrial and 
subendometrial VI 
and VFI 
VI and VFI are higher with live births than in 
miscarriage. 
Lazzarin et al.  2007 230 RPL and control TV Uterine artery PI Higher PI in Unexplained RPL, uterine 
abnormalities and antiphospholipid antibodies 
syndrome. 
Dechaud et al 2008 
 
124 IVF or ICSI TV Uterine artery PI, 
paradiastolic notch, 
end-diastolic flow, 
endometrial and 
sub-endometrial flow 
pattern 
end-diastolic blood flow with endometrial 
morphology and endometrial thickness gave 
sensitivity and specificity of 81%, PPV= 68% and 
NPV =89% 
Chen et al.  2010 134 RPL and control TV Endometrial and 
subendometrial VI, 
FI and VFI 
Low VI, FI and VFI in unexplained RPL. 
 
Table 1: Summary of data published about the role of uterine artery Doppler and 
endometrial/subendometrial vascularity in predicting outcome in IVF and recurrent pregnancy 
loss 
 ""
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1.1.6 Three-dimensional ultrasound "
3D ultrasound has been shown to have a low intra-observer and inter-observer 
variability for assessing endometrial volume, with the VOCAL method being the most 
reproducible technique. Endometrial vascularity can also be assessed using 3D 
power Doppler (27).  
 
Using B mode and colour Doppler imaging the cyclical changes of the uterine size, 
echogenicity and vascularity have been studied throughout the menstrual cycle in 
relation to a positive urinary luteinising hormone (LH) test and day 1 of next menses.  
The endometrial thickness was found to increase up to days 3 and 4 of the cycle 
then it remains relatively constant. This was associated with a gradual decrease in 
the uterine arterial PI throughout the cycle which significantly increased at the time of 
next menses (41). These cyclical changes have been further studied using 3D 
ultrasonography. The endometrial volume increases in the follicular phase and 
plateaus in the luteal phase (42). The vascularity of the endometrial and 
subendometrial regions increase from the mid-follicular phase and peak 3 days prior 
to ovulation before decreasing again over the next 5 days and then increasing until 
the next cycle (43, 44). Raine-Fenning et al further showed that endometrial and 
subendometrial vascularity indices were significantly lower in women with 
unexplained subfertility during the mid and late follicular phase, irrespective of 
estradiol and progesterone levels (45). The subendometrial region was defined as a 
1 mm shell around the defined endometrial contour. As would be expected from 
endometrial thickness data, 3D measurements of endometrial volume have showed 
a strong negative prediction for implantation failure. However, there have been 
conflicting results between different investigators regarding the differences in 
endometrial volume, as well as endometrial and subendometrial vascularity between 
conception and non-conception cycles (27, 46). Several factors have been cited as 
possible explanations for these conflicting results such as different ultrasound 
examination and analysis techniques, variations in the resolution of equipment used 
in the studies and different treatment protocols especially in the fertility groups (22). 
However, endometrial and subendometrial 3D power Doppler indices have been 
shown to have an acceptable reproducibility in evaluating the physiological and 
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pathological changes of the endometrium (47). Whilst Doppler studies of the uterine 
arteries have suggested a mechanism whereby uterine vascularity impacts on 
implantation, 3D Doppler studies of the endometrium have not supported this 
concept. We currently do not know if compromising endometrial vascularity leads to 
implantation failure.  ""
1.1.7 Uterine blood flow in recurrent pregnancy loss (RPL) "
A few studies have tested the hypothesis that changes in endometrial vascularity 
play an essential role in recurrent miscarriage (Table 1). Higher uterine artery PI was 
reported in women with RPL, especially for those with antinuclear antibodies, than in 
controls (48). Similar findings were found in women with unexplained RPL, uterine 
congenital abnormalities and with antiphospholipid antibodies syndrome (49). Most 
recently the endometrial and subendometrial vascularity in unexplained RPL were 
reported to be lower in RPL than in controls. This was carried out 7 days post 
ovulation (50). It is of interest to observe the same patterns of endometrial 
vascularity in patients with recurrent pregnancy loss and failed assisted reproduction 
suggesting that endometrial vascularity does play a role in endometrial receptivity 
and pregnancy maintenance.  
 
In a pre-conception study in this thesis we aimed to investigate the validity of 3D 
ultrasound and 3D Doppler in evaluating the longitudinal change in endometrial 
thickness, volume and vascularity indices (ET, EV, VI, FI and VFI) and the influence 
of physical injury to the endometrium (endometrial biopsy) on the change in these 
parameters and on implantation success. We also investigate the ability of these 
indices and their longitudinal change in predicting implantation success.  ""
1.2 The ovulation-to-implantation interval and pregnancy outcome  
 
Implantation of a human embryo in the endometrium takes place during a specific 
functional period that coincides with the mid-secretory phase (days 19–23) of the 
menstrual cycle. This transient period of uterine receptivity is widely referred to as 
the ‘window of implantation’ (WOI) (3) (4) (5) (51). During the WOI the endometrium 
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expresses a conserved family of receptivity genes, allowing a blastocyst to first 
adhere to the endometrial surface epithelium and then to invade the underlying 
decidualising stroma (6).  
 
Decidualisation denotes the transformation of endometrial stromal cells into 
epitheloid decidual cells (52-55). Upon decidualisation, endometrial stromal cells first 
mount an acute auto-inflammatory response, which in turn triggers the expression of 
key receptivity genes in the overlying surface epithelium. This pro-inflammatory 
phenotype is transient, determines the duration of the window of implantation, and is 
followed by an anti-inflammatory response essential for post-implantation embryo 
support. Recent evidence also suggests that decidual cells play an active role in the 
implantation process by encapsulating embryos that have breached the luminal 
epithelium (56-58). Endometrial stromal cells become highly secretory upon 
decidualisation, suggesting that they create the microenvironment and provide the 
nutrients that enable the conceptus to thrive (53). Co-culture experiments have also 
shown that decidualising cells are programmed to sense signals from 
developmentally compromised embryos and respond by shutting down the secretion 
of key cytokines and growth factors. Thus, once the luminal epithelium is breached, 
decidual cells engage in quality control and facilitate maternal rejection of 
undesirable embryos. (5, 16, 52, 59, 60).  
 
There is biochemical evidence that RPL is associated with an abnormal decidual 
response, which in turn prolongs the WOI, facilitates out-of-phase embryo 
implantation in an unsupportive environment (52). Clinical evidence that this 
mechanism may underpin miscarriage was provided when Wilcox and colleagues 
showed that delayed embryo implantation beyond the conventional WOI is strongly 
associated with sporadic early pregnancy loss (17).   
 
In this thesis, we describe a prospective study where we used commercially 
available home ovulation and pregnancy detection kits to approximate the length of 
the ovulation-to-implantation (O-I) interval in 126 conception cycles. Our aim was go 
investigate whether delayed appearance of a positive urine pregnancy test relative to 
the pre-ovulatory luteinising hormone (LH) surge is associated with subsequent 
pregnancy failure in both in women with and without a history of RM.  
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1.3 Pregnancy of Unknown Location (PUL) "
1.3.1 Background 
 
The term PUL is used when a woman has a positive pregnancy test, but no intra or 
extra-uterine pregnancy is visualised on TVS. There should, therefore, be no visible 
intra-uterine gestational sac or retained products of conception and no adnexal mass 
suggestive of an ectopic pregnancy (61). Whilst a proportion of these women will be 
diagnosed with an ectopic pregnancy, most ectopic pregnancies should be 
visualised at the time of the initial TVS examination (62). Studies have shown that 
74% of women with ectopic pregnancies had their ectopic pregnancies visualised on 
the initial TVS examination. Most of the remainder were initially classified as PULs 
and had their ectopic pregnancies visualised on subsequent TVS examinations (63).  
 
 
Figure 1: Flow diagram showing the different outcome groups that result of the use of TVS; the 
reported rate of PUL and ectopic pregnancy is widely variable 
 
 
While studies report variable rates of PULs between 8% and 31% of women referred 
for ultrasonography in early pregnancy, a panel of gynaecologist have produced a 
consensus statement that proposes an acceptable rate below 15% (64) (Figure 1).  It 
is also thought that the better the quality of scanning in a unit, the lower the rate of 
Positive  pregnancy test 
TVS 
90% 
Diagnostic  
Intra-uterine 
pregnancy (IUP) 
 Ectopic 
Pregnancy 
(EP) 
7-10% PUL 
Or up to 30% 
IUP failing PUL 
Persisting 
PUL 
EP 
7-20% 
or up to 
40% 
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ectopic pregnancies in the PUL population. In studies reported from specialist early 
pregnancy units, ectopic pregnancy rates vary from 9 to 14% (65) (66).  
!
!
1.3.2 Predicting the outcome: mathematical models  
 
A number of strategies have been described to predict the outcome of PUL (Figure 
2).  A progesterone level of < 20 nmol/L has been reported to predict failing PULs 
(67). Serum human chorionic gonadotrophin (hCG) is the most commonly measured 
hormone to assist in the management of PUL, while research in early pregnancy 
continues to explore new biochemical markers that can diagnose and exclude 
ectopic pregnancy with higher sensitivity and specificity (68)" (69)" (70)" (71). Both 
single and serial measurements have been used in for this purpose. An increase in 
the serum level of human chorionic gonadotrophin (hCG) of more than 66% has 
been used to distinguish IUPs from ectopic pregnancies (72)"(73).  A rise in serum 
hCG of greater than 66% has been shown to have a PPV of 96.5% for the prediction 
of IUPs (74).  The discriminatory zone, a level above which it is thought an IUP 
should be seen on TVS and a suboptimal rise in serum hCG (<66% in 48 hours) 
have been used to predict ectopic pregnancies (74). More recently mathematical 
models, both logistic regression and Bayesian networks have been described that 
can predict the outcome of PUL (63) (74)"(75) (76).  
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Figure 2: Summary of the published studies on the outcome prediction in PUL using the hCG 
discriminatory zone, hCG ratio and mathematical models 
 
 
Various mathematical models including logistic regression models have been 
developed to predict the outcome of PUL – Models M1, M4 and M5 (74) (77) (78).  
M1 is a logistic regression model based on the hCG ratio (hCG level at 48 hours / 
hCG level at 0 hours) and achieved, on its test data set of 196 PULs, an area under 
the receiver operating characteristic (ROC) curve (AUC) of 0.975 for the prediction of 
a failing PUL, 0.966 for the prediction of an IUP and 0.885 for the prediction of 
ectopic pregnancy (74). When tested in the clinical setting, this model was found to 
compare favourably with subjective assessment by experienced nurse operators 
(75).  M4 is based on the hCG average (hCG 0 hours + hCG 48 hours / 2), the hCG 
ratio and its quadratic effect.  After development on a set of 201 PULs, M4 gave a 
test set AUC of 0.978 (95% confidence interval (CI): 0.954-1.000) for the prediction 
of failing PUL, 0.974 (95% CI: 0.954-0.994) for the prediction of IUP and 0.900 (95% 
CI: 0.812-0.988) for ectopic pregnancy (77).  Model M5 incorporated the amount of 
vaginal bleeding along with the hCG average and the quadratic effect of the hCG 
ratio (78). Addition of this clinical information did not significantly improve 
performance of the model. The obvious advantage of these models is that their use 
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is independent of clinical experience and they do not require any understanding of 
clinical biochemistry in early pregnancy.  In a recent study it was also shown that M4 
can be used as a basis on which to rationalise the management of PULs as it can 
successfully minimise follow-up by rationalising the number of visits, scans and 
blood tests, as well as intervention rates (79). Thus, M4 has been shown to have 
impact on clinical practice, which is an essential goal of clinical prediction models 
(80) (81).  
 
 
1.3.3 Proposed nomenclature for PUL using subjective interpretation of 
ultrasound findings "
 
The number of PUL reported amongst women presenting with early pregnancy 
problems varies from 8 to 31% (82), and up to 20% of women classified as PUL will 
have an undiagnosed EP (61).  These reported variations might be due to 
inconsistencies in the application of definitions used for PUL, differences in the 
populations studied or the quality of the ultrasonography carried out. 
 
However, whilst the ultrasound criteria would seem clear, there is variation in relation 
to the criteria used to definitively diagnose both an IUP and EP. This led to a recent 
consensus paper that aimed to harmonise nomenclature in order to facilitate the 
comparison of studies on PUL from different institutions (83) (Table 2). This report 
identified a significant difference in some United Kingdom (UK) and United States 
(USA) practice. In the USA a wider definition may be used to define PUL, as more 
rigorous criteria are needed to state that a pregnancy site has been located. In order 
to diagnose an IUP a cystic structure compatible with a gestation sac should be 
visible in the uterus and a yolk sac (YS) and/or embryo must be seen (Table 3). 
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Feature visualised on TVS  Narrow   Broad 
Empty uterus, no signs of 
an IUP or EP 
 
Yes  Yes 
Early intra-uterine 
gestational sac 
 
No  Yes  
Extra-uterine 
inhomogeneous mass 
 
No  Yes  
Possible retained products 
of conception  
 
 Yes  Yes  
 
Table 2: Difference between narrow and broad definitions used to classifying a pregnancy as 
PUL 
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Features visualised on 
TVS to suggest an IUP 
 Narrow Broad 
Gestational sac only 
 
Yes  No 
Gestation sac with yolk 
sac 
 
Yes  Yes  
Gestation sac with CRL 
 
Yes  Yes  
Empty gestation sac 
(anembryonic) 
 
Yes  No 
Incomplete miscarriage 
 
Yes  No 
Table 3: Differences in between narrow and broad definitions used to classifying a pregnancy 
as intrauterine 
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 Similarly, in the USA an EP is generally not definitively diagnosed with ultrasound if 
a gestation sac is not visible in the adnexa. In contrast, a more narrow definition for 
PUL is used in the UK. It is defined as there being no evidence of an intra-uterine 
gestational sac, retained products of conception, or an adnexal mass suggestive of 
EP (61, 64),8) (Table 4). Using this approach an IUP can be presumed in the 
presence of a probable gestation sac even if a YS or embryo have not been 
visualised, and an EP if only an homogenous mass is seen. This narrow definition of 
PUL has been given the name “true PUL” in some reports. Perhaps not surprisingly, 
when a logistic regression prediction model developed in the UK was tested on a 
USA population it performed less well (84). This was thought to be because of these 
differing definitions of PUL. 
 
Features visualised on 
TVS to diagnose EP 
 narrow broad 
Gestation sac with a 
YS/embryo 
 
Yes  Yes 
Empty gestation sac  
 
Yes  No  
Inhomogeneous mass  
 
Yes  No  
No chorionic villi on uterine curettage and rising hCG level  Persisting PUL  Yes  
Table 4: Differences in between narrow and broad definitions used to classifying a pregnancy 
as ectopic 
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"
 
We aimed to prospectively evaluate the accuracy of ultrasound findings suggestive 
of IUP or EP as used in the narrow definition, and the impact on likely number of 
visits and blood tests as well as the detection rate for EP using the broad versus 
narrow definitions to classify a pregnancy as a PUL (83).  We also aimed to assess 
whether using the broad definition decreases the performance of logistic regression 
models developed to predict the final outcome of PUL using the narrow definition. 
 
 
1.3.4 Rationalising the follow up of PUL 
1.3.4.1 Timing of serial serum hCG 
 
Single and serial hCG measurements have been used to predict the outcome in 
PUL. A single serum hCG measurement is sometimes used as a discriminatory level 
to help identify women at risk of ectopic pregnancy within the PUL population (85) 
(86). This, however, has been shown to be of limited value for predicting the 
outcome of PUL as many ectopic pregnancies have relatively low initial hCG values 
(66).  
 
As highlighted above, serial serum hCG levels are used to indicate the likelihood of a 
PUL being a failing PUL, intra-uterine pregnancy (IUP) or ectopic pregnancy (EP).  
This judgment is usually made on the basis of the change in serum hCG level over 
48 hours. This change may be expressed as a ratio (87). Additionally, logistic 
regression models based on serum hCG levels taken at presentation and 48 hours 
later have been developed (9) (10).  
 
Whilst the timing of hCG measurement used to derive either ratios or mathematical 
models is assumed to be at 48 hour intervals, this time interval is not always 
achievable in practice. Furthermore it would be an advantage to reduce the time 
interval between blood samples in order to arrive at a management decision earlier 
or to have more flexibility when arranging follow up blood tests. We aimed to assess 
the variability in the inter-sample interval observed in three London teaching 
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hospitals, and investigate whether the inclusion of this information in relation to 
timing in a prediction model influences the prediction of PUL outcome.  
 
1.3.4.2 Modifying and validating risk prediction model  
 
In clinical practice, women classified as having a PUL often receive lengthy follow-up 
in order to confirm the location and viability of the pregnancy. The management of 
PUL varies due to a lack of standardized protocols, and follow-up varies in intensity 
according to the level of suspicion of ectopic pregnancy. Women may have multiple 
blood tests to measure serum hCG and progesterone levels and undergo numerous 
transvaginal ultrasound scans. They are usually only discharged following a negative 
pregnancy test indicating a resolved failed PUL or after visualisation of an IUP or EP 
on a subsequent TVS examination. While this intensive follow-up approach is 
warranted for EP, it is not necessary for failed PUL or IUP. The latter two groups, 
representing at least 70% of the PUL population (61), can be labelled as a low-risk 
group. For these women early discharge or reduced follow-up can be applied, which 
would reduce the clinical workload and improve patient’s convenience (79).  
 
In order to rationalise the management of PUL, it is important to reliably detect 
pregnancies that can be safely managed with reduced follow-up. In the literature, a 
number of strategies have been described to predict low-risk PUL (failed PUL or 
IUP). However, many of these strategies were designed to predict either failed PUL 
(e.g. (82) (67)) or IUP (e.g. (88) (72)), but not both. On the other hand, various risk 
prediction models based on multinomial logistic regression have been developed to 
predict the three different PUL outcomes ((74) (77) (78) (89)). As detailed above, the 
prediction model M4 uses the ratio of the serum hCG level at 48 hours with the level 
at presentation and the average of the two hCG levels to estimate the risk of failed 
PUL, IUP, and EP. Based on these risks, a system was suggested to classify 
pregnancies with the aim of achieving a high detection rate (sensitivity) for each 
outcome. For example, in an interventional trial, this system reported detection rates 
of 86% for failed PUL, 86% for IUP, and 73% for EP, such that 27% of patients with 
an EP would be selected for early discharge or reduced follow-up (79). More 
recently, more sensible management strategies based on risk rather than making a 
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certain diagnosis have been considered (90), the aim being focus on PUL that are 
likely to be EP whilst reducing follow for IUP and failed PUL. In addition, no 
extensive temporal or external validation of M4 has been undertaken, which are 
crucial steps for the eventual deployment of any prediction model in clinical practice 
(91).  
 
We aimed to propose a classification system for PUL based on M4 that is designed 
to reliably classify a group of PUL as low risk in order that the follow-up for these 
PUL can be reduced. The usefulness of this system, as well as the performance of 
the M4 logistic regression model were temporally and externally validated using 
more recent data from the unit where M4 was developed and data from four other 
units. 
 
1.3.4.3 Correlating urinary and serum hCG levels 
 
HCG is a glycoprotein hormone that comprises two subunits, alpha and beta. HCG is 
secreted by trophoblastic placental cells, the pituitary gland, and a variety of tumours 
(92, 93). HCG, together with LH, FSH and TSH form the glycoprotein hormone 
(GPH) family, all of which are heterodimers that share a common 92 amino acid α-
subunit called GPHα. Only the intact αβ -heterodimer of hCG is biologically active 
mediating sex steroid production through the G-protein-coupled receptor (LH/hCG-R)"
(94). HCG exists not only as the intact heterodimer but also as free subunits and an 
array of molecular variants that are recognised by different hCG assays to a variable 
degree"(95-97).  
 
In pregnancy serum, hCG immune-reactivity consists of intact hCG (>95%) together 
with minor amounts of hCGβ. When excreted into urine much of hCG is degraded to 
the core fragment of hCGβ (hCGβcf) and, in urine, it is present at concentrations 
similar to those of intact hCG (92, 98). hCG stimulates corpus luteal progesterone 
production, trophoblast differentiation and plays a role in myometrial spiral artery 
angiogenesis and fetal nutrition (99). hCG that is produced by the conceptus 
becomes detectable in the maternal serum and urine only from the time of 
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implantation i.e. 6.5-9.5 days after ovulation (100, 101). Assays for hCG comprise 
one-site competitive polyclonal radioimmunoassays (RIAs) in use at some regional 
trophoblast reference centres and a large variety of commercially available two-site 
‘sandwich-type’ immunometric assays that have been developed primarily for use in 
pregnancy (102-104).  
 
Measurement of serum concentrations of hCG by immunoassay is central to the 
detection and clinical management of pregnancy, pregnancy related disorders 
including ectopic pregnancy and several types of cancer (63, 87, 105). Serial serum 
hCG measurements are of particular importance in the management of pregnancies 
classified as PUL.  
 
Although hCG is mostly catabolised by the liver, approximately 20% is also excreted 
in the urine after degradation to subunits and nicked forms (93). Quantitative 
measurement of hCG in urine has been reported and validated (106, 107). Urine is 
used instead of serum in the follow up of certain pregnancy related conditions such 
as gestational trophoblastic disease (108). Women with a PUL often undergo 
protracted follow up and have several blood tests before the outcome of the 
pregnancy is known. Using measurements of urinary rather than serum hCG would 
represent a major advantage as this cohort of patients often have difficulties 
arranging child care and time from work for repeated visit to hospital phlebotomy.  
 
In this study, we investigated the correlation between serum and urine hCG levels in 
early pregnancy using two different immunoassays. In addition, we examined 
whether serial measurements of urinary hCG have potential use for clinical decision 
making in the management of PUL.  ""
1.4 Intra-Uterine Pregnancy of Uncertain Viability (IPUV) ""
1.4.1 Definition 
 
Prior to the work presented in this thesis, the term IPUV was used when an 
intrauterine gestational sac (<20mm mean diameter) was seen on ultrasonographgy 
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with no obvious yolk sac or fetus, or fetal echo <6mm crown–rump length with no 
obvious fetal heart activity"(109). Of these pregnancies, about one third is destined to 
fail and will eventually result into a miscarriage. Recently, the hCG ratio, better than 
a single progesterone level, has been proposed as an early predictor of viability"
(110)"(111).  "
1.4.2 The RCOG guidelines in the diagnosis of miscarriage / IPUV 
 
Before our work, the previously adopted criteria that was being used in the diagnosis 
of miscarriage showed variation. In the UK, an empty gestation sac visualised using 
TVS with MSD > 20 could have been classified as a miscarriage according to the 
Royal College of Obstetricians and Gynaecologists (RCOG) guideline for the 
management of early pregnancy loss (2006)"(109). An empty gestation sac of < 20 
mm was defined as IPUV and, in order to confirm or refute viability, a repeat scan at 
a minimal interval of one week was advised (109)."The same guideline suggested an 
embryo with CRL of > 6mm and no fetal heartbeat could also be classified as a 
miscarriage. Following a previous public enquiry in the UK, cutoff values for MSD of 
20mm and 10 mm for CRL were also proposed, but never on the basis of a single 
scan and only after a repeat scan has been carried out at least seven days later"
(112). In contrast, the American College of Radiologists (ACR) guidelines define a 
miscarriage on the basis of an empty gestation sac with an MSD of > 16 mm or if 
present, an embryo with a CRL measuring > 5 mm and no heartbeat" (113). This 
guidance is based on two small studies from the late eighties (114) (115). Other 
studies have concluded that an empty gestation sac with an MSD of > 25 mm or an 
MSD of > 20mm with a yolk sac present can be used as a safe approach to diagnose 
miscarriage" (116). A CRL cutoff value of >4 mm with no cardiac activity has also 
been suggested (117). A review article has proposed a CRL cutoff of > 5 mm, and an 
appropriate cutoff value for MSD of > 13 mm with or without a yolk sac (118). Against 
this background it is concerning that Elson et al reported that two pregnancies with 
empty gestation sacs measuring 18 and 20 mm were found to be viable after further 
follow up in their study (119). The authors point out that: “ultrasound is an operator-
dependent method and it is conceivable that an inexperienced operator may fail to 
detect an embryo in a relatively large sac due to a poor examination technique”.  
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In a recent study, our group has shown clinically significant inter-observer variation in 
MSD measurements taken by two experienced examiners (120). The implications of 
this finding for the use of cutoff values for MSD to define miscarriagee are important. 
Great care must be taken around whatever decision boundary is used if a mistake is 
not to be made. The variation in both the literature and national guidelines regarding 
the definitions used to make such a fundamental decision as the viability of a human 
embryo is concerning, especially as any error may be associated with inadvertent 
termination of pregnancy.  
 
In this thesis, we present a prospective multi-centre observational study that aimed 
to establish the false positive rate for miscarriage for different cutoff values of MSD 
with and without a yolk sac and CRL. We further aimed to define cutoff values for 
both MSD and CRL that can be confidently used to classify a pregnancy as non-
viable. 
 "
1.4.3 Gestational sac and embryonic growth in IPUV 
 
Limited understanding of the growth and appearance of embryonic structures in this 
group also results in further controversies surrounding criteria to diagnose 
miscarriage in different countries.  In the UK an empty gestation sac visualised using 
TVS with MSD >20 used to be defined as a miscarriage, whereas in the United 
States, the cutoff for MSD is >16 mm" (113). When there was an empty sac below 
these thresholds, the pregnancy was classified as IPUV. The RCOG guidelines 
suggested that in order to confirm viability, a repeat scan at a minimal interval of one 
week was advised (109). This and other protocols did not define what ultrasound 
findings should be expected in a week. There was a general presumption that the 
gestation sac should grow significantly, or that a yolk sac or embryo should be 
visualised on the second scan. Absence of any of these features was used to make 
a diagnosis of miscarriage. The evidence base to support this approach is very 
limited.  
 
It was previously thought that the embryo and its associated structures except for the 
yolk sac grow at a similar consistent velocity (121), with both CRL and MSD 
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increasing at approximately 1 mm per day. However, more recent studies have 
shown that MSD and CRL grow at variable rates. A smaller than expected embryo 
size in the first trimester has been strongly linked with subsequent miscarriage (122). 
A further study showed that a CRL below the 50th centile on the 28th day of 
gestation was associated an early pregnancy loss rate of 19.4%, compared to 3.3% 
when the CRL was above the 50th centile (123). In a population of women who 
suffered miscarriage the mean CRL was significantly smaller than in those that 
remained viable. The initial CRL was below the expected mean for gestational age in 
all women, while in 61% the CRL was at least 2 SD below the mean (124). Data on 
twin pregnancies has demonstrated that subsequent single fetal loss is associated 
with a discrepancy in the CRL measurements of the embryos. When the discrepancy 
was > 60% there were no cases of both twins remaining viable (125).  The above 
studies all refer to differences in embryo size in relation to expected size for 
gestation. They do not refer to longitudinal changes or growth in CRL or MSD. More 
recently it has been shown that serial measurements analysed using functional linear 
discriminatory analysis (FLDA) can better discriminate between viable pregnancies 
and those which subsequently fail (126). The same authors have also shown that 
embryo growth is not fixed and is influenced by factors such as maternal age and 
ethnicity (127). 
 
Growth in MSD is also variable. The only study that has looked at gestation sac 
growth prospectively concluded that growth of less than 0.6 mm/day is associated 
with miscarriage (116). However, this paper does not suggest that a definitive 
diagnosis of miscarriage be based on the basis of sub-optimal growth rates. 
Although these growth patterns for MSD and CRL in the first trimester have been 
described, the utility of using a relative lack of gestation sac growth in particular to 
define miscarriage has not been explored.  
 
 In this thesis we present a study that aimed to establish growth rate ranges for both 
the gestation sac (expressed as MSD) and embryo (expressed as CRL) in IPUV 
subsequently shown to be viable and non-viable. We investigated whether cutoff 
values for MSD and CRL growth could be defined that could definitively predict a 
miscarriage.  For gestation sac growth we further set out to investigate whether a 
failure for a yolk sac or embryo to be visible on scans carried out at an interval was a 
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predictor of miscarriage. In this way currently accepted approaches to defining 
miscarriage could be tested. 
 "
1.4.4 Clinical characteristics 
 
The clinical characteristics or symptoms of pain and vaginal bleeding in the first 
trimester of pregnancy are commonly associated with threatened miscarriage, but it 
is unclear in literature whether their presence alone is predictive of adverse outcome 
(128). It has been demonstrated that a normally rising hCG does not predict live birth 
in women presenting with pain and bleeding in early pregnancy" (129). Further, 
vaginal bleeding was shown to be associated with adverse pregnancy outcomes 
independently of the presence of intrauterine haematoma (130). However, the 
influence of these symptoms on IPUV has not yet been explored in the literature.  ""
1.4.5 Sonographic markers 
 
Subchorionic hematoma (SCH) or intrauterine haematoma (IUH) have been 
described in the literature as crescent-shaped, echo-free areas between the 
chorionic membrane and the myometrium (131) (Figure 3 and Figure 4).  However, 
the influence of SCH presence or size on the pregnancy outcome has not been 
clearly studied in IPUV.  
 
 
Figure 3: Transvaginal image of a sub-chorionic haematoma in the sagittal view. The SCH is 
located above the sac at the fundal end of the uterus 
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Figure 4: Transvaginal image of a sub-chorionic haematoma in the sagittal view. The SCH is 
located below the sac at the cervical end of the uterus 
 
Specific sonographic criteria have been used to describe the morphology of normal 
and abnormal gestational sac shape (GSS). This included distorted shape; thin-
edged (less than or equal to 2 mm), weakly echogenic, or irregular chorio-decidual 
reaction, absence of a double decidual sac and low position (132) (Figure 5 and 
Figure 6). Three-dimensional ultrasound was also used to describe early normal 
gestational sacs (133)" (134) and it was suggested that morphological and 
quantitative analysis of the gestational sac may be helpful in predicting early 
pregnancy failure.   
 
 
 
Figure 5: Trans-vaginal image of a regular gestational sac in the sagittal and transverse view "
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Figure 6: Trans-vaginal image of an irregular gestational sac in the sagittal and transverse 
view 
 
We proposed to investigate the relationship between certain sonographic soft 
markers and the viability of IPUV. These soft markers include the gestational sac 
shape and SCH. In addition, we aimed to establish whether symptoms of pain and 
bleeding could be of added value in the predicting the viability in these pregnancies.  """"""""""""""""""""""
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2 Hypothesis and Aims 
2.1 Hypothesis 
 
Advanced ultrasound technology as well as serum and urine biochemistry markers 
can be utilised before and after conception to establish novel strategies that would 
optimise the diagnosis and management of early pregnancy complications. 
 
 
2.2 Aims 
 
1. In the pre-conception stage we aimed to investigate the relationship between 
morphological and vascular features of the peri-implantation uterus and implantation 
success, as well as early pregnancy complications. This study utilised advanced 
ultrasound technologies i.e. 3D mode and 3D Doppler.  
 
2. In the peri-implantation phase we aimed to investigate the relationship 
between the length of the OI interval and subsequent pregnancy failure in both 
women with and without a history of RPL. 
 
3. In the post-conception stage our aim was to develop strategies to enable us to 
predict pregnancy viability in two groups: 
• Pregnancies of unknown location (PUL): we first set out to develop standardised 
ultrasound criteria to characterise pregnancy location. Subsequently, we aimed to 
use these criteria in conjunction with measurements of serum biochemical 
markers to develop prediction models to rationalise the management in PUL. In 
addition, we set out to investigate the validity of measurements of biomarkers in 
urine rather than serum for the follow up of PUL and the influence of sample 
timing. 
• Intra-uterine pregnancies of uncertain viability (IPUV): aimed to establish 
sonographic criteria that can definitively diagnose a miscarriage. In addition, we 
studied early pregnancy growth and investigated its relationship with pregnancy 
viability and the appearance of early embryonic structures. 
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3 Methods ""
Women were recruited into the pre-conception and early pregnancy studies in the 
Early Pregnancy and Acute Gynaecology Unit (EPAGU) at Queen Charlotte’s 
Hospital. This is an emergency Gynaecology/Early Pregnancy Unit in a central 
London teaching and it is open five days a week. Ethical approval was obtained for 
the pre-conception studies from the NRES Committee London, Harrow. Ref: 
10/H0709/19. Initial approval was granted on 10/05/2010 with subsequent 
amendments on 04/08/2010 and 12/05/2011. A recruitment poster was advertised in 
the hospital, local GP surgeries, local newspaper and on the trust webpage. Ethical 
approval was not required for the early pregnancy studies and these were registered 
with the local audit department at Imperial College NHS Trust. Study ref: 609. 
December 15th 2009. Details on multi-centre data used in a number of the studies in 
this thesis are provided in each study-specific methods in the results section below. 
 
3.1.1 Ultrasound setting and image optimisation  ""
Women were examined in the lithotomy position with an empty bladder using an 
ultrasound system equipped with high-frequency transducers of 5-9 MHz (Voluson® 
E8 Expert, GE Healthcare Ultrasound, Milwaukee, Wisconsin, USA). For the 2D 
mode, the following settings were applied and followed in all the examinations 
performed: 
• Frequency: Harmonics High 
• 2D gain: level 1 
• Dynamic contrast: level 7 
• Grey map: level 5 
• Persistence (frame averaging): level 3 
• Edge enhancement: level 3 
• Speckle Reduction (SR): level 3 
 
For the 3D mode, the 3D ultrasound probe was introduced into the vagina. Once a 
longitudinal view of a satisfactory grey-scale image of the uterus was obtained, the 
endometrial thickness was measured. The uterus was then centralised within the 3D 
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sector on the screen, the ultrasound system was switched into the power Doppler 
mode and the 3D mode was switched on. Women were asked to remain as still as 
possible, and a 3D power Doppler data set of the uterus was acquired. The resultant 
multiplanar display was examined to ensure that a complete volume of the 
endometrial and subendometrial area had been captured. Volumes of satisfactory 
quality and with no artefacts are being stored on a hard disk for later analysis. 
 "
3.1.2 Volume and 3D Doppler analysis 
 
 
Analysis of stored ultrasound volumes will be done off- line on a personal computer. 
The VOCALTM (Virtual Organ Computer-aided Analysis) imaging program was used 
to calculate endometrial volume and endometrial power Doppler flow indices. The 
acquired volumes yield multi-planar views of the uterus in the mid-sagittal, axial and 
coronal planes. All calculations were done on these multiplanar images. The 
longitudinal view was used as the reference image with rotation steps of 30◦, 
resulting in the definition of six contours of the endometrium. Endometrial contours 
were manually drawn in all six sections using the computer mouse. Once all 
contours were drawn, the volume of the endometrium was calculated automatically. 
 
Using the histogram facility of the VOCAL software, three vascular indices were 
generated: vascularisation index (VI), flow index (FI) and vascularisation flow index 
(VFI). VI is the ratio of color voxels to all voxels in the region of interest, expressed 
as a percentage. It reflects the density of vessels in the volume analysed. FI is the 
mean intensity of all the power Doppler voxels in the volume analysed (the sum of 
the weighted color voxels divided by the number of all color voxels in the region of 
interest). It represents the energy reflected from the blood corpuscles in the vessels 
of the volume, i.e. the more blood corpuscles in the blood vessels, the higher the FI 
values. VFI is the sum of the weighted color voxels divided by all voxels in the region 
of interest. It reflects both the density of vessels and the density of blood corpuscles 
in the vessels.  
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4 Results  "
This chapter is divided into nine sections; each section describes study-specific 
methods, the data, the statistical analysis and the conclusions drawn.  
 
 
4.1 Pre-conception studies "
 
4.1.1 3D USS and 3D Doppler studies and implantation  
 
Objectives  
To study the longitudinal changes in endometrial thickness, volume and vascularity 
indices, and the influence of performing an endometrial physical injury on these 
parameters. In addition, to study the ability of these parameters to predict 
implantation success.  
 
 
This was a prospective longitudinal study. Women who were planning to conceive 
were invited to take part. Following ethical approval, recruitment took place between 
July 2010 and April 2011.  
 
The inclusion criteria were: 
• Age 20–45 years 
• Regular menstrual cycles of 26–32 days with 3–8 days of bleeding  
• No cycle disturbances for at least one year 
• No hormonal contraception for the previous 2 months 
• No intrauterine contraceptive device 
• No previous major gynecological surgery  
• Normal ovaries at a baseline scan 
 
Upon recruitment, part of the study cohort was consented for endometrial biopsies in 
the luteal phase. The latter group were advised to refrain from unprotected sexual 
intercourse for one cycle. The endometrial biopsy was planned for the middle of the 
luteal phase of a non-conception cycle between days 19-26. To confirm ovulation in 
that cycle, women were provided with urine ovulation kits to detect the LH surge 
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(Clearblue digital ovulation test kits provided by SPD Development Company 
Limited). Women were instructed to carry out daily testing from day 9 of the cycle 
until ovulation is detected. 
 
All women had their first study visit in the luteal phase of the first non-conception 
cycle and underwent a baseline TVS examination. Those who had endometrial 
biopsies planned underwent the ultrasound examination prior to the biopsy on the 
same visit. A subsequent ultrasound scan was then performed in the luteal phase of 
the following cycle.  "
Seven days after ovulation, participants were instructed to start daily urine 
pregnancy tests (Clearblue digital home pregnancy test kits provided by SPD 
Development Company Limited) until they reached either a positive pregnancy test, 
in which case it was repeated the next day for confirmation, or reached 
menstruation. Women who had a positive pregnancy test were followed up with 
serial ultrasound scans. The first ultrasound scan was performed within a week after 
the first positive pregnancy test. Participants were then scanned every two weeks till 
week 12, or earlier if they had miscarriage. Both 2D and 3D transvaginal ultrasound 
scans were performed with the above-described protocol. Standardised 
assessments of sonographic variables included measurement of CRL crown-rump 
length, MSD in three orthogonal planes (two in the sagittal plane and one in 
transverse), the presence of a yolk sac and the detection of embryonic cardiac 
activity. On-going pregnancies at the time of the 2nd scan were defined ‘viable’ 
whereas those that miscarried before the dating scan were described as ‘nonviable’. 
 
Statistical analysis 
 
Student t test was used for the continuous variable age and the Wilcoxon test for the 
ordinal demographic variables. For ethnicity all non-white i.e. Asian, Middle Eastern, 
Black and other were considered as one group. Fisher’s Exact test was used to 
analyse White compared to others. 
 
Comparison was made of the ultrasound variables, which included endometrial 
thickness (ET), endometrial volume (EV), velocity index (VI), flow index (FI) and 
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volume flow index (VFI) between the women that became pregnant and those that 
did not using Student t test. Furthermore the difference () in the respective 
ultrasound variables between the first and second scan was compared between the 
pregnant and non - pregnant group. 
 
Results  
 
As outlined in Figure 7, recruitment into this study commenced in July 2010. A total 
of 69 women were recruited. 55 women had a history of recurrent miscarriages (RM) 
and the control group comprised of 14 women.  
 
 
Figure 7: recruitment flow chat in the pre-conception study  
 
 
There were no significant differences in the maternal age, ethnicity or parity between 
the two groups (Table 5). The mean age of the RM group and the control group was 
pre-conception"
non-pregnant RPL and controls 
N=69 
Serial 3D USS and 3D Doppler 
Urine kits to detect ovulation and first pregnancy test  
Ovulation-implantation interval 
27  not pregnant 42 pregnant  
Outcome at week 12 
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37 years. The mean parity of the control group was 0.3 +/- 0.5 and of the RM group 
was 0.9 +/- 2. As expected in the analysis of the ordinal variables: gravida and the 
number of previous miscarriages did show a statistically significant difference 
between the two groups (p value < 0.001 for both variables). 
 
 All 
(N = 69) 
Control 
(N = 14) 
RM 
(N = 55) 
P-value 
        
Age       0.96 
Mean ± stdev 37 ± 6 37 ± 5 37 ± 6 t-test 
Median (min-max) 37 (22 – 49) 36 (29 – 46) 37 (22 – 49)  
Ethnicity       0.33* 
Asian 6 (9%) 2 (14%) 4 (7%) Fisher 
Exact 
Middle East 4 (6%) - - 4 (7%)  
Black 3 (4%) - - 3 (5%)  
White 51 (74%) 12 (86%) 39 (71%)  
Other 5 (7%) - - 5 (9%)  
Gravida        
Mean ± stdev 4.3 ± 3.1 1.5 ± 0.9 5.0 ± 3.0 <0.001 
Median (min-max) 4 (0 – 23) 1 (0 – 3) 4 (2 – 23) Wilcoxon 
Parity        
Mean ± stdev 0.8 ± 1.8 0.3 ± 0.5 0.9 ± 2.0 0.15 
Median (min-max) 0 (0 – 14) 0 (0 – 1) 0 (0 – 14) Wilcoxon 
Miscarriages        
Mean ± stdev 3.2 ± 1.9 0.9 ± 1.0 3.8 ± 1.5 <0.001 
Median (min-max) 3 (0 – 9) 0.5 (0 – 3) 3 (2 – 9) Wilcoxon 
        
* White versus other ethnicity 
 
Table 5: Demographic characteristics versus RM/control 
 
 
Of the 69 women 42 conceived and 27 did not become pregnant. Overall statistical 
analysis of the categorical and ordinal variables; ethnicity, parity, gravida and 
number of miscarriages did not show any statistical significant differences. However 
age was significantly higher in those woman who did not become pregnant (mean 40 
+/- 6 years) compared to those women who did (mean 35 +/- 5 years) P < 0.001 
(Table 6). Of the 42 women who became pregnant; 30 women had a viable 
pregnancy and 12 women had a non-viable pregnancy at 12 weeks gestation. There 
were no significant differences in the demographic variables between these two 
groups. 
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 Non-pregnant 
(N = 27) 
Pregnant 
(N = 42) 
P-value Pregnant, not 
viable 
(N = 12) 
Pregnant, viable 
(N = 30) 
P-
value 
           
Age     <0.001     0.89 
Mean ± stdev 40 ± 6 35 ± 5  35 ± 6 35 ± 5  
Median (min-max) 41 (22 – 49) 35 (22 – 46)  34 (23 – 43) 36 (22 – 46)  
Ethnicity     0.59*     0.12* 
Asian 3 (11%) 3 (7%)  2 (17%) 1 (3%)  
Middle East - - 4 (10%)  2 (17%) 2 (7%)  
Black 2 (7%) 1 (2%)  - - 1 (3%)  
White 19 (70%) 32 (76%)  7 (58%) 25 (83%)  
Other 3 (11%) 2 (5%)  1 (8%) 1 (3%)  
Gravida     0.93     0.88 
Mean ± stdev 4.6 ± 4.3 4.0 ± 1.9  4.2 ± 2.4 4.0 ± 1.6  
Median (min-max) 4 (0 – 23) 4 (1 – 10)  4 (1 – 10) 4 (1 – 7)  
Parity     0.14     0.83 
Mean ± stdev 1.1 ± 2.6 0.6 ± 1.0  0.4 ± 0.7 0 7 ± 1.2  
Median (min-max) 1 (0 – 14) 0 (0 - 4)  0 (0 – 2) 0 (0 – 4)  
Miscarriages     0.45     0.69 
Mean ± stdev 3.4 ± 2.3 3.0 ± 1.5  3.4 ± 2.3 2.9 ± 1.1  
Median (min-max) 3 (0 – 9) 3 (0 – 9)  3 (0 – 9) 3 (0 – 4)  
           
* White versus other ethnicity 
 
Table 6: Demographic characteristics versus 12 weeks outcome "
 
The ultrasound variables ET, EV, VI, FI and VFI were compared between those 
women who became pregnant and those did not at the first scan and the second 
scan. There was no statistically significant difference at the time of either scan (Table 
7). The only exception was the VFI at the first scan that demonstrated significant 
association with implantation (P = 0.03). The VFI mean value was 3.9  +/- 4 in the 
non-pregnant group and 5.8 +/- 4 in the pregnant group. The area under the ROC 
curve of VFI at the first scan for predicting implantation success is only 0.66. 
Furthermore there was no statistically significant difference in the longitudinal 
change of these vascularity indices between the first and second scan when 
compared in the pregnant and non - pregnant group. 
 
 ""
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 Non pregnant 
(N = 27 ) 
Pregnant 
(N = 42 ) 
P-value 
SCAN 1    
    
ET    0.42 
Mean ± stdev 8.6 ± 2.2 9.2 ± 2.7  
Median (min-max) 8.4 (5.2 to 12.8) 8.9 (4.6 to 15.4)  
EV    0.28 
Mean ± stdev 4.2 ± 3.8 4.0 ± 1.8  
Median (min-max) 3.2 (1.2 to 21.1) 3.6 (1.3 to 7.9)  
VI    0.16 
Mean ± stdev 14.3 ± 13.8 17.5 ± 11.8  
Median (min-max) 9.8 (1.2 to 55.8) 14.9 (0.01 to 46.5)  
FI    0.85 
Mean ± stdev 25.5 ± 3.7 24.8 ± 5.3  
Median (min-max) 25.2 (19.7 to 35.8) 25.4 (7.6 to 32.3)  
VFI   0.03 
Mean ± stdev 3.9 ± 4.0 5.8 ± 4.0  
Median (min-max) 2.8 (0.3 to 16.3) 5.3 (0.008 to 14.4)  
SCAN 2    
    
ET    0.08 
Mean ± stdev 9.6 ± 2.6 10.8 ± 2.7  
Median (min-max) 9.3 (4.9 to 15.4) 10.4 (4.7 to 18.2)  
EV    0.08 
Mean ± stdev 4.6 ± 4.4 5.0 ± 2.1  
Median (min-max) 3.7 (0.8 to 25.1) 4.9 (1.1 to 10.4)  
VI    0.18 
Mean ± stdev 19.7 ± 15.1 23.4 ± 13.9  
Median (min-max) 14.9 (3.7 to 71.6) 24.8 (0.2 to 49.6)  
FI    0.16 
Mean ± stdev 26.0 ± 3.7 26.5 ± 5.3  
Median (min-max) 25.3 (18.7 to 35.8) 27.6 (6.7 to 34.1)  
VFI    0.11 
Mean ± stdev 6.0 ± 5.0 7.1 ± 4.0  
Median (min-max) 4.0 (1.0 to 22.5) 7.1 (0.04 to 16.2)  
DIFFERENCE BETWEEN THE TWO SCANS    
    
ΔET    
Mean ± stdev 1.0 ± 1.8 1.6 ± 2.1 0.28 
Median (min-max) 1.1 (-2.5 to 5.3) 1.5 (-1.7 to 7.1)  
ΔEV    
Mean ± stdev 0.5 ± 1.3 0.9 ± 1.3 0.23 
Median (min-max) 0.3 (-2.2 to 3.9) 0.8 (-1.2 to 4.1)  
ΔVI    
Mean ± stdev 5.4 ± 10.8 5.9 ± 11.6 0.94 
Median (min-max) 2.8 (-17.0 to 29.4) 1.8 (-9.9 to 41.7)  
ΔFI    
Mean ± stdev 0.5 ± 3.3 1.6 ± 3.8 0.20 
Median (min-max) 0.8 (-8.7 to 7.1) 2.1 (-7.3 to 11.3)  
ΔVFI    
Mean ± stdev 2.1 ± 3.6 1.3 ± 2.9 0.52 
Median (min-max) 1.0 (-4.0 to 12.5) 0.9 (-4.9 to 9.2)  
    "
Table 7: Ability of ET, EV, VI, FI and VFI (1st scan, 2nd scan and difference between the two 
scans) to predict implantation success (pregnant vs. non pregnant) "
 
Performing an endometrial biopsy had a statistically significant influence on the 
longitudinal change in ET, EV and FI between two cycles. The change in these 
parameters was significantly higher in women who had the biopsy than in those who 
did not have a biopsy (Table 8). However, performing the biopsy had no statistically 
significant influence on implantation success or, in those who conceive, on the 12 
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week viability (Table 9). Of note, the sample size for latter analysis is small which 
makes this part of the study underpowered.  ""
 
 All 
(N = 69) 
No endometrial 
biopsy 
(N =24 ) 
Endometrial biopsy 
(N =45 ) 
P-value 
        
ΔET       <0.001 
Mean ± stdev 1.4 ± 2.0 -0.6 ± 0.9 2.4 ± 1.5  
Median (min-max) 1.4 (-2.5 to 7.1) -0.3 (-2.5 to 0.7) 2.2 (-0.7 to 7.1)  
ΔEV    <0.001 
Mean ± stdev 0.7 ± 1.3 -0.5 ± 0.6 1.4 ± 1.1  
Median (min-max) 0.6 (-2.2 to 4.1) -0.4 (-2.2 to 0.6) 1.3 (-0.3 to 4.1)  
ΔVI    0.15 
Mean ± stdev 5.7 ± 11.3 3.8 ± 8.3 6.7 ± 12.5  
Median (min-max) 2.0 (-17.0 to 41.7) 0.5 (-7.2 to 23.8) 2.8 (-17.0 to 41.7)  
ΔFI    0.03 
Mean ± stdev 1.2 ± 3.6 -0.2 ± 3.3 1.9 ± 3.6  
Median (min-max) 1.6 (-8.7 to 11.3) -0.9 (-8.7 to 4.6) 2.0 (-7.3 to 11.3)  
ΔVFI    0.29 
Mean ± stdev 1.6 ± 3.2 1.0 ± 2.6 1.9 ± 3.5  
Median (min-max) 1.0 (-4.9 to 12.5) 0.4 (-4.9 to 6.2) 1.1 (-4.0 to 12.5)  
 
ΔET = ET 2nd scan – ET 1st scan 
ΔEV = EV 2nd scan – EV 1st scan 
ΔVI = VI 2nd scan – VI 1st scan 
ΔFI = FI 2nd scan – FI 1st scan 
ΔVFI = VFI 2nd scan – VFI 1st scan 
 
Table 8: Change of endometrial thickness, volume and vascularity indices between two scans 
and the influence of endometrial biopsy on the change in these parameters "
 
 
Endometrial 
 biopsy 
Non-pregnant 
(N = 27) 
Pregnant 
(N = 42) 
P-value Pregnant, not viable 
(N = 12) 
Pregnant, viable 
(N = 30) 
P-value 
ALL 
PATIENTS 
(N = 69) 
          
No 41% (11/27) 31% (13/42) 0.45 8% (1/12) 40% (12/30) 0.07 
Yes 59% (16/27) 69% (29/42)  92% (11/12) 60% (18/30)  
CONTROL 
(N = 14) 
          
No 50% (3/6) 38% (3/8) 1 - - 60% (3/5) 0.20 
Yes 50% (3/6) 63% (5/8)  100% (3/3) 40% (2/5)  
RM 
(N = 55) 
          
No 38% (8/21) 29% (10/34) 0.56 11% (1/9) 36% (9/25) 0.23 
Yes 62% (13/21) 71% (24/34)  89% (8/9) 64% (16/25)  
 
Table 9: The influence of endometrial biopsy on implantation success and 12 weeks and 
outcome 
 
Discussion  
 
Our data provide evidence to the role of endometrial biopsy in enhancing the 
endometrial receptivity in women with a history of recurrent pregnancy failure. As 
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highlighted in the introduction, it has been well argued that inducing an inflammatory 
response in the endometrium through physical insult would improve the chances of 
achieving successful implantation. Our data showed an increase in the endometrial 
flow index in the RM group after subjecting them to endometrial biopsy. Furthermore, 
there was a significant change in both endometrial thickness and endometrial 
volume in the same group. However, our findings did not show the same statistical 
significance on the pregnancy outcome. This is possibly due to the relatively small 
sample size of our study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 "
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4.1.2  Ovulation – implantation (OI) interval studies  "
Objectives 
 
To investigate the impact of the length of the ovulation-to-implantation (O-I) interval 
on pregnancy viability and early embryonic growth in women with and without a 
history of recurrent miscarriage (RM).  
 
A total of 200 subjects were recruited across two UK centres; 69 at our centre in 
Queen Charlotte’s Hospital, Imperial College Healthcare NHS Trust and 131 at the 
Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust (Centre 1), by 
research fellow (AM). Figure 8 provides a flowchart outlining recruitment of 
participants. All women were healthy and non-smokers. The study received ethical 
approval from the local Research Ethics Committee for both centres and written 
consent was obtained at the time of recruitment. 
 
 
Figure 8: Recruitment flow chart 
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Participating subjects were aged between 20 and 45 years, had regular 26 to 32 
days menstrual cycles with periods lasting between 3–8 days, had no history of any 
menstrual cycle disturbances for at least one year, had not taken hormonal 
contraception for the previous 2 months, and planned to conceive.  
 
Age, ethnicity, last menstrual period (LMP), as well as a detailed menstrual and 
reproductive history were recorded at recruitment. Recurrent miscarriage (RM) was 
defined as 3 or more consecutive pregnancy losses (135). Participants were asked 
to perform daily ovulation tests from the 6th day of their LMP until the urine LH surge 
was detected and then daily urinary pregnancy tests from 8 days after the LH surge 
until they either had three consecutive positive pregnancy tests or their next period.  
In the absence of pregnancy, testing was repeated for a maximum of 12 cycles.  
 
The day of ovulation was calculated as the  ‘LH surge + one day’ as described 
previously (136) (137). The day of the first positive pregnancy test using digital urine 
pregnancy test kits was reported as the ‘implantation day’ (138). The urinary tests 
have been previously validated against urinary assays for detection of the LH surge 
and βhCG by Swiss Precision Diagnostics, GmbH (Bedford, UK) (139).  The O-I 
interval was defined by the number of days between the presumed day of ovulation 
(LH+1 day) and the presumed implantation day as determined by the first positive 
pregnancy test.  
 
Ultrasonography was performed at 6-7 weeks to confirm the location and viability of 
the pregnancy; and again at 10-14 weeks to establish gestational age based on 
measurement of embryo crown-rump length (CRL) using Robinson’s charts (140). 
On-going pregnancies at the time of the 2nd scan were defined ‘viable’ whereas 
those that miscarried before the dating scan were described as ‘nonviable’. A pre-
clinical miscarriage was defined as a pregnancy loss at less than 6 completed weeks 
gestation following three consecutive positive pregnancy tests or no demonstrable 
viable pregnancy at the 6 weeks scan followed by a confirmed diagnosis of ‘missed’ 
miscarriage. A clinical miscarriage was defined as a pregnancy loss between 6 and 
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12 completed weeks gestations following confirmation of a viable pregnancy on an 
ultrasound scan at 6 weeks. 
 
In order to detect a statistically significant difference in the O-I interval of 2 days with 
80% power and an error of 0.05, it was estimated that a sample size of at least 25 
viable and 25 nonviable pregnancies was needed in each group. Statistical analysis 
was performed using the Statistical Package for Social Sciences (SPSS Version 
18.0.0, 2009, SPSS Inc., Chicago, USA). The data was checked for normality of 
distribution and data are expressed as mean ± standard deviation and median ± 
inter-quartile range (IQR) or range as appropriate. The O-I interval was compared 
between all the viable and non-viable pregnancies, between viable pregnancies in 
the control and RM group, and separately between the nonviable pregnancies in the 
control and RM group using non-parametric Mann-Whitney U test. The difference 
between the incidence of viable and non-viable pregnancies in the control group and 
in women with RM was compared using chi-square test. 
 
 
Results  
 
The demographics of the study population are described in Table 10. As shown in 
Figure 8, the study group included 200 women, and a total of 126 (63%) women in 
the cohort conceived. Of these, 76  (61%) were control subjects, 57 (75%) of whom 
had a viable pregnancy and 19 (25%) a miscarriage. Our case group consisted of 50  
(39 %) women with a history of RM. In this group, there were 32 (65%) viable and 18 
(35%) non-viable pregnancies. There was no significant difference between the 
viable and non-viable pregnancies in relation to the median day of ovulation or 
median day of implantation (Table 10).  
 
 
 
 
 "
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A. Characteristics Viable  Non-viable   
 (N=89) (N=37) P 
Age (years) 32 (29-35) 35 (30-39) 0.06 
Nulliparous 55 (62%) 20 (54%) 0.4 
Multiparous 34 (38%) 17(46%) 0.4 
B. O-I interval    
Day of ovulation 16 (15-18) 16 (14-118) 0.3 
Day of Implantation 27 (25-29) 28 (27-31) 0.06 
O-I interval 11 (10-11) 
(n = 78) 
12 (11-14)** 
(n = 35) 
 
<0.001 
Data are median (IQR).  O-I interval was available in 78/89 viable pregnancies and in 35/37 non-viable pregnancies. 
*P <0.05 is significant by Mann-Whitney U test 
 
Table 10: Viable versus non-viable pregnancies: demographics and O-I interval details 
 
 
Taking all pregnancies in account, the O-I interval preceding a miscarriage was 
significantly longer when compared to a viable pregnancy [median (IQR): 11 days 
(10-11) and 12 (11-14), respectively; P=0.001] (Table 10). Comparing the control 
and case groups, there was no significant statistical difference between the controls 
and RM groups in relation to pregnancy viability, CRL at 12 weeks, CRL Z score 
[defined as observed CRL - expected by Pexsters curve (23)] or O-I interval (Table 
11). There was no difference between the median ovulation day in viable 
pregnancies between the control and RM group (16 and 17 respectively, P=0.4), or 
in the median implantation day between the control and RM group (day 27 in both 
groups, P=0.7). There was also no difference in the median day of ovulation leading 
to non-viable pregnancies between the control and RM group (day 15 and 16 
respectively, P=0.7) or in the median day of implantation (days 28 and 29 
respectively, P=0.1). However, the O-I interval was longer in the non-viable 
pregnancies in the RM group compared to the non-viable pregnancies in the control 
group (P=0.01) (Table 11).  
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A. Characteristics Controls RM  
 (N=76) (N=50) P 
Age (years) 31 (29-35) 35 (32-39)* 0.001 
Nulliparous 52 (68%) 21 (42%) 0.002 
Multiparous 24 (32%) 29 (58%) 0.002 
B. O-I interval (viable)    
Day of ovulation  16 (14-18) 16 (16-17) 0.4 
Day of Implantation  27 (25-30) 28 (27-30) 0.7 
O-I interval 11 (10-12) 11 (10-13)* 0.8 
Time to conceive, months 4 (2-6) 4 (1-5) 0.08 
C. O-I interval (non-viable)    
Day of ovulation  15 (14-19) 16 (15-17) 0.6 
Day of Implantation  28 (25-30) 29 (27-32) 0.1 
O-I interval 12 (10-13) 13 (12-15) 0.01 
Time to conceive, months 4 (1-7) 3 (2-8) 0.6 
D. Pregnancy outcome    
Viable (%) 57 (75%) 32 (64) 0.3# 
Non-viable (%) 19 (25%) 18 (36) 0.3# 
CRL (mm) 65 (60-72) 66 (56-70) 0.5 
Z-score CRL -0.08 [(-0.8)-0.6] 0.5 [(-0.02)-0.7] 0.05 
Data are median (IQR). * O-I interval = ovulation to implantation interval. CRL= crown-rump length. *P <0.05 is significant by 
Mann-Whitney U test. # P <0.05 is significant by two-tailed Chi-square test. 
 
Table 11: Difference in the O-I interval scatter between the viable and non-viable pregnancies 
(error bars denote the interquartile range and each case is represented by a “°”) 
 
 
The odd's ratio of viable /non-viable pregnancy with an O-I interval of <12 days and 
>/= 12 days is 8.8 (95% CI: 4.1-18.7). The relative risk of having a viable pregnancy 
is 3.1 (95% CI: 1.9, 5.0) with an O-I interval of <12 days compared to that >/= 12 
days. 
 
Discussion  
 
In this study we confirmed that pregnancies that miscarry are preceded by a longer 
O-I interval than viable pregnancies (138). We also observed that the O-I interval 
prior to pregnancy loss is even longer in RM patients when compared to women 
experiencing a sporadic miscarriage. Importantly, the O-I interval was comparable in 
viable pregnancies, irrespective of a prior history of recurrent pregnancy loss or not. 
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Furthermore, the CRL Z scores in viable pregnancies were comparable in RM and 
control subjects. Taken together, our data suggest that out-of-phase implantation, 
i.e. beyond the normal WOI, underpins both sporadic miscarriage as well as 
recurrent loss. If anything, RM patients seem to have a more accentuated 
phenotype. Nevertheless, the O-I interval in 26 (81%) of the 32 (65%)viable 
pregnancies in this group was < 12 days, indicating that a prior history of RM does 
not preclude successful in-phase implantation.  
 
There was, however, a considerable overlap in the O-I intervals between viable and 
non-viable pregnancies, suggesting that neither out-of-phase nor in-phase 
implantations accurately predict subsequent events in the 1st trimester of pregnancy. 
This may, at least in part, be due to inherent inaccuracies associated with assessing 
the O-I interval on basis of urinary LH and hCG kits. It is well established that the 
interval between the LH surge and ovulation is variable and hCG kits are still 
relatively insensitive, with a threshold of detection 25-100 times higher than the 
methodology used by Wilcox and colleagues (141). Furthermore, it is well 
established that the rise in hCG levels in early pregnancy can be erratic, which in 
turn can profoundly impact on the rank order of the approximated day of 
implantation. If, as assumed, decidualization determines the duration of the WOI 
(52), secreted endometrial markers may be useful to more accurately assess the O-I 
interval. Candidate molecules include LEFTY-A (also known as endometrial 
bleeding-associated factor or EBAF), a soluble cytokine of the TGF-β superfamily 
expressed upon closure of the WOI (142); and possibly secreted decidua-specific 
microRNAs (143). Regardless of these caveats, follow-up studies are warranted to 
assess if pregnancy following a prolonged O-I interval is associated with increased 
risk of obstetrical disorders caused by placental dysfunction, such pre-eclampsia, 
intrauterine growth restriction, and preterm birth. Conversely, it would be interesting 
to test if the incidence of fetal aneuploidy differs in miscarriages following in-phase or 
out-of-phase implantations.  
 
In a relevant work, our group has previously shown that there are significant 
differences in the O-I interval, which in turn dictates embryo size later in the 
pregnancy (27).  We have now shown in that delayed implantation outside the 
normal O-I interval is associated with an increased likelihood of miscarriage. This 
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gives important evidence to support the view that disorders of decidualisation are 
responsible for miscarriage. """"""""""""""""""""""""""""""
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4.2 Pregnancy of unknown Location (PUL) ""
This was a prospective observational study. After registering the study, our local 
recruitment took place between November 2009 and March 2011 at QCCH.  
 
Multi-centre data collected previously at St George’s Hospital team was also used for 
temporal and external validation of the model M4 as well as for the development of 
the new model. Centres that have also contributed to the studies are:  
 
• St George’s hospital (SGH): a central London teaching hospital 
• St. Mary’s Hospital (SMH): a central London teaching hospital  
• Chelsea and Westminster Hospital (CWH): a central London teaching 
hospital 
• West Middlesex Hospital (WMH): a west London teaching hospital 
 
Women classified with a PUL were included in the study unless they were clinically 
unstable, had an acute abdomen or had blood in the pouch of Douglas according to 
the ultrasound images at the time of the initial TVS examination (Figure 9).  
 
The final outcomes were recorded including: IUP, ectopic pregnancy and failing PUL. 
Interventions needed were recorded including medical treatment with methotrexate 
injections or surgical procedures such as ERPC, Laparoscopy, Laparotomy, 
salpingectomy, salpingostomy or oopherectomy. ""
Classifying a pregnancy as PUL "
Women were classified as a PUL if there was no evidence of an IUP or ectopic 
pregnancy on TVS.  An IUP was diagnosed if there was an intra-uterine gestational 
sac with or without a yolk sac or fetal pole or heterogeneous tissue within the 
endometrial cavity suggestive of retained products of conception.  An ectopic 
pregnancy was diagnosed on TVS if no IUP was seen and one of the following was 
visualised: 1) an inhomogeneous adnexal mass separate from the ovary (144), 2) an 
empty extra-uterine gestational sac seen as an hyperechoic ring (‘bagel sign’) in the 
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adnexal region (145)  or 3) a yolk sac or fetal pole ± cardiac activity in an extra-
uterine sac in the adnexal region.  
 
 
 
Figure 9: PUL studies  
 
 
Serial serum hCG "
Those included in the studies had serum hCG levels taken at 0 and 48 hours after 
presentation. The times of taking the blood samples for the hCG assays were 
recorded. When the 48 hours hCG ratio was < 0.87, a follow up serum hCG at day 7 
and urine hCG at day 14 were organised. Women were then followed up until the 
final clinical outcome of the pregnancy was known – failing PUL, IUP or ectopic 
pregnancy. The exact method and timing of follow-up was decided on an individual 
case basis.  A failing PUL was diagnosed by a spontaneous decrease in serum hCG 
level to < 15 IU/L.  An IUP was diagnosed either after visualisation on TVS using the 
above criteria or after histological confirmation of products of conception confirmed 
post conception 
Postive pregnancy test  
PUL 
Ultrasound characterisation  
N=347  
Rationalising the management  
Urine vs Serum  hCG 
N=200 
Timing of follow 
up 
N= 427  
Model development 
and validation 
N= 1962 
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after surgical evacuation.  An ectopic pregnancy was diagnosed using the 
ultrasonographic criteria previously mentioned or after confirmation at the time of 
laparoscopy or laparotomy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55""
4.2.1 Ultrasound subjective impression 
 
Objectives  
 
To compare two definitions of pregnancy of unknown location (PUL). One based on 
the absence of any features of either an intrauterine pregnancy (IUP), or ectopic 
pregnancy (EP) and another based on a broader definition including suggestive, but 
not definitive, ultrasound findings of an IUP, EP or failed PUL (FPUL). 
 
An initial TVS was carried out and all possible TVS outcomes are summarised in 
Figure 10. The ultrasound based classification of the pregnancy by the examiner 
included four categories of PUL (83):  
 
1. PUL: No signs of either an EP or IUP. 
2. Probable IUP: visualisation of a possible intra-uterine gestation sac but 
no YS or fetal pole visible.  
3. Probable EP: possible visualisation of an adnexal mass  
4. Probable failing/resolving PUL (FPUL): visualisation of possible POC in 
the uterine cavity with no previous USS examination confirming an IUP. 
This category is not proposed in the consensus paper (83); however it 
is commonly used in clinical practice.  
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Figure 10: Proposed categorisation for ultrasound diagnosis in woman with a positive 
pregnancy test taken from reference 9 with permission 
 
 
Criteria 1 represents the narrow criteria for a PUL generally used in the UK, whilst 
criteria 1 to 3 encompass the wider criteria that may be used to define a PUL in the 
USA and are proposed in the PUL consensus document.  All PUL included in the 
study had serum hCG levels taken at 0 and 48 hours after presentation.  The end 
point of the study was the final clinical outcome of the PUL. These possible final 
outcomes are shown below and illustrated in Figure 11. The exact method and 
timing of follow-up was left to the discretion of the managing clinician.  
 
1. IUP: visualisation of an intra-uterine gestation sac with a YS and/or foetal pole 
or heterogeneous tissue within the endometrial cavity suggestive of retained 
products of conception or after histological confirmation of products of 
conception confirmed after surgical evacuation. 
2. EP: if one of the following was clearly visualised: 
a. Inhomogeneous adnexal mass separate from the ovary (144) 
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57""
b. Empty extra-uterine gestational sac seen as an hyper-echoic ring 
(‘bagel sign’) in the adnexal region (145) 
c. Yolk sac or fetal pole ± cardiac activity in an extra-uterine sac in the 
adnexal region 
d. Confirmation at the time of laparoscopy or laparotomy  
3. Failed PUL (treated or spontaneously resolved): was defined by decrease in 
serum hCG level, spontaneously or after medical management, without 
confirmation of location to < 15 IU/L. 
 
 
Figure 11: Proposed classification of PUL outcome based on final location taken from 
reference 9 with permission 
 
 
We compared the area under the ROC curve (AUC) for all final outcomes when the 
logistic regression model M4 was applied to populations of PUL identified using both 
the broad and narrow definitions described.  We also compared the clinical 
consequences associated with using the two definitions for PUL in relation to the 
number of clinical visits required, blood tests and missed EP’s. Using the narrow 
PUL definition, we only apply M4 in cases where there is no evidence of the location 
of the pregnancy. With the wider definition we apply M4 to all cases including when 
the location of the pregnancy has already been suggested according to ultrasound 
criteria. When M4 is used, EP is predicted if the estimated probability of EP 
according to M4 is at least 5% (146).  
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Results  "
5184 patients were seen during the study recruitment period and 347 consecutive 
women were classified with a PUL using the wider definition. A total of 8 cases were 
excluded because of missing outcomes, being lost to follow-up or because 
information about the type of PUL was missing. The final cohort included in this 
study was 339 patients of which 32 patients had missing hCG values.  Using this 
definition of PUL, 45 women (13%) were classified as “PUL Probable EP”, 47 (14%) 
as “PUL Probable IUP”, 137 (40%) as “Probable FPUL” and 110 (32%) as “PUL”. 
The final outcomes for all PUL were: 51 (15 %) EP, 62 (18 %) IUP   and 226 (67 %) 
FPUL (Table 12). The final outcomes for the 32 cases with missing hCG data were 3 
EP, 12 IUP and 17 FPUL.  
 
  Outcome 
  FPUL 
N; % (95% CI) 
IUP 
N; % (95% CI) 
EP 
N; % (95% CI) 
Total 
N; % 
Subgroup of 
the broad 
definition of 
PUL  
FPUL 
124; 91% (83-95) 5; 4% (1-10) 8; 6% (3-13) 137; 40% 
IUP 16; 34% (20-51) 28; 60% (42-75) 3; 6% (2-20) 47; 14% 
EP 15; 33% (19-51) 4; 9% (3-24) 26; 58% (40-74) 45; 13% 
Narrow 
definition 
of  PUL   
71; 65% (53-74) 25; 23% (15-34) 14; 13% (7-22) 110; 32% 
Total 226; 67% 62; 18% 51; 15% 339 
 
Table 12: Subjective assessment by TVS versus final outcome. For each subjective 
impression, the N and percentage of patients that were confirmed as an FPUL IUP and EP are 
given 
 
When the model M4 was applied to the 307 patients with two hCG values that were 
defined as a PUL using the broad PUL definition, AUC’s of 0.96 (0.93-0.97), 0.95 
(0.92-0.97) and 0.88 (0.81-0.93) were obtained for FPUL, IUP and EP respectively. 
Applying the model M4 on the 110 patients defined as having a PUL using the 
narrow definitions for a PUL, the AUC for M4 was 0.95 (0.90-0.98), 0.95 (0.89-0.98) 
and 0.85 (0.68-0.93) for FPUL, IUP and EP respectively (Table 13).  """""
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 FPUL IUP EP 
M4 on PUL defined 
using broad criteria  0.96 (0.93-0.97) 0.95 (0.92-0.97) 0.88 (0.81-0.93) 
M4 on PUL defined 
using narrow 
criteria 
0.95 (0.90-0.98) 0.95 (0.89-0.98) 0.85 (0.68-0.93) 
 
Table 13: Performance of model M4 on all data vs the performance when applied to the PUL 
(narrow definition) group only 
 
Applying the broad definition of PUL on our entire patient cohort would have resulted 
in at least 339 patient visits and 678 blood tests. For the 307 patients for whom hCG 
values were available this would mean that 4 EP’s were missed (8.3% of all 48 
EP’s). Table 14 shows that applying the narrow definition policy would reduce the 
minimum number of visits to 110 and the blood tests needed to 220. However the 
number of missed EP would increase to 12 out of 48 (25%). Table 15 and Table 16 
include details of the hCG ratio and interventions required in the missed EP cases 
resulting from each policy.  
 
 
 
Patients 
classified as 
PULs 
Minimal 
additional visits 
needed 
Minimal blood 
tests needed 
EP missed  
M4 applied to 
PUL defined 
using the narrow 
definition of a 
PUL  
 
110 (32%) 110 2*110=220 12/48 (25%) 
M4 applied to 
PUL defined by 
the broad 
definition of a 
PUL  
 
339 (100%) 339 2*339=678 4/48 (8.3%) 
 
Table 14: The clinical impact of using wide and narrow definitions of PUL 
 
 
 
hCG 
initial 
hCG 
48 
hour Intervention if any hCGratio 
78 225 None  2,88 
1707 878 Laparoscopy 0,51 
225 133 None  0,59 
1220 4356 Laparoscopy 3,57 
 
Table 15: EP missed with broad definitions N=4 
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hCG 
initial 
hCG 48 
hour Intervention if any hCGratio 
78 225 None  2,88 
1707 878 Laparoscopy 0,51 
106 107 Methotrexate 1,01 
112 108 Laparoscopy 0,96 
450 705 None  1,57 
37 74 None  2 
70 84 Methotrexate 1,2 
262 264 Methotrexate 1,01 
1493 2087 Laparoscopy 1,40 
364 313 Methotrexate 0,86 
180 205 Methotrexate 1,14 
621 1090 None  1,76 
 
Table 16: EP missed with narrow definitions N=12 
 
 
Discussion  
 
This study has shown that applying a relatively narrow definition of PUL based on 
diagnosing an early IUP or EP in the absence of a visible GS or YS using ultrasound 
leads to some EP being missed. The study also demonstrates that when a broad 
definition of PUL is applied, the number of missed EP will be reduced, but at the 
clinical cost of significantly increasing the number of pregnancies classified as a PUL 
with an associated increase in the number of visits and blood tests required to plan 
management.  
 
In practice, the management of PUL is focussed on defining risk and predicting 
whether intervention is likely to be necessary. If an EP is suspected, a PUL will be 
classified as high risk and most clinicians would apply strict follow up protocols until 
the location of the pregnancy has been confirmed using ultrasound. When the 
predicted outcome is either a failed PUL or a very early IUP, the pregnancy will be 
considered low risk. Less intrusive management may then be initiated that may often 
involve only a urinary pregnancy test or repeat ultrasound scan two weeks later (90) 
(146). Such patients are likely to be reassured that an EP is unlikely and so may 
ignore signs that might alert them that there is a problem. Accordingly managing 
PUL based on risk assessment is dependant on the compliance and of the patient 
population being treated.  
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If ultrasound examiners do not use the presence of a YS or embryo to define the 
presence of a pregnancy, but rely on their subjective interpretation of the ultrasound 
images, our data show that the accuracy associated with this approach was 91% 
and 60% for the PUL initially predicted to be failing pregnancies or IUP respectively. 
The rate of missed EP amongst both these predicted groups was 6%. Of importance 
is that 4 out of 45 pregnancies thought to be an EP using this approach were IUP. 
This is clinically relevant. In the event of an EP being suspected on the basis of a 
homogenous mass, great care must be taken before considering medical 
intervention with methotrexate as in this study 9% of these cases were an IUP. 
Previous data has also suggested that when using narrow vs. strict definition to 
diagnosis EP the sensitivity was higher using the narrow definition (42.1 vs. 13.2) but 
the positive predictive value was lower (82.7 vs. 98.0) (147).  
 
A strength of our study is that it prospectively followed the recent recommendations 
of the international consensus statement for PUL nomenclature (83). In this way it 
should be possible for clinicians working in different settings to interpret the results 
according to their own definition. Furthermore, the ultrasound scans were performed 
on high-quality equipment, and by clinicians working in dedicated acute gynaecology 
and early pregnancy assessment units. It is probable that the quality of the scans in 
this study is relatively good. A weakness in the study is one of the endpoints. In our 
study the finding of an inhomogeneous adnexal mass visualised using ultrasound 
was deemed a definitive diagnosis for EP, in the consensus paper “Definite EP” was 
defined as: an extra-uterine gestational sac with yolk sac and/or embryo (with or 
without cardiac activity). However we have previously published data suggesting that 
the diagnosis of an EP on the basis of the finding of a homogenous mass using TVS 
has a high positive predictive value (147)"(148).  
 
While the diagnostic criteria used to define EP and PUL vary, the management of 
these conditions also show significant variation. In the USA, more interventional 
strategies are often adopted for women at risk of EP and in some circumstances 
uterine curettage is carried out to distinguish a nonviable IUP from an EP (83, 148). 
A more conservative approach is generally used in the UK where the diagnosis of 
pregnancy location is generally made by repeated ultrasound scans without surgical 
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intervention (67). As a result errors arising from using a narrow definition for PUL are 
less likely to lead to intervention.  Of interest is that we found that results obtained 
using the M4 prediction model remained nearly unchanged when applied to PUL 
defined using either the narrow or broad definitions. This surprised us, as we had 
previously been unable to validate the performance of the M4 model on data 
obtained from a unit in the USA (84). We had previously assumed this failure was a 
result of different definitions being used for PUL. It seems likely that there must be 
some other factor impacting on test performance such as the nature of the patient 
populations, or the scanning technique that we need to consider. This is important 
for researchers carrying out systematic reviews and meta-analysis as it would seem 
harmonising diagnostic tests on different populations in different countries is not as 
simple as agreeing on definitions.  
 
Medical decision-making has to take into account the balance between the risk of a 
certain strategy and the cost of reducing that risk to the lowest reasonable level. Our 
data show that the PUL rate can be reduced by subjectively using ultrasound to 
determine whether there is a small intrauterine gestation sac or retained products in 
the cavity. However the cost of this is that EP will be misclassified. If the presence of 
a visible YS or embryo are required to define an intrauterine pregnancy very few 
EP’s will be classified as low risk, but far more women will be allotted into the high 
risk category. Which approach to use may be determined by other factors such as 
the health care setting and patient compliance. If women are given very clear 
instructions to return in the event of any symptoms and have twenty-four hour 
access to medical review, misallocating some EP may not lead to patient harm. In 
the absence of prospective data we cannot say anything definitive on this point. Of 
the EP classified as low risk the majority underwent intervention, however review of 
the cases shows medical management being used when serum hCG levels were 
both increasing and decreasing. Quantification of the financial costs of diagnosing 
and excluding EP was shown to be challenging"(149). Accordingly it is not possible 
to comment on the appropriateness of these interventions. 
 
This study shows that how we define a PUL determines the outcomes contained 
within the group of pregnancies categorized in that way. Those who are confident of 
their ultrasound quality or have very robust follow up arrangements in place may 
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choose to adopt narrow definitions for PUL. In situations where ultrasound quality is 
less certain, or patient supervision more difficult the broad definition would seem 
more likely to be appropriate. Either can be justified as long as the consequences of 
using the definitions are known. In this way both clinicians and patients will be 
making informed decisions about their treatment. "
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4.2.2 Studying the influence of hCG timing  
 
Objective  
For the management of PUL, use of the hCG ratio is based on the assumption that 
there is a 48 hour interval between samples. In practice the timing varies. This study 
aimed to assess this variability, and establish whether the time interval between hCG 
assays influences the prediction of PUL outcome. 
 
This was a multi-centre prospective observational study. Data were collected 
between November 2009 and March 2011 at Queen Charlotte’s (QCCH) and 
Chelsea and Westminster Hospitals (CWH). "
Two different prediction models were constructed using multinomial logistic 
regression. These models estimate for each patient the probability that the PUL is an 
EP, failing PUL, or IUP. The reference model was based only on hCG levels, and 
used the log of the initial hCG level and the log of the hCG ratio (ratio between the 
second and first hCG value). The extended model added information on the inter-
sample interval by including the time interval and the interaction between the log of 
the hCG ratio and time interval as covariates. In order to study the difference 
between the prediction models, we computed for each outcome the difference of the 
predicted probabilities from the two models. Thus, the predicted probability based on 
the extended model was subtracted from predicted probability based on the 
reference model. 
 
Results   
 
The final study group contained 427 patients. 58 (13.6%) patients had EP, 275 
(64.4%) had a failed pregnancy and finally 94 (22.0%) had an IUP (see Table 17).  
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 Median (IQR) 
 All patients EP FPUL IUP 
Age 32 (26-36) 33 (28-36) 32 (26-36) 30 (25-35) 
Initial hCG  529 (196-1368) 495.5 (173-1110) 531 (166-1755) 509 (255-1091) 
48h hCG 370 (116-986) 681 (222-1296) 204 (69-553) 994 (642-1909) 
hCG ratio 0.53 (0.32-1.28) 1.18 (0.98-1.55) 0.37 (0.25-0.53) 2.15 (1.49-2.71) 
Time interval 47.0 (43.5-49.5) 45.8 (42.2-49.3) 47.0 (44.1-50.0) 47.1 (43.7-48.9) 
 
Table 17: Descriptive statistics  
 
There were 190 (44%) patients who had the second blood sample taken between 45 
and 51 hours after the first, which is within three hours of the target interval of 48 
hours (Figure 12). The inter-sample interval was within six hours of the target interval 
for 292 (68%) patients. Of the remaining patients, 16% had an interval more than six 
hours too early and 16% more than six hours too late. These percentages were 
similar for EPs, failed pregnancies, and IUPs. 
 
 
Figure 12: Histogram of the time interval 
 
In Figure 13, the differences of the predicted probabilities given by the reference and 
extended models are shown separately for ectopic pregnancies, failed pregnancies 
and intra-uterine pregnancies. The models estimate for each patient the probability 
for each outcome, such that each patient is represented three times in the plots. 
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These plots suggest an influence of the time interval on the predicted probabilities. 
For ectopic pregnancies (Figure 13 a) the extended model gave higher probabilities 
of IUP and lower probabilities of failing PUL than the reference model when the 
interval was short. The opposite was seen for long intervals. For failed PULs (Figure 
13 b) the difference between the reference and extended models was very small. For 
IUPs (Figure 13 c) the extended model gave higher probabilities of IUP and lower 
probabilities of EP than the reference model when the interval was short. Again, the 
opposite was seen for long intervals. However, given that most patients had a limited 
deviation from the target 48-hour interval, these differences were very small for the 
majority of patients in our sample.   
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Figure 13: Difference in the probabilities for each outcome given by the reference and 
extended models (probability from reference model minus probability from extended model) 
for ectopic pregnancies (panel a), failed PULs (panel b) and IUPs (panel c). The difference in 
the probability of EP are presented by plus signs and a full trend line. The difference in the 
probability of failed PUL are presented by stars and a gray dotted trend line. The difference in 
the probability of IUP are presented by squares and a gray dashed trend line 
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Discussion  
 
Most PUL management protocols that rely on serial hCG measurements assume 
that these measurements are repeated in 48 hours. Although this time interval is not 
strictly followed in practice, two thirds of the patients came back in a range of 6 hours 
around 48 hours. Our data suggested that the time interval may have an impact on 
predicted probabilities, as expected. However, we have shown that accurate time 
intervals between assays are not critical for the management of PUL as long as the 
patient returns at 48 hours +/- 6 hours. This is clinically important as it suggests that 
there may be significant flexibility in relation to the timing of blood samples in this 
patient group. One reason that small deviations from a 48 hour interval have limited 
influence is that models relying on information on initial and 48 hour hCG levels 
already perform very well in the discrimination of EP, failed pregnancy and IUP (77)"
(89), leaving little room for further improvement.  
 
While most PUL management protocols that use serial hCG measurements currently 
adopt a 48 hours interval between blood sampling, it might be possible to obtain the 
same information derived from the hCG ratio in a much shorter timeframe such as 
twenty-four hours. This may well improve the efficiency in managing the high risk 
patient group, reduce complications and provide better patient convenience. Thus, 
prospective studies to test the reliability of shorter follow-up intervals than those 
currently adopted are needed.  
 
In conclusion, in the management of PUL, women can be given some flexibility when 
returning for a second sample, as long as the time between both measurements is 
between 42 and 54 hours. The reliability of using shorter time intervals for the hCG 
ratio, such as 24 hours, is yet to be prospectively studied.  
 
 
 
 "
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4.2.3 Rationalising PUL management using M4 model  "
 
Objectives 
 
The aim of this study was to accurately define a group of low-risk pregnancies of 
unknown location (PUL) in order to safely reduce follow-up for these pregnancies 
and allocate resources to pregnancies at increased risk of being ectopic. In addition, 
to temporally and externally validate the usefulness of this system, as well as the 
performance of the M4 logistic regression model, using more recent data from the 
unit where M4 was developed and data from four other units that includes our own. 
 
 
This was a multi-centre observational diagnostic accuracy study of women with a 
pregnancy of unknown location. Temporal validation data collection from London’s 
St. George’s Hospital (SGH), where M4 was developed, was collected according to a 
strictly defined study protocol (79) (77) between July 2003 and February 2007 (Table 
18). External validation data from the following four London university hospitals was 
prospectively collected between April 2009 and April 2011 (Table 18): Queen 
Charlotte’s (our recruitment) and Chelsea Hospital (QCCH), Chelsea and 
Westminster Hospital (CWH), West Middlesex Hospital (WMH), and St. Mary’s 
Hospital (SMH). 
 
At SGH, women were classified as having a PUL if there was no evidence of an IUP 
or EP on TVS. The data collected for external validation incorporated new definitions 
of PUL contained within a recent consensus paper (83) that includes in the PUL 
population small possible intra-uterine gestation sacs or possible EP where 
embryonic structures have not been visualised. According to these criteria, a 
pregnancy can be classified as: PUL - probable intra-uterine, PUL - probable ectopic 
or true PUL (which is consistent with the older definition used at SGH).  
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Unit 
   Characteristic 
Failing 
PUL IUP EP 
St. George’s (N=1341)    
Recruitment period July 2003 – February 2007 
N, % 713, 53% 517, 39% 111, 8% 
Age 31 (26-36) 30 (24-34) 31 (28-36) 
Serum hCG 0h 221 (60-716) 595 (295-1034) 368 (186-1039) 
Serum hCG 48hrs 95 (24-321) 1271 (684-2196) 473 (221-1168) 
hCG ratio 0.39 (0.28-0.60) 2.20 (1.92-2.47) 1.18 (0.95-1.41) 
    
Queen Charlotte’s and Chelsea (N=309)    
Recruitment period April 2009 – July 2011 
N, % 209, 68% 51, 17% 49, 16% 
Age 32 (27-36) 30 (25-35) 33 (29-36) 
Serum hCG 0h 420 (158-1663) 471 (259-1243) 545 (222-1034) 
Serum hCG 48hrs 158 (56-640) 861 (593-2151) 608 (222-1090) 
hCG ratio 0.38 (0.26-0.54) 2.15 (1.66-2.68) 1.14 (1.00-1.40) 
    
Chelsea and Westminster (N=130)    
Recruitment period November 2009 – June 2010 
N, % 73, 56% 37, 28% 20, 15% 
Age 33 (29-37) 29 (23-33) 31 (28-35) 
Serum hCG 0h 606 (224-1279) 467 (255-699) 435 (156-907) 
Serum hCG 48hrs 207 (98-338) 961 (681-1493) 638 (226-1320) 
hCG ratio 0.34 (0.23-0.48) 2.21 (1.83-2.74) 1.26 (0.99-1.61) 
    
West Middlesex (N=101)    
Recruitment period November 2009 – June 2010 
N, % 71, 70% 17, 17% 13, 13% 
Age 30 (24-35) 28 (26-33) 30 (24-34) 
Serum hCG 0h 766 (296-2705) 1088 (569-3519) 1029 (653-1361) 
Serum hCG 48hrs 336 (132-868) 1905 (1141-2185) 1186 (801-2085) 
hCG ratio 0.41 (0.23-0.56) 1.13 (0.91-2.68) 1.30 (0.94-1.48) 
    
St. Mary’s (N=81)    
Recruitment period December 2009 – June 2010 
N, % 38, 47% 33, 41% 10, 12% 
Age 33 (27-35) 29 (26-37) 32 (29-34) 
Serum hCG 0h 392 (136-1367) 650 (343-1140) 821 (170-1323) 
Serum hCG 48hrs 131 (49-375) 1401 (579-2038) 977 (325-2120) 
hCG ratio 0.35 (0.30-0.56) 1.80 (1.17-2.24) 1.18 (1.01-1.53) 
Descriptive statistics for age and hCG information are presented as median (interquartile range). 
PUL: pregnancy of unknown location; IUP: intra-uterine pregnancy; EP: ectopic pregnancy; hCG: human chorionic 
gonadotrophin. 
 
Table 18: Overview of units and descriptive statistics 
 
IUP, Failing PUL and EP were diagnosed according to the criteria described above. 
As persistent PUL most likely represent missed EP that behave in the same way 
biochemically, persistent PUL were analysed as EP. Failed PUL and IUP were 
considered to be low-risk PUL, and EP were considered to be high-risk PUL.  
For the external validation data, any interventions carried out were recorded 
including medical treatment with methotrexate or surgical procedures such as 
evacuation of retained products of conception, laparoscopy or laparotomy (leading to 
salpingectomy, salpingostomy or oophorectomy). 
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Our aim was to identify low-risk PUL with a high level of confidence, such that it is 
safe to select these women for reduced follow-up. Misclassification of an EP as low 
risk is thus considered much more harmful than misclassification of a low-risk 
pregnancy as high risk. This suggests the choice of a low cut-off for the risk that a 
PUL is an EP, given the direct relationship between risk cut-off and relative 
misclassification costs (150) (151) (152). We considered it sensible to refer PUL for 
extensive follow-up if their risk of being EP was at least 5%. Because the desired risk 
threshold is partly subjective, we also present results for a cut-off of 3%. If a PUL 
was classified as low risk, we predicted a failed PUL or IUP depending on which 
outcome had the highest estimated risk. The risk of each outcome category was 
estimated by M4. This model is based on the hCG ratio (hCG level at 48 hours 
divided by hCG level at presentation) and the log of the average hCG level as 
predictors.  
The M4 risk prediction model is a multinomial logistic regression model that uses the 
hCG ratio and the log of the average hCG levels, i.e. the natural logarithm of (hCG 
level at presentation + hCG level at 48 hours)/2, as predictors. A multinomial logistic 
regression model defines a reference category (i.e. IUP) and derives an equation for 
each other category versus the reference category. For M4 the equations are: 
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PFailed, PIUP, and PEP represent the estimated risks of the three categories. Using the 
equations, and using the exponential constant e, these risks are derived as: 
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Statistical analysis 
 
M4 was applied to each PUL and the estimated risks of failed PUL, IUP, or EP were 
recorded. Performance evaluation consists of two parts: evaluation of the estimated 
risks estimated from M4 with respect to discrimination and calibration, and evaluation 
of PUL triage as high versus low risk based on a risk cut-off. We focused on the 
latter as this is clinically most relevant. Regarding triage, the main performance 
measures are the percentage of low-risk classifications (percentage of PUL selected 
for reduced follow-up), negative predictive value (the percentage of failed PUL or 
IUP among low-risk classifications), sensitivity (the percentage of EP classified as 
high risk), and false positive rate (the percentage of failed PUL or IUP classified as 
high risk).  
 
Results were obtained for all five hospitals separately and for the aggregate data of 
the four external validation hospitals to increase numbers. As the definition of what 
constitutes a PUL was different for the prospectively collected external validation 
data following the recent consensus statement (83), we also obtained results for the 
aggregate validation data based on the PUL definition used for developing M4 and 
for temporal validation.  
 
All analyses were performed using SAS 9.2. 
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Results  
 
A flow chart of this study is presented in Figure 14.  
 
 
Figure 14: Flowchart of the study 
 
 
The total number of PUL was 2184. This includes 1467 PUL from SGH and 717 PUL 
from the four external units. Overall, 222 patients were excluded, 120 (5.5%) were 
lost to follow-up and 102 of the remaining patients (4.9%) had missing hCG levels 
because of the following reasons: an intra- or extra-uterine pregnancy was detected 
prior to the second blood sample being taken, the patient was only followed up with a 
urinary pregnancy test due to a very low initial hCG level, or the patient returned out 
of hours for the second blood sample. The EP rate varied between 8%-16% across 
the five units. Table 18 above presents the recruitment periods, the distribution of the 
reference standard, and descriptive statistics for all units.  
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Table 19 presents cross-tabulations of the classification as low or high risk, and Table 
20 summarises the performance measures of the classifications using risk cut-offs of 
5%, and 3% for the risk of EP. Figure 15 visualises the high-risk classification 
conditional on the initial serum hCG level and the hCG ratio. Focusing on triage 
using the 5% cut-off, 980 (73%) of PUL at SGH and 432 (70%) at the external units 
were considered to be low risk (the percentage for these units varies between 62 
and 75%). The low-risk classification was correct for 98% of the women at SGH and 
for 97% of the women at the four external units (the percentage varies between 96 
and 98%). At SGH 85% of EP were correctly classified as high risk, whilst this was 
88% at the external units (the percentage varies between 80 and 92%).  
 
 
 
  Classifications 
  5% risk cut-off 3% risk cut-off 
Unit Final diagnosis Low risk High risk Low risk High risk 
SGH Low risk (IUP / failed PUL) 963 267  906 324 
 High risk (EP) 17 94 14 97 
      
All  Low risk (IUP / failed PUL) 421 108 404 125 
external High risk (EP) 11 81 9 83 
      
QCCH Low risk (IUP / failed PUL) 211 49 204 56 
 High risk (EP) 4 45 4 45 
      
CWH Low risk (IUP / failed PUL) 94 16 91 19 
 High risk (EP) 4 16 2 18 
      
WMH Low risk (IUP / failed PUL) 62 26 58 30 
 High risk (EP) 1 12 1 12 
      
SMH Low risk (IUP / failed PUL) 54 17 51 20 
 High risk (EP) 2 8 2 8 
SGH: St. George’s Hospital; QCCH: Queen Charlotte’s and Chelsea Hospital; CWH: Chelsea and Westminster Hospital; WMH: 
West Middlesex Hospital; SMH: St. Mary’s Hospital; IUP: intra-uterine pregnancy; PUL: pregnancy of unknown location; EP: 
ectopic pregnancy 
 
Table 19: Two-by-two cross-tabulations of the prediction of PUL as low or high risk. 
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Unit 
Percentage 
classified 
as low risk 
True 
positive  
rate 
False 
positive  
Rate 
Positive 
predictive 
value 
Negative 
predictive 
value 
 5% risk cut-off 
SGH 73.1% 84.7% 21.7% 26.0% 98.3% 
All external 69.6% 88.0% 20.4% 42.9% 97.5% 
QCCH 69.6% 91.8% 18.9% 47.9% 98.1% 
CWH 75.4% 80.0% 14.6% 50.0% 95.9% 
WMH 62.4% 92.3% 29.6% 31.6% 98.4% 
SMH 69.1% 80.0% 23.9% 32.0% 96.4% 
 3% risk cut-off 
SGH 68.6% 87.4% 26.3% 23.0% 98.5% 
All external 66.5% 90.2% 23.6% 39.9% 97.8% 
QCCH 67.3% 91.8% 21.5% 44.6% 98.1% 
CWH 71.5% 90.0% 17.3% 48.7% 97.9% 
WMH 58.4% 92.3% 34.1% 28.6% 98.3% 
SMH 65.4% 80.0% 28.2% 28.6% 96.2% 
* A positive value indicates that the model has more benefit than the classification of all PUL as high risk (i.e. without model) at 
the relative misclassification costs implied by the risk cut-off. 
 
Table 20: Summary performance measures of the classification of PUL as low or high risk 
 
 
 
 
 
 
Figure 15: Visualisation of high-risk classification based on initial hCG level and hCG ratio. 
PUL located inside the ellipsoid line are classified as high risk. Data from all five units are 
shown 
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Of the 11 misclassified EP in the external units (Table 21), five resolved without 
intervention, three received methotrexate injections (of which one despite a declining 
serum hCG), and three underwent laparoscopic surgery. Thus, for six cases out of 
621 PUL (1.0%) intervention was deemed necessary. Of all 92 EP in the external 
units, 41 received a surgical intervention of which three were misclassified (7%), 37 
received methotrexate of which three were misclassified (8%), and 14 did not receive 
an intervention of which 5 were misclassified (36%).   
 
 
 
Unit Initial hCG 
48h 
hCG 
hCG 
ratio 
Risk of 
ectopic (M4) 
Intervention 
Misclassified as IUP 
QCCH 78 225 2.88 <0.1% Expectant management 
QCCH 1220 4356 3.57 <0.1% Salpingotomy 
CWH 168 530 3.15 <0.1% Expectant management 
SMH 147 325 2.21 1.1% Methotrexate 
WMH 911 2085 2.29 0.5% Laparoscopy 
CWH 112 229 2.04 4.0% Expectant management 
CWH 829 1674 2.02 4.4% Methotrexate 
Misclassified as failed PUL 
CWH 62 21 0.34 <0.1% Expectant management 
SMH 170 67 0.39 <0.1% Methotrexate  
QCCH 225 133 0.59 0.8% Expectant management 
QCCH 1707 878 0.51 2.6% Laparoscopy 
 
Table 21: The 11 EP misclassified as low risk at the external validation units 
 
 
 
The classification of the original reference standard (failed PUL, IUP, and EP) into 
low risk – failed PUL, low risk – IUP, or high risk is shown in Table 22.  
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  Classifications 
  5% risk cut-off 3% risk cut-off 
Unit 
Final 
diagnosi
s 
Low 
risk – 
Failed 
Low 
risk – 
IUP 
High 
risk 
Low 
risk – 
Failed 
Low 
risk – 
IUP 
High 
risk 
SGH Failed 594 7 112 576 6 131 
 IUP 3 359 155 3 321 193 
 EP 5 12 94 4 10 97 
        
All Failed 337 2 52 326 0 65 
external IUP 14 68 56 12 66 60 
 EP 4 7 81 4 5 83 
        
QCCH Failed 179 1 29 174 0 35 
 IUP 3 28 20 2 28 21 
 EP 2 2 45 2 2 45 
        
CWH Failed 68 0 5 66 0 7 
 IUP 2 24 11 2 23 12 
 EP 1 3 16 1 1 18 
        
WMH Failed 55 1 15 52 0 19 
 IUP 3 3 11 3 3 11 
 EP 0 1 12 0 1 12 
        
SMH Failed 35 0 3 34 0 4 
 IUP 6 13 14 5 12 16 
 EP 1 1 8 1 1 8 
 
Table 22: Three-by-three cross-tabulations of the prediction of PUL as low risk – failed, low 
risk – IUP,  or high risk 
 
 
When reanalysing the external validation data using only PUL that would be 
classified as PUL using the definitions used at SGH, very similar results were 
obtained (Table 23). 
 
 
Risk 
cut-off 
Percentage 
classified 
as low risk 
True 
positive  
rate 
False 
positive  
Rate 
Positive 
predictive 
value 
Negative 
predictive 
value 
5% 68.2% 86.7% 22.1% 41.1% 97.1% 
3% 64.6% 88.9% 26.0% 37.7% 97.4% 
 
Table 23: Summary performance measures of the classification of PUL as low or high risk in 
the external centres based on the PUL satisfying the PUL definitions used at SGH 
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Discussion  
 
This study has shown that the M4 risk prediction model for PUL based on 
measurements of serum hCG can be used as a triage tool to significantly reduce the 
number of visits, blood tests and scans in a large proportion of women attending 
hospital in early pregnancy with a PUL. The model still performed well on external 
validation. The most important result is that M4-based triage of PUL as low or high 
risk using a 5% risk cut-off for EP managed to select around 70% of PUL for reduced 
follow-up while still referring at least 85% of EP for extensive follow-up. Among the 
PUL selected for reduced follow-up, 96 to 98% were later confirmed as failed PUL or 
IUP.  
 
We can illustrate how the model would be used in practice using some examples. A 
42-year-old with a history of two first trimester miscarriages presented with light 
vaginal bleeding and lower abdominal pain at six weeks gestation according to her 
last menstrual period. TVS revealed an empty uterus with an endometrial thickness 
of 8mm. The serum hCG level was 570 IU/L at presentation and 1467 IU/L 48 hours 
later (hCG ratio 2.57). M4 predicted low risk IUP, for which we would suggest a 
repeat scan after one week. This woman had a viable IUP. Another woman, age 29, 
in her first pregnancy  presented with a history of light vaginal spotting. TVS revealed 
an empty uterus with an endometrial thickness of 5mm. Both ovaries appeared 
normal and no adnexal masses were seen. The hCG level was 245 IU/L at 
presentation and 237 IU/L at 48 hours (hCG ratio 0.97).  M4 predicted high risk, so 
we would suggest a repeat scan and hCG assessment after a further 48 hours. The 
woman was later found to have an inhomogeneous mass in the right adnexa next to 
the right ovary, and a laparoscopic right salpingectomy was performed. Finally, a 26-
year-old woman in with one previous normal delivery at term presented with a history 
of heavy bleeding with clots at 10 weeks gestation according to her last menstrual 
period. The uterus appeared empty on TVS with no adnexal masses seen.  The 
serum hCG was 2303 IU/L at presentation and 749 IU/L at 48 hours (hCG ratio 
0.33).  M4 predicted low risk – failed, for which we would suggest a urinary 
pregnancy test after one week. This pregnancy was indeed a failed PUL.  
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The cases classified as low risk would not be discharged completely but undergo 
reduced follow-up, for example a urinary pregnancy test or scan after one week. 
Patients on a reduced follow-up protocol would also be given strict instructions to 
return in the event of a change in their symptoms. This approach seems reasonable 
and is likely to lead to women with an EP returning for review. Nonetheless, 
classifying EP as low risk is undesirable, as the risk of tubal rupture should be 
minimised and treatment enabled as early in the natural history of the disease as 
possible. Reviewing  the data from the four external units, five of the 11 misclassified 
EP resolved without intervention and management would not have been improved by 
classifying them as high risk. For six patients intervention was deemed necessary 
and lack of closer follow-up may have led to harm. In most cases, EP misclassified 
as an IUP would be identified at the time of any follow-up scan at an interval. 
Although there were no complications reported in this study amongst the EP falsely 
classified as low risk, this study was not interventional. We therefore do not know 
whether these patients would have come back to the unit in the event of symptoms 
or come to harm prior to follow-up, and we do not know the exact time period until 
making the correct diagnosis of EP. To demonstrate this, an interventional trial is 
currently ongoing. Of all EP in the external units, M4-based triage classified nearly all 
EP that received intervention as high risk whereas it misclassified one third of EP 
that did not receive intervention. This suggests that triage performs particularly well 
for EP that require surgery or medical treatment.  
 
Two limitations on the performance of M4 are the decreased discrimination 
performance in one external hospital (WMH) and the overestimation of the risk of EP 
in the external units. WMH data contained an unusually high number of non-viable 
IUP. This may be due to a tendency to classify women with evidence of retained 
products on ultrasound as a PUL due to the absence of a visible gestation sac. 
However, triage results for WMH were not worse than those for other units. Also, 
given the clinical requirement not to categorise many EP as low risk, a minor 
overestimation of the risk of EP whilst not ideal, is not a major drawback. Moreover, 
it did not negatively affect triage results.  
 
The prospective external validation of M4 in four hospitals supports the view that this 
approach will have general applicability in other units. A drawback, however, is that 
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all units are related to London-based university units. Accordingly further validation in 
different clinical settings and different geographical locations would be 
advantageous.  
 
A similar approach to the management of PUL was proposed using a single-visit 
strategy based on the initial serum progesterone and hCG levels (153). When tested 
prospectively on a total of 518 PUL, this approach correctly eliminated 84% of low-
risk PUL from further follow-up but simultaneously misclassified 67% of EP (153). 
Another single-visit strategy was described in a recent prospective interventional 
study in which a single measurement of serum progesterone of <10 nm/l at 
presentation was used to discharge PUL (90). Using this approach Cordina and 
colleagues classified 37% of their PUL population as low risk. Fifteen (6.6%) out of 
227 discharged women returned to the unit because of worsening symptoms and 
four (1.7%) needed surgical intervention of which two of the five were discharged 
EP. Whilst the single progesterone approach has the advantage of giving a result on 
the basis of one blood test, using M4 enables significantly more women to be 
classified as low risk. It is important to emphasise that the Cordina study is 
interventional so whilst M4 may have theoretical advantages, an interventional study 
is needed to enable us to compare these approaches to PUL triage appropriately. 
 
Undoubtedly the management of PUL takes up a significant amount of time and 
resources in units caring for women with early pregnancy complications. By far the 
majority of PUL are low risk and the number of blood tests and visits to hospital for 
review represent a significant burden both on patients and clinicians. We have 
shown that the M4 prediction model with a risk cut-off of 5% on the risk of EP could 
be used to reduce follow-up in over 70% of PUL. This would make more time 
available to concentrate on women at high risk of complications and potentially better 
use of resources. The good performance of M4 when validated externally suggests 
that the use of this approach prospectively would lead to a change in the 
management of the majority of women with a PUL and a more efficient use of 
resources. 
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4.2.4 Urine and serum hCG correlation  
 
 
Objectives  
 
To investigate the correlation between serum and urine hCG levels in women in 
early pregnancy, and whether the level of agreement is sufficient to allow reliable 
clinical decision making for the management of pregnancies of unknown location.  
 
The study cohort included 62 PUL subjects who provided urine samples upon 
presenting to EPAU, just prior to having phlebotomy to obtain serum samples. Urine 
was pipetted into 6 Eppendorf tubes and placed immediately into a fridge at -20o C. 
Blood samples were centrifuged within one hour and placed into a -80o C fridge for 
longer-term storage. As the clinic runs in the morning all samples were taken at that 
time, but were not first morning samples. Serial samples were obtained from part of 
the cohort when a repeat test was clinically indicated. For the correlation study 96 
samples of matched urine and blood were collected from the 62 women recruited. 
For outcome prediction, serial samples were available from 34 patients at 0 and 48 
hours after presentation. Serial samples were not available in 28 patients either 
because a diagnosis of an IUP or EP was made before 48 hours or one of the visits 
was over the weekend or at night. The final clinical outcome was recorded in all 
cases. The exact method and timing of follow-up was left to the discretion of the 
managing clinician. The end point of this part of the study was the final clinical 
outcome of the PUL, as detailed above in this document.  
 
HCG immunoassays 
 
Aliquots of urine and serum were removed from each sample's original cryo-vial for 
hormone measurement. Blood was separated and centrifuged within one hour of 
venipunture and stored at – 80o C.  Serum and urine samples were analysed for 
total hCG (hCG + hCGβ + other identified variant forms) using the ‘Charing Cross’ in-
house radioimmunoassay assay (CX-RIA) and the Siemens Immulite total hCG 
assay run by the Siemens Immulite 2000 instrument (Siemens Healthcare 
Diagnostics 1717 Deerfield Road, Deerfield, IL, USA).  
 
82""
The CX-RIA is an in-house developed competitive radioimmunoassay, which uses a 
polyclonal rabbit antiserum (96). The lower limit of detection was 1.6 IU/L (calculated 
as 2 SD’s above the zero standard) and the functional limit of detection was 
approximately 3 IU/L (at a coefficient of variation (cv) of 14%). Overall percentage cv 
for the assay was approximately 10% between 10 and 60 IU/L. Specificity as 
determined by cross-reactivity with human pituitary LH (NIBSC, Herts, UK, 2nd 
International Standard 80/552) was 0.6%. Samples were measured in duplicate and 
pre-diluted to achieve a result within the linear portion of the inhibition calibration 
curve.  
 
The Immulite 2000 total hCG assay is a solid phase two-site immunoassay that uses 
a chemiluminescent detection system to determine sample hCG concentration. 
According to the manufacturers kit insert the analytical sensitivity of the assay is 0.4 
IU/L. Performance is monitored daily and internal quality control samples ranging 
between 5 and 250 IU/L yield intra- and interassay cv’s of less than 10%.  
 
The upper reference limit for hCG in menstruating women is 3 IU/L and in 
postmenopausal women is 5 IU/L" (98). According to the kit insert supplied with the 
Siemens Immulite 2000 assay, 95% (351 of 369) of non-pregnant females had 
serum hCG values below 2.7 IU/L. 
 
The fourth international standard (4th IS) 75/589 issued by WHO (NIBSC, Herts, UK) 
was used to calibrate all immunoassays for total hCG either (i) directly by dilution of 
the standard (as for in-house assays) or (ii) by use of the manufacturer’s supplied 
calibrants that are formulated with value assignment standardised to those of IS 
75/589.   
 
Firstly, we examined the correlation between serum and urine hCG in the 96 
matched samples. Secondly, we assessed the accuracy for predicting the final 
pregnancy outcome using both serum and urine in the 34 patients who had provided 
serial samples of blood and urine. When predicting PUL outcome, an hCG ratio of > 
1.66 indicated an IUP, and hCG ratio of < 0.87 a FPUL and a ratio between (0.87 – 
1.66) indicated EP (67).  
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Results  
 
Comparing the RIA and Immulite serum hCG measurements for the entire cohort 
demonstrated good agreement with a Passing & Bablok derived slope value of 0.93 
(95% CI 0.90 to 0.97) and y-intercept of 19.1 (95% CI -5.80 to 34.18%; n=95; see 
Figure 16).  
 
 
Figure 16: Passing & Bablok comparison of serum hCG (pM) determinations made using the 
Immulite 2000 total hCG assay (ordinate) with hCG determined using the CX-RIA assay 
(abscissa) 
 
 
Bland-Altman analysis calculated a mean difference in determinations of 4.9% lower 
by the Immulite assay (95% CI -9.7 to 0.0%; p=0.049). Urine measurements showed 
similar agreement with a Passing & Bablok derived slope value of 0.90 (95% CI 0.84 
to 0.94) and y-intercept of -2.55 (95% CI -9.53 to 6.04; n=91; see Figure 17).  
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Figure 17: Passing & Bablok comparison of urine hCG (pM) determinations made using the 
Immulite 2000 total hCG assay (ordinate) with hCG determined using the CX-RIA assay 
(abscissa) 
 
 
When measuring urine hCG the slight relative negative bias was greater with the 
mean % difference in measurements 11.1% lower by the Immulite method (95% CI -
17.5 to -4.6%, p<0.001). The magnitude of difference was small, however, and 
overall the 2 methods showed good agreement. This interpretation was further 
confirmed using the linear fit method of Deming (154) which showed no significant 
difference between a slope value of unity and intercept of zero in either urine or 
serum. 
 
Bland-Altman analysis revealed that paired serum and urine hCG measurements 
were variant using either the RIA (95% CI of % difference; -38.8 to 2.8%; p = 0.090; 
n=91) or Immulite method (-49.9 to -6.8%; p< 0.01; n=93). While urine 
determinations ranged to higher levels than serum using either the RIA (serum 
range, 21- 77000 vs. urine range, 12 – 246600 pmol/L) or Immulite method (serum 
range, 9- 69200 vs. urine range, 12 – 228400 pmol/L) the mean % difference in 
measurement of hCG was lower in the urine; 18.0% lower (p =0.090) for the RIA and 
27.4% lower (p< 0.01) for the Immulite method.  
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For both the RIA and Immulite methods serum, urine and creatinine corrected hCG 
results were normalised by logarithmic transformation. Despite the variation in paired 
urine and serum hCG determinations RIA determined hCG, urine and serum 
measurements were significantly correlated (Pearson r-statistic 0.82; 95% CI 0.73 to 
0.88; p<0.0001; n=91; Figure 18) and the degree of correlation was improved after 
creatinine correction; (Pearson r-statistic 0.90; 95% CI 0.85 to 0.93; p<0.0001; 
Figure 19). Immulite determined hCG urine and serum measurements were also 
significantly correlated (Pearson r-statistic 0.84; 95% CI 0.77 to 0.89; p<0.0001; 
n=93; Figure 18) and the degree of correlation was also improved after creatinine 
correction; (Pearson r-statistic 0.90; 95% CI 0.85 to 0.93; p<0.0001; Figure 19).  
 
 
 
Figure 18: Pearson correlation of log10 serum and urine hCG (pM) measurements using the CX-
RIA (filled circles) and Immulite 2000 (open circles) assays 
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Figure 19: Pearson correlation of log10 serum and urine hCG (pM)/ creatinine (pM) ratios using 
the CX-RIA (filled circles) and Immulite 2000 (open circles) hCG assays 
 
 
Clinical outcome prediction 
 
Of the 34 patients with serial (i.e. 0 and 48hr samples) serum and urine samples, 3 
(8.8%) were finally diagnosed with EP, 9 (26.5%) with an IUP and 22 (64.7%) with 
FPUL. The final outcome of the 28 patients who did not have serial testing was 6 
(21.4%) EP, 7 (25%) with an IUP and 15 (53.6%) FPUL.  
 
Applying the serum hCG ratio cut-offs described above to the 34 patients with serial 
testing predicted EP, IUP and FPUL with an accuracy of 66%, 77.7% and 100%, 
respectively, using the RIA method. The accuracies were 100%, 44.4% and 100%, 
respectively, using the Imm2K method (Table 24). Applying the hCG ratio cut-offs on 
serial urine samples (creatinine corrected) predicted EP, IUP and FPUL with 
accuracy of 33.3%, 77.7% and 81.8%, respectively, using the RIA method. The 
accuracies were 33.3%, 55.6% and 86.4%, respectively, using the Imm2K method. 
The overall accuracy associated with serum hCG was 91.1% and 65.3% using RIA 
and Imm2K, respectively, compared to 76.5% and 73.5% with urine hCG. The 
accuracy in predicting the low risk category (combined IUP and FPUL) was 93.5% 
and 83.8% for serum hCG, respectively, using RIA and Imm2K, compared to 80.6% 
and 77.4% with urine.  
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RIA 
 
Imm2K 
 
 
Overall 
accuracy  
accuracy 
for EP 
accuracy 
for IUP 
accuracy 
for FPUL 
acc 
low-risk 
overall 
accuracy  
accuracy 
for EP 
accuracy 
for IUP 
accuracy 
for FPUL 
acc 
low-risk 
Blood  91.10% 66.60% 77.70% 100% 93.50% 65.30% 100% 44.40% 100% 83.80% 
Urine 76.50% 33.30% 77.70% 81.80% 80.60% 73.50% 33.30% 55.60% 86.40% 77.40% 
Failed if hCGratio < 0.87  
IUP if hCGratio > 1.66 
Ectopic if 0.87 ≤ hCGratio ≤ 1.66 
 
Table 24: Accuracies of serum and urine serial hCG levels in predicting PUL outcome using 
RIA and Imm2K  
 
 
Discussion 
 
We have shown that there is correlation between related serum and urine hCG 
levels in early pregnancy and that the degree of correlation was improved after 
creatinine correction. These results are similar whether the RIA or Immulite method 
is used for analysis (0.82 and 0.84, vs CR corrected values respectively). Thus, 
creatinine correction appears to compensate for the concentrating, or diluting, effect 
of the kidneys. Other factors may be proposed to affect the correlation between urine 
and serum hCG values including the variation in metabolism and excretion of hCG 
isoforms and their variable detection by different immunoassays.  
 
The slight negative bias of the Immulite method compared with the CX-RIA method 
reflects differential sensitivity to variant hCG isoforms. Recent studies using the 
latest WHO standard preparations for common hCG protein variants have 
demonstrated that the Immulite assay shows a relative slight overestimation of the 
hCGβ and underdetection of the hCGβcf form, while for the CX-RIA assay the 
opposite is true (96) (95). Since hCGβcf is the predominant degradation form cleared 
to the urine, the relative underdetection of this form by the Immulite method may 
account for the greater disparity in urine measurements compared with those of the 
RIA (93).  
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Measurements of urinary hCG have previously been shown to predict pregnancy 
outcome. When reviewing hCG measurements collected to estimate gestation in a 
cohort of IVF patients, urinary hCG was below a gestation-linked curve in 92% 
women with an ectopic pregnancy, 67% with a spontaneous miscarriage, and in 4% 
of viable intrauterine pregnancies (155). In contrast, 95% (predictive value negative) 
of those with normal range test values may be predicted to have a non-failing term 
pregnancy. Although these findings are of interest, they have limited clinical 
applicability in the prediction and management of early pregnancy complications.  
 
When applied to clinical decision-making, our preliminary data suggest that 
measurements of urinary hCG may have utility for selecting viable intrauterine as 
well as failing pregnancies of unknown location and so help triage women at low risk 
of complications. The use of serial creatinine-corrected urine hCG measurements for 
predicting the clinical outcome of PUL gave variable results. Changes in urinary hCG 
over time were unable to reliably predict the location of a pregnancy, and its ability to 
predict EP was poor. However, the accuracy associated with the other two outcomes 
i.e IUP and FPUL, were comparable whether hCG was measured in urine or serum. 
This mirrors the published experience with measurement of serial serum hCG alone 
which is also less accurate for the prediction of EP (66).  
 
The findings relating to the prediction of a FPUL or viable IUP are promising. Women 
with a PUL often have multiple blood tests to measure serum hCG and progesterone 
levels and undergo several TVS examinations before the outcome is certain. The 
majority are discharged with a negative pregnancy test indicating a failed pregnancy 
or after visualising an IUP or EP on TVS. While such intensive follow up is justified 
for the EP group, reducing the number and nature of the follow up required to identify 
women with either an IUP or FPUL would be be a major benefit for patients and 
reduce the burden on health care resources. The latter two groups, who account for 
approximately 70% of the PUL population (61) and constitute a low-risk group for 
complications, could have their follow up rationalized (79). Our data suggest that 
measuring hCG in urine may have the potential to identify this low risk group of PUL. 
Developing “urine specific” algorithms and using first morning urine samples may 
enhance test performance further with the aim of developing a simple test that may 
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enable us to reduce the need for aggressive follow up for the majority of the PUL 
population. 
 
One weakness of our study is that the urine samples analysed although collected in 
the morning, were random. Though more difficult clinically, it is possible that using 
first morning samples may produce more reliable results both for correlation and 
clinical management purposes. In addition, while all blood samples were stored at -
80o C, the urine samples were stored at -20o C.  A recent study has suggested that 
storage at -20oC might affect hCG levels (156).  This, together with the under-
detection of hCGBcf, may account for the lower mean hCG concentration in the urine 
relative to the serum. A further issue is that we used hCG ratio values derived from 
previous studies using serum to interpret changes in urine hCG levels. It may be that 
models based solely from data derived from urinary hCG could be developed that 
would increase the accuracy of changes in urine hCG for predicting PUL outcome 
and diagnosing ectopic pregnancy. The number of samples in the study is sufficient 
to make conclusions about the correlation between serum and urinary levels of hCG. 
However, the number of serial samples available is relatively small and so any 
results in relation to clinical utility should be interpreted with caution. It is very likely 
that a reported accuracy of 100% was achieved due to the fact that the clinical study 
group is too small to be statistically valid. However, this does suggest a trend 
towards significance, which may well be demonstrated with an increased dataset 
size and performance of ROC analysis. By recruiting consecutive PULs we were 
unable to obtain time-matched urine and blood on the patients in the study, but this 
reflects the reality of trying to collect these samples after hours and at weekends, but 
we do not believe there was systematic bias associated with the cases with no 
repeat samples. Notwithstanding these limitations the data are promising in terms of 
developing a test on urine that might help triage women in early pregnancy. 
 
 """""
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4.3 Intra-Uterine Pregnancy of Uncertain Viability (IPUV) "
This was a prospective observational study. After registering the study, recruitment 
took place between November 2009 and March 2011.  
 
In addition to our data at QCH, multi-centre data was also used for the development 
of miscarriage criteria and for the growth study. Centres that have contributed to 
these two studies were St George’s Hospital (SGH), St. Mary’s Hospital (SMH) and 
Chelsea and Westminster Hospital (CWH).  
Women classified with IPUV were eligible for inclusion unless they were clinically 
unstable or subsequently underwent termination of the pregnancy. Indications for 
ultrasonography included lower abdominal pain, vaginal bleeding, poor obstetric 
history and estimation of gestational age. Demographic variables recorded included 
the last menstrual period or known date of conception after infertility treatment, the 
woman’s age and gestational age at presentation. Symptoms recorded included 
vaginal bleeding with or without clots and pain. Outcomes at the follow up visit were 
a viable pregnancy with detectable cardiac activity, non-viable pregnancy or a 
complete miscarriage before the follow-up visit (Figure 20).  
 
 
Figure 20: IPUV studies  
Study 3: post conception  
TVS 
IPUV 
USS criteria for 
miscarriage 
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Growth studies 
N=359 
USS soft markers 
N=171 
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Classifying a pregnancy as IPUV 
 
In three hospitals, IPUV was defined using transvaginal ultrasound according to the 
RCOG green-top guidelines (109) as an intrauterine sac of <20 mm MSD with no 
obvious yolk sac or embryo, or an embryo with a CRL of <6 mm with no fetal heart 
activity. At QCCH the definition of IPUV was extended to include an intrauterine sac 
of < 30 mm MSD or an embryo of < 8 mm. In order to establish immediate viability, 
scans were repeated 7-14 days later.  The final outcome of the study was the 
viability of the pregnancy at 11 to 14 weeks at the time of the routine nuchal 
translucency scan. 
 
Standardised ultrasound assessment  
 
All women underwent an ultrasound assessment using a transvaginal (6–12 MHz) 
transducer for B mode imaging, with a Voluson E8 (GE Medical Systems, Zipf, 
Austria) Aloka SSD 5000 (Aloka Japan) or Medison Accuvix (Medison, Korea). 
Standardized assessments of sonographic variables included measurement of CRL 
crown-rump length, MSD in three orthogonal planes (two in the sagittal plane and 
one in transverse), the presence of a yolk sac and the detection of embryonic 
cardiac activity.  
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4.3.1 MSD and CRL cutoff values for the diagnosis of miscarriage 
 
Objectives  
 
There is significant variation in cut-off values for mean gestational sac diameter 
(MSD) and embryo crown–rump length (CRL) used to define miscarriage, values 
suggested in the literature ranging from 13 to 25 mm for MSD and from 3 to 8 mm for 
CRL. We aimed to define the false-positive rate (FPR) for the diagnosis of 
miscarriage associated with different CRL and MSD measurements with or without a 
yolk sac in a large study population of patients attending early pregnancy clinics. We 
also aimed to define cut-off values for CRL and MSD that, on the basis of a single 
measurement, can definitively diagnose a miscarriage and so exclude possible 
inadvertent termination of pregnancy. "
A total of 1060 women were recruited. The breakdown of cases for each unit is 
shown in (Table 25).  For Queen Charlottes and Chelsea Hospital, of 406 women 
recruited 9 were excluded as measurements of MSD and CRL were missing, leaving 
397 in the analysis. At St Georges hospital, of 540 initially recruited, 80 were 
excluded as viability data were missing and 1 case due to no MSD being available 
leaving 459 in the analysis. For Chelsea and Westminster 22 of 108 women were 
excluded for absent viability data or missing MSD measurements, leaving 86 cases. 
None of the 118 cases from St Mary’s hospital were excluded. Of the total 1060 
women recruited, 473 cases (44.6%) remained viable at follow up scan and 587 
cases (55.4%) were non viable by the time of the follow up scan (Table 25). 
 
For the four centres separately as well as for the combined set, we calculated the 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) for MSD with or without yolk sac from 8 to 30 mm, and for CRL from 3 to 8 
mm.  
 
When the yolk sac and embryo were not visualized on ultrasound scan, the use of an 
MSD of 16 mm to diagnose miscarriage was associated with a false positive rate 
(viable pregnancy) of 4.4% (Table 26).  
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Hospital Group no    viable (%)     non-viable (%) 
QCCH MSD, no YS, no CRL 140 45 (32.1) 95 (67.9) 
MSD, YS, no CRL 165 86 (52.1) 79 (47.9) 
CRL 92 15 (16.3) 77 (83.7) 
SMH MSD, no YS, no CRL 33 13 (39.4) 20 (60.6) 
MSD, YS, no CRL 63 48 (76.2) 15 (23.8) 
CRL 22 3 (13.6) 19 (86.4) 
St Georges MSD, no YS, no CRL 267 117 (43.8) 150 (56.2) 
MSD, YS, no CRL 156 104 (66.7) 52 (33.3) 
CRL 36 2 (5.6) 34 (94.4) 
Chelsea and 
Westminster 
MSD, no YS, no CRL 22 8 (36.4) 14 (63.6) 
MSD, YS, no CRL 35 28 (80) 7 (20) 
CRL 29 4 (13.8) 25 (86.2) 
All centres MSD, no YS, no CRL 462 183 (39.6) 279 (60.4) 
MSD, YS, no CRL 419 266 (63.5) 153 (36.5) 
CRL 179 24 (13.4) 155 (86.6) 
All groups 1060 473 (44.6) 587 (55.4) 
  
Table 25: Data overview from 4 London teaching hospitals 
 
MSD (mm) Sensitivity, % Specificity, % Accuracy, % PPV NPV 
8 49.1 63.9 55.0 0.67 0.45 
10 35.8 80.3 53.5 0.74 0.45 
12 26.5 88.0 50.9 0.77 0.44 
14 17.6 92.9 47.4 0.79 0.43 
16 13.6 95.6 46.1 0.83 0.42 
18 6.5 98.9 43.1 0.90 0.41 
20 2.9 99.5 41.1 0.89 0.40 
21 2.9 100 41.3 1 0.40 
 
Table 26: Sensitivity, specificity, accuracy, PPV and NPV in all centres for selected 
 
 
This false positive rate fell to 0.5% with an MSD of 20 mm. There were no 
misdiagnosed cases when an MSD of > 21 mm was used.  When the yolk sac was 
visualized the false positive rate was 2.6% and 0.4% at MSD of 16 and 20 mm, 
respectively, with no misdiagnosed cases when the MSD was > 21mm (Table 27). 
MSD (mm) Sensitivity, % Specificity, % Accuracy, % PPV NPV 
8 69.9 35.7 48.2 0.38 0.67 
10 47.7 59.8 55.4 0.41 0.67 
12 36.6 77.8 62.8 0.49 0.68 
14 27.5 91.7 68.3 0.66 0.69 
16 20.9 97.4 69.5 0.82 0.68 
18 13.7 98.1 67.3 0.81 0.66 
20 9.8 99.6 66.8 0.94 0.66 
21 9.2 100 66.8 1 0.66 
 
Table 27: Sensitivity, specificity, accuracy, PPV and NPV in all centres for selected MSD cutoff 
values with  yolk sac but no embryo 
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For an embryo where the CRL measured 4 mm the false positive rate for miscarriage 
was 8.3%, and at 5mm 8.3%. There were no false positive results for a CRL ≥5.3mm 
(Table 28). False positive rates and optimal cutoff values were similar for the 4 units 
individually.  
 
CRL (mm) Sensitivity, % Specificity, % Accuracy, % PPV NPV 
3 71.6 75.0 72.1 0.95 0.29 
3.2 67.1 83.3 69.3 0.96 0.28 
3.4 63.9 87.5 67.0 0.97 0.27 
3.6 61.9 87.5 65.4 0.97 0.26 
3.8 56.8 87.5 60.9 0.97 0.24 
4 49.7 91.7 55.3 0.97 0.22 
4.2 41.9 91.7 48.6 0.97 0.20 
4.4 37.4 91.7 44.7 0.97 0.18 
4.6 34.2 91.7 41.9 0.96 0.18 
4.8 29.7 91.7 38.0 0.96 0.17 
5 22.6 91.7 31.8 0.95 0.15 
5.2 20.0 91.7 29.6 0.94 0.15 
5.3 16.8 100 27.9 1 0.16 
 
Table 28: Sensitivity, specificity, accuracy, PPV and NPV in all centres for selected CRL cutoff 
values in absence of a fetal heart activity 
 
 
If a cutoff of 16 mm for MSD had been used for those 462 women with an empty 
gestational sac, 38 of 279 (13.6%) miscarriages would have been foreseen at first 
scan, whilst 8 out of 183 viable pregnancies (4.4%) would have been terminated if 
these women with IPUV had gone forward to surgical or medical evacuation of the 
pregnancy. When a yolk sac was visible, 32 out of 153 miscarriages (20.9%) and 7 
of 266 viable pregnancies (2.6%) had an MSD of  > 16 mm. 
 
Discussion 
 
To our knowledge this is the largest prospective study carried out to assess the 
criteria currently used to define miscarriage using ultrasound. We have shown that 
national guidelines should be reviewed or applied with caution if pregnant women 
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are to be confident that when they are informed that they have suffered a 
miscarriage.  
 
A strength of this study is that it was prospective and took place in four different early 
pregnancy units, so the results are unlikely to be a reflection of an individual unit or 
clinician’s practice. In addition the ultrasound scans were all carried out on high-
quality equipment, and by practitioners with a special interest in the diagnosis and 
management of early pregnancy complications. It is therefore likely that the quality of 
any ultrasound examination performed is relatively good. The results therefore may 
reflect the “best case” scenario, with more false positive results for miscarriage 
occurring with less experienced operators or with poor equipment. Using viability at 
11 to 14 weeks as the primary outcome measure is also more clinically useful, as 
around 14% of first trimester pregnancies with visualised cardiac activity 
subsequently miscarry"(124), while the miscarriage rate after 12 weeks is very much 
lower.  This has allowed us to demonstrate that empty sacs with an MSD greater 
than those currently used to define miscarriage may remain viable and are not a 
definitive marker of impending pregnancy failure. A weakness of the study is that 
despite the large number of cases included, there are still a relatively small number 
of cases at or around the critical decision boundaries used to define miscarriage. 
 
Unpublished data of a recent survey conducted by the association of early 
pregnancy units in the United Kingdom (UK) illustrates the size of the potential 
problem (157) . This survey suggests that at least 500,000 women attend such units 
each year. The prevalence of IPUV with an empty gestation sac of < 20 mm in a 
recent publication of all women attending such an early pregnancy unit was 16% 
(158).  If we apply a cutoff for MSD in the absence of a yolk sac to define 
miscarriage of 16 mm, this would lead to 3520 viable pregnancies in the UK each 
year being classified as a miscarriage and potentially undergoing termination. To put 
this in context, this compares to approximately 4000 stillbirths reported in the UK 
annually"(159). Applying a cutoff for MSD of 20 mm leads to 400 viable pregnancies 
being misclassified, compared to approximately 300 “cot deaths” reported in the UK 
each year"(160). These numbers are significant and relate to pregnancies that would 
be highly likely to reach term"(161).   
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Our recent study on the inter- and intra-observer variability of MSD and CRL 
measurements revealed that for MSD, the limits of agreement were ± 18.78%"(120). 
So, an MSD measurement of 20 mm by one examiner may translate to a 
measurement anywhere between 16.8 to 24.5 mm for a second examiner.  
Furthermore, for a CRL measurement of 6 mm the range for a second examiner is 
between 5.4 mm and 6.7 mm. This suggests that safe cutoff values to define 
miscarriage may have to be significantly increased to exclude any errors. These data 
suggest that decisions to intervene and allow the potential termination of a viable 
pregnancy are being taken based on inappropriate guidance. It is now almost twenty 
years since the landmark Cardiff enquiry in the UK into cases of early pregnancy 
inappropriately classified as a miscarriage. This report essentially emphasized the 
Hippocratic oath “to do no harm”. A version of this report was published in 1995"
(112).  For most women with a possible miscarriage there is nothing we can do to 
prevent it happening but there are many things we can do to intervene 
inappropriately.   
 
The problem does not just relate to clinicians. Patient expectation needs to be 
managed as well.  Home pregnancy tests are leading to more women knowing they 
are pregnant at an earlier stage. If they attend for a scan it is more likely that they will 
have an inconclusive result and so be potentially at risk of a diagnostic error. Patient 
groups have a role to play by educating women that a result is not always possible 
on the basis of one scan or blood test. The management of miscarriage has also 
changed. In many developed countries, many can now be managed expectantly 
without the need for medical treatment or surgery. Waiting a week to 10 days in 
order to repeat a scan is highly unlikely to lead to physical harm. Undoubtedly the 
anxiety associated with being uncertain about the status of a pregnancy is very 
significant. However inadvertent termination of a wanted pregnancy is surely the 
worst possible outcome for any women. Taking inter and intra-observer variation of 
measurements into account, an empty MSD cutoff of 24.9 mm, MSD cutoff with a 
yolk sac present of 24.9 mm and CRL cutoff of 6.1 mm could be introduced, and 
based on the available evidence, would be associated with a minimal risk of a false 
positive diagnosis of miscarriage. ""
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4.3.2 Gestational sac and embryonic growth  "
 
Objectives  
 
We studied changes in mean gestational sac diameter (MSD) and embryonic crown–
rump length (CRL) in intrauterine pregnancies of uncertain viability (IPUVs). We 
aimed to establish cut-off values for MSD and CRL growth that could be definitively 
associated with either viability or miscarriage, and to establish the relationship 
between growth in MSD and appearance of embryonic structures in the gestational 
sac. 
 
Of 359 women included in the study, 192 cases (53.5%) were viable at 12 weeks, 
whilst 167 cases (46.5%) had failed by 12 weeks (Table 29). Growth in CRL and 
MSD and the difference in growth according to diagnosis and appearance of 
embryonic structures were studied. Growth was considered independent of 
gestational age, in order to include all cases, regardless of availability of date of the 
last menstrual period. Growth in CRL and MSD between the first and second scan of 
each pregnancy was expressed in mm/day for viable versus non-viable pregnancies 
separately and for pregnancies with or without a certain embryonic structure. The 
two-sample t-test was applied with the null hypothesis that viable and non-viable 
pregnancies follow the same distribution for growth rate with equal mean. Analyses 
were performed in Matlab R2011a for mac. 
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Hospital Group no    Viable (%)     Non-viable (%) 
QCCH MSD 196 109 (55.6) 87 (44.4) 
CRL 30 11 (36.7) 19 (63.3) 
SMH MSD 62 45 (72.6) 17 (27.4) 
CRL 7 2 (28.6) 5 (71.4) 
St Georges MSD 37 3 (8.1) 34 (91.9) 
CRL 1 0 (0.0) 1 (100) 
Chelsea and 
Westminster 
MSD 64 35 (54.7) 29 (45.3) 
CRL 16 3 (18.7) 13 (81.3) 
All centres MSD 359 192 (53.5) 167 (46.5) 
 MSD, empty at 
both scans 
47 0 (0.0) 47 (100.0) 
 MSD, empty at 
first scan only 
76 50 (65.8) 26 (34.2) 
 MSD, non-empty 
at both scans 
218 142 (65.1) 76 (34.9) 
 CRL 54 16 (29.6) 38 (70.4) 
 All groups 359 192 (53.5) 167 (46.5) 
 
Table 29: Overview different categories of IPUV from 4 London teaching hospitals with 
inclusion of pregnancies with at least 2 scans during first trimester 
 
 
An overlap in MSD growth rate was seen between the viable and non-viable groups 
of IPUV. The MSD growth rate was significantly higher in the viable than the non-
viable group (mean 1.003 vs. 0.503 mm/day; p<0.001; 95% CI [0.403; 0.596]). 
Median growth rate for MSD (25th–75th percentile) was 0.965 [0.803 – 1.176] in the 
viable compared to the non-viable group 0.460 [0.170 – 0.849] (Table 30).  This is 
notable in Figure 21 which illustrates growth trends of MSD measurements between 
the two scans according to the final outcome. The interaction between MSD 
measurement at first scan, MSD growth rate and the first trimester outcome can be 
seen in Figure 22. It shows that the majority of MSD measurements are less than 15 
mm on first scan.  A significant difference in CRL growth was also found between the 
two groups respectively (mean 0673 vs. 0.148 mm/day; p<0.001; 95% CI [0.345; 
0.703] with the CRL median growth rate (25th–75th percentile) being 0.661 [0.5-
0.904] and 0.068 [-0.022 - 0.2] in the viable and non-viable groups respectively. No 
overlap was observed in CRL growth rate ranges between the viable and non-viable 
groups (Table 31). This can also be seen in Figure 23 which shows growth trends of 
CRL measurements between the two scans according to the final outcome. The 
interaction between CRL measurement at first scan, CRL growth rate and the first 
trimester outcome can be seen in Figure 24. It also shows that the majority of CRL 
measurements are less than 3 mm on first scan.   
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 Non-viable Viable 
Number of pregnancies 167 192 
Mean growth rate (std) 0.503 (0.564) 1.003 (0.356) 
Median growth rate (25th – 75th percentile) 0.460 [0.170 0.849] 0.965 [0.803 1.176] 
p-value two-sample t-test <0.0001 (1.8e-21) 
95% confidence interval of the true mean of the difference 
in growth rate between viable and non-viable pregnancies 
[0.403 0.596] 
 
Table 30: The growth MSD related to the DIAGNOSIS AT 12 WKS (growth rate expressed in 
mm/day)  
 
 
 
Figure 21: MSD growth in pregnancies with viable (blue) and non-viable (red) outcome at 12 
weeks 
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Figure 22:  The interaction between MSD measurement at first scan, MSD growth rate and the 
first trimester outcome. The majority of MSD measurements are less than 15 mm on first scan 
 
 
 
 Non-viable Viable 
Number of pregnancies 38 16 
Mean growth rate (std) 0.148 (0.330) 0.673 (0.208) 
Median growth rate (25th – 75th percentile) 0.068 [-0.022- 0.2] 0.661 [0.5-0.904] 
p-value two-sample t-test <0.0001 (3.1e-7) 
95% confidence interval of the true mean of the difference 
in growth rate between viable and non-viable pregnancies 
[0.345 0.703] 
 
Table 31: The growth in CRL related to the DIAGNOSIS AT 12 WKS (growth rate expressed in 
mm/day) 
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Figure 23: CRL growth in pregnancies with viable (blue) and non-viable (red) outcome at 12 
weeks "
 
 
Figure 24:  The interaction between CRL measurement at first scan, CRL growth and the first 
trimester outcome. The majority of CRL measurements are less than 3 mm on first scan 
 
Cutoff values to define miscarriage in the 4 units were generated, and the sensitivity, 
specificity, accuracy, positive predictive values and negative predictive values in 
terms of miscarriage prediction (growth rate smaller than the cut-off) were calculated. 
The results are show in (Table 32).  
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Growth 
cut-off 
Sens Spec Acc PPV NPV TP FN TN FP 
-2 0 100 53.5 n/a 0.53 0 167 192 0 
-1.8 0.6 100 53.8 1 0.54 1 166 192 0 
-1.6 0.6 100 53.8 1 0.54 1 166 192 0 
-1.4 0.6 100 53.8 1 0.54 1 166 192 0 
-1.2 0.6 100 53.8 1 0.54 1 166 192 0 
-1.0 0.6 100 53.8 1 0.54 1 166 192 0 
-0.8 1.8 100 54.3 1 0.54 3 164 192 0 
-0.6 1.8 100 54.3 1 0.54 3 164 192 0 
-0.4 3.0 100 54.9 1 0.54 5 162 192 0 
-0.2 8.4 100 57.4 1 0.56 14 153 192 0 
0 13.2 100 59.6 1 0.57 22 145 192 0 
0.2 28.7 99.0 66.3 0.96 0.61 48 119 190 2 
0.4 43.1 94.8 70.8 0.88 0.66 72 95 182 10 
0.6 61.7 90.1 76.9 0.84 0.73 103 64 173 19 
0.8 73.7 75.0 74.4 0.72 0.77 123 44 144 48 
1.0 80.8 45.3 61.8 0.56 0.73 135 32 87 105 
1.2 88.6 24.0 54.0 0.50 0.71 148 19 46 146 
1.4 94.6 10.9 49.9 0.48 0.70 158 9 21 171 
1.6 97.6 7.8 49.6 0.48 0.79 163 4 15 177 
1.8 98.8 2.6 47.4 0.47 0.71 165 2 5 187 
2.0 99.4 1.6 47.1 0.47 0.75 166 1 3 189 
2.2 99.4 0.5 46.5 0.46 0.50 166 1 1 191 
2.4 99.4 0 46.2 0.46 0 166 1 0 192 
2.6 99.4 0 46.2 0.46 0 166 1 0 192 
2.8 100 0 46.5 0.47 n/a 167 0 0 192 
 
Table 32: The performance of different cutoff values for MSD growth (in mm/day) to predict 
miscarriage 
 
 
When the growth rate for MSD between two scans is 0.2 mm/day the specificity of a 
diagnosis of miscarriage was 99% with 2 false positive test results. An MSD growth 
rate of 0.6 mm/day was associated with a specificity of 90.1%, a sensitivity of 61.7% 
and 19 false positive test results.  
 
A similar table was generated for CRL growth rates (mm/day). Interestingly at a 
mean CRL growth rate of 0.2mm/day miscarriage was diagnosed with a specificity of 
100% with no false positive cases. At a CRL growth rate of 0.6 mm/day the 
specificity to diagnose miscarriage is 56.3% with 7 false positive cases (Table 33). 
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Growth 
cut-off 
Sens Spec Acc PPV NPV TP FN TN FP 
-0.6 0 100 29.6 n/a 0.30 0 38 16 0 
-0.4 5.3 100 33.3 1 0.31 2 36 16 0 
-0.2 5.3 100 33.3 1 0.31 2 36 16 0 
0 26.3 100 48.1 1 0.36 10 28 16 0 
0.2 76.3 100 83.3 1 0.64 29 9 16 0 
0.4 76.3 87.5 79.6 0.94 0.61 29 9 14 2 
0.6 89.5 56.3 79.6 0.83 0.69 34 4 9 7 
0.8 94.7 31.3 75.9 0.77 0.71 36 2 5 11 
1.0 97.4 0 68.5 0.70 0 37 1 0 16 
1.2 100 0 70.4 0.70 n/a 38 0 0 16 
 
Table 33: The performance of different cutoff values for CRL growth (in mm/day) to predict 
miscarriage 
 
 
When the gestational sac was empty on both the first scan and initial follow up scan 
all cases (47) ended with miscarriage. When gestation sacs described as being 
empty on the first scan developed embryonic features by the time of the initial follow 
up scan, 26 cases miscarried and 50 were viable. Of those sacs with embryonic 
structures visible on both scans 76 cases miscarried and 142 were viable (Table 29).  
 
In the miscarriage group the appearance of these embryonic structures had a 
significant influence on the MSD growth rates. Pregnancies with empty sacs at both 
scans compared to those with non-empty sac at both scans had a mean growth rate 
of 0.278 and 0.569 mm/day respectively (P=0.006). Furthermore, empty sacs that 
developed embryonic structures on the second scan grew at a higher rate of 0.827 
mm/day. This was also significant when compared to the growth rate when there 
was an empty sac at both scans (P=0.04) (Table 34). On the other hand, the 
appearance of embryonic structures had no significant influence on the MSD growth 
in the viable cases (Table 34). MSD growth rates when embryonic structures were 
present at both scans were comparable to those when the whole dataset was 
examined regardless of the appearance of embryonic structures (Table 35). 
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 Miscarriage Viable 
Embryonic structures Mean growth rate 
(std) 
P-value two-sample 
t-test wrt non-
empty at both 
scans 
Mean growth rate 
(std) 
P-value two-
sample t-test wrt 
non-empty at both 
scans 
Non-empty at both 
scans 
0.569 (0.573)  1.000 (0.387)  
Empty at first scan only 0.827 (0.460) 0.040 1.010 (0.255) 0.874 
Empty at both scans 0.278 (0.530) 0.006   
 
Table 34: MSD growth in function of appearance of embryonic structure 
 
 
 
Growth 
cut-off 
Sens Spec Acc PPV NPV TP FN TN FP 
-0.6 0 100 65.1 NaN 0.65 0 76 142 0 
-0.4 1.3 100 65.6 1 0.65 1 75 142 0 
-0.2 9.2 100 68.3 1 0.67 7 69 142 0 
0 11.8 100 69.3 1 0.68 9 67 142 0 
0.2 30.3 98.6 74.8 0.92 0.73 23 53 140 2 
0.4 39.5 93.7 74.8 0.77 0.74 30 46 133 9 
0.6 56.6 87.3 76.6 0.70 0.79 43 33 124 18 
0.8 67.1 71.8 70.2 0.56 0.80 51 25 102 40 
1.0 75.0 43.7 54.6 0.42 0.77 57 19 62 80 
1.2 86.8 25.4 46.8 0.38 0.78 66 10 36 106 
1.4 93.4 12.7 40.8 0.36 0.78 71 5 18 124 
1.6 96.1 9.2 39.4 0.36 0.81 73 3 13 129 
1.8 98.7 2.8 36.2 0.35 0.80 75 1 4 138 
2.0 98.7 2.1 35.8 0.35 0.75 75 1 3 139 
2.2 98.7 0.7 34.9 0.35 0.50 75 1 1 141 
2.4 98.7 0 34.4 0.35 0 75 1 0 142 
2.6 98.7 0 34.4 0.35 0 75 1 0 142 
2.8 100 0 34.9 0.35 N/A 76 0 0 142 
 
Table 35: Cutoff values for mean MSD growth (in mm/day) for the prediction of miscarriage 
when non-empty at both scans.  N=218 
 
 
 
Discussion 
 
Our results in the growth study carry some important implications on the diagnosis 
and management of miscarriage. We have shown that slow or absent gestation sac 
growth is not necessarily associated with miscarriage. We have also demonstrated 
that CRL growth can be very slow in pregnancies that subsequently turn out to be 
viable at 11 to 14 weeks gestation. These findings are a concern when set against 
many protocols used to define miscarriage in early pregnancy. Our data further 
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showed that the failure to visualise a yolk sac or embryo on a repeat scan after at 
least 7 days was always associated with miscarriage. 
 
A recent study reported that 29% of women attending an inner London early 
pregnancy assessment unit (EPAU) were classified as having an IPUV according to 
current United Kingdom criteria (158). The majority of these were empty gestation 
sacs. Current guidelines advise that in such cases a repeat scan should be arranged 
seven to ten days later. However these guidelines to not stipulate what findings on a 
repeat scan can definitively be used to define a miscarriage. There is an inference 
that if the pregnancy is viable the gestation sac should grow in the time interval 
between scans and/or a yolk sac or embryo should become visible. The finding of an 
IPUV where the gestation sac does not grow over a time interval of 7 days and 
where no embryonic structure has appeared is highly likely to be labelled as a 
miscarriage.   
 
In the present study we have shown a clear overlap in gestation sac (expressed as 
MSD) growth rates between viable and non-viable IPUV. Therefore, we were unable 
to establish daily or weekly MSD growth cutoff values below which a diagnosis of 
miscarriage can be safely made. The results were different with embryo (expressed 
as CRL) growth rates. Below a CRL growth rate of 0.2 mm/day pregnancies were 
associated with miscarriage with a specificity of 100%.   This means that a CRL that 
grows by as little as 1.4 mm in a week or 2.8 mm in 2 weeks can potentially be 
associated with a viable pregnancy.  
 
These findings are a concern, especially as our recent study of the inter- and intra-
observer variability of MSD and CRL measurements showed that for MSD, the limits 
of agreement were ± 18.78% (120). This means that an MSD measurement of 20 
mm by one examiner may be measured anywhere between 16.8 to 24.5 mm for a 
second examiner.  Furthermore, for a CRL measurement of 6 mm the range for a 
second examiner is between 5.4 mm and 6.7 mm. Applying these figures to MSD 
and CRL measurements around the decision boundaries makes it clear that there 
can be an absence of gestation sac or embryonic growth over at least a week and 
the pregnancy may still be viable. Whilst  the MSD and CRL growth rate in viable 
pregnancies is thought to be always > 0.6 mm/day (121, 132), our data shows that 
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using this cutoff in the growth rate to diagnose miscarriage is associated with a 
significant false positive rate of 12.2% and 37.5% respectively. 
 
The results of our study show that if a gestation sac is empty on an initial scan, a 
failure for a yolk sac or embryo to be visible on a second scan seven or more days 
later was always associated with miscarriage, As might be expected there was a 
significant difference in the growth rate of gestation sacs that remained empty 
compared to those where an embryonic structure was present on one or both initial 
scans.  
 
 Although a large number of IPUV were included in the study, a weakness of the 
study is the relatively small number of cases with slow growth in the dataset that 
remained viable.  Furthermore only a small number of IPUV showed an absence of 
embryonic structures on both scans. 
 
The results of this study are in keeping with our findings on the MSD and CRL cutoff 
values for the diagnosis of miscarriage, discussed earlier in this document.  Our data 
suggest that some of the presumptions made about IPUV, gestation sac growth and 
viability should be questioned. We have demonstrated that pregnancies may be 
viable despite little or no growth in MSD over quite prolonged periods, however we 
did observe and that an absence of embryonic structures from a gestation sac on 
two separate scans 7 to 14 days apart may be a definitive sign of miscarriage. The 
number of cases fulfilling these criteria in the study was relatively small, and larger 
prospective studies are needed to confirm this. The difference in CRL growth 
between viable and non-viable pregnancies is significant. However the inter-observer 
variation inherent to measurement of CRL means that care must be taken before 
assuming a slow growing embryo will always miscarry.  
 
Current protocols in the UK and elsewhere make a presumption that in the event of 
an IPUV, if a repeat scan shows no growth in the gestation sac, then this is definitive 
evidence of a miscarriage. Similar assumptions are made about an absence of 
growth in CRL. Our data suggest great care should be taken before making a 
diagnosis of miscarriage in these circumstances and guidance should be reviewed to 
reflect this. 
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4.3.3 Sonographic soft markers and clinical symptoms in IPUV "
Objectives  
 
To assess the potential influence of vaginal bleeding, pain, gestation sac shape 
(GSS), and the presence or absence of subchorionic haematoma (SCH) in predicting 
viability among intrauterine pregnancies of uncertain viability (IPUV). We 
hypothesised that these soft markers may predict the outcome in this group, and a 
miscarriage index can be potentially designed to prospectively identify (IPUV) that 
are destined to miscarry at an earlier stage. 
 
One hundred and seventy one cases classified as IPUV on initial scan were 
included. Gestational sac morphology, presence or absence of SCH and clinical 
symptoms were analysed according to the final outcome. Of the total 171 
pregnancies recruited, 87 cases (51%) remained viable at the follow up scan and 84 
cases (49%) miscarried. All gestational sac measurements were performed 
transvaginally in a gestational age range from 35 to 84 days. 
 
In order to study the influence of gestational sac morphology, SCH and clinical 
symptoms on the final outcome, we conducted a frequency analysis with the two-
sided Fisher exact test using SAS. Further details are explained in the results 
section.  
 
Table 36 shows the influence of the following factors on the diagnosis (viable vs. 
non-viable): 
• Gestational sac shape (regular or irregular) 
• Presence or absence of SCH 
• Site of SCH: below the sac, next to sac or above the sac 
• Pain 
• Vaginal bleeding: with or without clots  
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 Viable Non-viable Two-sided p-value Fisher exact test 
Sac shape    
Regular 81 15  
Irregular 6 21 2.6e-9 
SCH    
Absent 66 27  
Present 21 9 1.00 
Site haematoma    
Below to sac 6 1  
Next to sac 6 6  
Above to sac 9 2 0.2063 
SCH below    
Absent 66 27  
Below to sac 6 1 0.6696 
SCH next    
Absent 66 27  
Next to sac 6 6 0.1869 
SCH above    
Absent 66 27  
Above to sac 9 2 0.7236 
PC pain    
No pain 49 29  
Pain 39 8 0.0253 
PC clots    
PVB clots 3 4  
PVB no clots 28 15 0.4039 
PC bleeding    
No bleeding 57 18  
Bleeding (with/without clots) 31 19 0.1113 
PC 3 categories    
No bleeding 57 18  
PVB clots 3 4  
PVB no clots 28 15 0.1008 
 
Table 36: the influence of the different factors on the diagnosis (viable vs. non-viable). An 
irregular sac shape occurs significantly more in non-viable pregnancies (p-value 2.6e-9) 
 "
Regular sacs were reported in 81 of 171 total cases (47%). The sensitivity, 
specificity, positive predictive vlaue PPV and negative predictive value NPV of 
regular sac shape in predicitng viability were 93%, 60%, 70% and 89%. An irregular 
sac shape occurs significantly more in non-viable pregnancies (P<0.001) (Table 36).  "
The presence or absence of SCH was reported in 123 cases. Of these, SCH was 
present in 30/123 (24%) cases. In 43% of the cases, the haematoma was located 
above the gestational sac as opposed to next or below the sac. Neither the presence 
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or absence of SCH nor its location was found to be statistically relevant to the 
outcome at the second visit (Table 36).  "
Vaginal bleeding was reported in 35% and 51% of the viable and non-viable groups 
respectively. Vaginal bleeding irrespective of its severity, with or without clots, was 
not found to have a significant impact on viability. However, pain as a presenting 
complaint was found to have a statistically significant association with final outcome 
(P=0.025) (Table 36).  
 
 
 
Discussion  
 
 
This is the first study which prospectively follows up IPUV pregnancies and 
investigates the role of different sonographic parameters and clinical symptoms in 
predicting viability. We hoped that this can provide adjunct counselling tools when 
dealing with pregnancies of uncertain viability. Indeed, this is a clinically and 
psychologically challenging situation. Evidence suggests that early pregnancy loss 
can be a highly distressing event with some women even rating it amongst the worst 
traumatic events that they have ever experienced. Appropriate support and 
counselling offered to women at risk of miscarriage was shown to have significant 
beneficial effects (162)"(163).  
 
Morphological description of the early gestational sac has not been well established. 
One study in 1986 used two criteria; large sac and distorted shape, which had 100% 
specificity and were called major criteria (132). Using the 3D and VOCAL early 
normal gestational sacs were described as ellipsoid or discoid structures with a 
concave indentation from the placenta (133)" (134) and it was suggested that 
morphological and quantitative analysis of the gestational sac may be helpful in 
predicting early pregnancy failure. In this study we have shown that regular 
gestational sac shape can be used to predict viability in IPUV, whereas an irregular 
sac is invariably associated with miscarriage.  
 
One limitation to this study is that the description of the sac shape is subjective and 
may not be always reproducible. This remains a challenge to ultrasound reporting of 
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“normal” and “abnormal” shapes even with the more advanced technologies such as 
3D (134). However it has always been postulated that ultrasound is an operator-
dependant examination and, to a large extent, it depends on pattern recognition 
(117) (119). 
 
Our data reveals no role for the presence or absence of sub-chorionic haematomas 
(SCH) in determining the viability of IPUV. This is irrespective of its site in relation to 
the gestational sac within the uterine cavity. In contrast, the literature suggests a 
clear influence of SCH on viability and ultimate pregnancy outcome (164). The 
presence and size of SCH have been proposed as sonographic markers associated 
with early spontaneous miscarriage and late pregnancy problems (128)" (130)" (164)"
(165)"(166)"(167). Such an effect may possibly be demonstrated with a large sample 
size or in a prospective study on selected cohort of pregnancies with SCH.  
 
Similarly, we have shown no statistically significant role for the vaginal bleeding in 
predicting the viability of IPUV. In the literature, vaginal bleeding was shown to be of 
less influence on immediate or long-term pregnancy outcome when it occurs in the 
early first trimester (168). However, when it occurs at 7–12 weeks, even in the 
presence of detectable fetal cardiac activity, it increases the risk of miscarriage and 
also leads to adverse pregnancy outcome at later gestations (131) (169)"(170)"(171). 
This is consistent with our findings since the gestational age in most of the IPUV 
pregnancies is less than 7 weeks. """"""""""""""
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5 Conclusions  ""
Early pregnancy loss accounts for over 50,000 admissions in the UK annually. The 
rate of ectopic pregnancy is 11 per 1000 pregnancies, with a maternal mortality of 
0.2 per 1000 estimated ectopic pregnancies (172).  Miscarriage is the most common 
complication of pregnancy. This is largely attributable to the high incidence of 
embryo loss, estimated to be 30% prior to implantation (pre-implantation loss) and a 
further 30% before 6 weeks gestation (pre-clinical/biochemical pregnancy loss) (3). 
In addition, in excess of 10% of clinical pregnancies result in miscarriage, mostly 
prior to 12 weeks gestation, and 1-2% of couples experience recurrent pregnancy 
loss (135). In addition to the physical trauma, evidence suggests that early 
pregnancy loss (EPL) can be a highly distressing event with some women even 
rating it amongst the worst traumatic events that they have ever experienced (162).  
Improvement in the diagnosis and management of early pregnancy loss is therefore 
of vital importance, in order to reduce the incidence of the associated psychological 
morbidity and avoid the unnecessary deaths of women with ectopic pregnancies as 
well as to improve cost effectiveness.  
 
The advancement in ultrasound technology has led to the development of 3D-
ultrasound and 3D-Doppler studies which enable a more detailed examination of 
uterine morphology and blood flow. This, alongside the evolving insight into the 
biochemistry of the endometrium and its relationship with embryo selection and 
miscarriage, offered an opportunity to improve our understanding and optimize our 
management of early pregnancy complications from the preconception phase, 
through early implantation, to the post conception phase.  
 
Our endometrial blood flow studies suggest that the 3D and 3D Doppler technology 
may have the potential to be used for the prospective assessment of the quality of 
decidualisation response in the endometrium, and when this is tested in 
appropriately sized studies, it may offer a tool to predict the likelihood of successful 
implantation and pregnancy outcome.  Examining the events leading to implantation 
using the available biochemistry we observed that pregnancies that ended in 
miscarriage were associated with longer O-I intervals. This was especially so in 
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women with a history of RM. the results offer further in vivo evidence that 
miscarriage, and especially RM, may be caused by prolonged endometrial receptivity 
and out-of-phase implantation.  
 
In the early pregnancy studies, we established a number of new concepts using 
ultrasound and biochemistry. We examined the proposed nomenclature for PUL 
using subjective interpretation of ultrasound findings. We generated 
recommendations with regards to definitions of PUL and provided evidence that care 
must be taken when diagnosing an IUP or EP on the basis of a small gestation sac 
or homogenous mass without a visible yolk sac or embryo. In the management of 
PUL with serial hCG testing, we demonstrated that women can be given some 
flexibility when returning for a second sample, as long as the time between both 
measurements is between 42 and 54 hours. This highlights the potential for 
examining the reliability of using shorter time intervals for the hCG ratio, such as 24 
hours. Undoubtedly the management of PUL takes up a significant amount of time 
and resources in units caring for women with early pregnancy complications. By far 
the majority of PUL are low risk and the number of blood tests and visits to hospital 
for review represent a significant burden both on patients and clinicians. We have 
shown that the M4 prediction model with a modification to the risk cut-off could be 
used to reduce follow-up in over 70% of PUL. This would make more time available 
to concentrate on women at high risk of complications and potentially better use of 
resources. The good performance of M4 when validated externally suggests that the 
use of this approach prospectively would lead to a change in the management of the 
majority of women with a PUL and a more efficient use of resources. When we 
examined the potential role for urine hCG testing in the management of PUL. There 
was a significant and promising correlation between urine and serum hCG 
measurements. Although serial serum hCG measurements appear to be slightly 
better than urine for the overall prediction of PUL outcome, serial urine hCG 
measurements may have a role in identifying the above mentioned low-risk PUL that 
require less intensive clinical follow up.  
 
Later in early pregnancy, we have shown that some current definitions used to 
diagnose miscarriage are potentially unreliable. Furthermore, we studied the growth 
of pregnancies of uncertain viability in a longitudinal fashion.  Interestingly, we found 
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that, unlike MSD growth, cutoff values for CRL growth rates can be suggested below 
which a miscarriage is predicted. However this should be considered carefully in light 
of the inter and intra-observer variability of first trimester measurements. We 
proposed that national guidelines, adopted prior to our studies, should be reviewed 
to avoid inadvertent termination of wanted pregnancies.  """""""""""""""""""""""""""""""""
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ABSTRACT
Emerging evidence suggests that early embryo implanta-
tion is a more active maternal process than hitherto appre-
ciated, involving active encapsulation of the implanting
blastocyst by maternal decidual cells and coordinated
changes in the underlying inner myometrium, known as
the junctional zone. These concepts raise the possibil-
ity that early ultrasound markers predictive of adverse
pregnancy outcome could be identified. In this review we
assess the role of ultrasound in predicting the likelihood
of different pregnancy outcomes and highlight potential
novel markers that could be tested. Copyright © 2012
ISUOG. Published by John Wiley & Sons, Ltd.
INTRODUCTION
Successful embryo implantation can take place only
in a receptive uterus. In human beings, the uterus
becomes receptive during the mid-secretory phase (days
19–23) of the menstrual cycle, a functional period
widely referred to as the window of implantation
(WOI)1–3. During this transient WOI, the endometrium
undergoes profound molecular changes that enable a
developmentally competent blastocyst to contact the
luminal epithelium and then invade the underlying
stroma4. Importantly, the signals that induce this
receptive phenotype in the luminal epithelium are derived
from underlying stromal cells5. In fact, the WOI is
characterized by profound changes in this stromal
compartment, which include recruitment of specialized
natural killer cells, vascular remodeling and – perhaps
most striking – transformation of stromal fibroblasts into
specialized rounded decidual cells4,6,7.
Decidual transformation of the stromal compartment
occurs only in those mammalian species where implan-
tation involves breaching of maternal tissues by the
embryo8,9. Furthermore, a correlation exists between the
extent of the decidual process and the depth of trophoblast
invasion among various species7. Human placenta forma-
tion, however, involves not only trophoblast invasion of
the maternal decidua but also of the inner layer of the
myometrium, a highly specialized uterine structure known
as the junctional zone (JZ). Importantly, trophoblast inva-
sion of the decidua and JZ, which forms the placental bed,
is not only interstitial but also intravascular9–11. In fact,
this process of intravascular trophoblast invasion criti-
cally controls the transformation of high-resistance, low-
capacity spiral arteries into low-resistance, high-capacity
vessels of pregnancy9,12. In other words, the decidua and
JZ form a functional unit that largely determines the
likelihood of successful pregnancy outcome13.
The current model of fetal–maternal interactions views
the trophoblast as the active invader of the passive
decidua. However, this paradigm has been challenged
by recent observations demonstrating that decidual cells
acquire an invasive phenotype upon contact with the
trophoblast14. Rather than being passively invaded, decid-
ual cells may in fact actively encapsulate embryos that
breach the luminal epithelium. Furthermore, emerging
evidence suggests that decidual cells are programmed to
respond to embryos of limited developmental potential,
thus serving as biosensors that enable the mother to limit
investment into failing pregnancies15. Furthermore, it has
been suggested that impaired decidualization is associ-
ated with a prolonged WOI and lack of embryo quality
control, thus facilitating implantation of developmentally
compromised embryos15. This concept is supported by the
landmark study of Wilcox and colleagues, demonstrating
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that implantation delayed beyond the conventional WOI
is strongly associated with early pregnancy loss16.
These observations suggest that prospective assessment
of the quality of decidualization response in the
endometrium may be an important tool for predicting
the likelihood of successful implantation and pregnancy
outcome. Since its introduction into the clinic, ultrasound
has been used widely to assess uterine features such as
endometrial thickness, endometrial pattern and uterine
blood flow that may be predictive of pregnancy, especially
in the context of assisted reproductive technology.
Furthermore, the development of three-dimensional (3D)
ultrasound and 3D Doppler studies has enabled a
much more detailed examination of uterine morphology,
including visualization of the JZ.
In this review, we critically assess the role of various
ultrasound techniques and markers in predicting the
likelihood of conception and subsequent pregnancy
outcome. In addition, we argue that, with the introduction
of high-resolution ultrasound technologies, imaging of
extremely early implantation events may yield novel
markers predictive of pregnancy outcome.
ENDOMETRIAL THICKNESS
Several early studies assessed the value of endometrial
thickness measurements by ultrasonography in predicting
the likelihood of pregnancy. The data were conflicting.
While the endometrium was reported to be thicker in
conception cycles than in non-conception cycles17, this
was not confirmed by another study18. In an in-vitro
fertilization (IVF) population, endometrial thickness on
the day after embryo transfer was reported to be higher in
patients who subsequently conceived19. In contrast, from
a review of the early literature, it was concluded that
endometrial thickness is comparable between successful
and unsuccessful IVF treatment cycles (range, 8.6–11.8
and 8.6–11.9 mm, respectively)20. The concept that the
endometrium must measure at least 6 mm to sustain a
pregnancy in natural cycles was first established two
decades ago21. This concept was subsequently refined by
the recommendation that endometrial thickness should
be ≥ 7 mm on the day of human chorionic gonadotropin
(hCG) administration and ≥ 8 mm on the day of embryo
transfer22. These recommendations were supported by the
observation that endometrial thickness of < 6 mm has a
high negative predictive value (NPV) for pregnancy20.
Thus, while ‘normal’ endometrial thickness does not
necessarily predict pregnancy, a thin endometrium means
that implantation is highly unlikely to occur.
ENDOMETRIAL MORPHOLOGY
The appearance of the endometrium on ultrasound
changes in a cycle-dependent manner. Consequently,
endometrial morphology has been studied widely in
an attempt to predict the likelihood of pregnancy. The
results are similar to those of endometrial thickness in
that a normal trilaminar appearance of the endometrium
(multilayered or presence of midline echo) has a low
positive predictive value (PPV) for pregnancy (33.1%),
whereas the absence of a multilayered pattern does
not exclude conception but renders it unlikely (NPV,
85.7%)20,23.
UTERINE BLOOD FLOW
Uterine artery blood flow can be expressed usefully
by impedance indices, the pulsatility index (PI) and
resistance index (RI) (Table 1). An early study in 198824
reported that a poor uterine artery blood flow response
to treatment with exogenous hormones (estradiol and
norgestrel) was associated with a low pregnancy rate in
IVF cycles. The authors hypothesized that a decreased
uterine perfusion response is a contributing factor to
infertility. In addition, they reported greater pregnancy
rates after hormone therapy and improvement in uterine
perfusion. This was in agreement with their previous
study the same year, which showed increasing uterine
perfusion with rising levels of plasma estradiol and
progesterone25. Taking this work a step further in
1992, Steer et al. reported higher pregnancy rates and
implantation rates and more multiple pregnancies with
lower uterine blood flow impedance before embryo
transfer26. They concluded that uterine artery blood
flow is a useful method for assessing uterine receptivity
in assisted conception programs27. In agreement with
these findings, other reports demonstrated that low
impedance uterine artery blood flow in the early and
mid luteal phase is associated with higher conception
rates in assisted reproduction cycles23, while high uterine
artery impedance (PI> 3.3) predicts treatment failure with
relatively high sensitivity but low specificity (88% and
26%, respectively)28. In a review of the literature in
1996, Friedler et al. reported a high NPV and sensitivity
(range, 88–100% and 96–100%, respectively) and a
relatively higher PPV and specificity (range, 44–56%
and 13–35%, respectively) with Doppler assessment of
uterine artery blood flow using an upper limit for PI of 3
or 3.3, compared with the other ultrasonic parameters20.
These data suggest that uterine vascularity, or the factors
that affect it, are important for implantation and for the
subsequent pregnancy to be successful.
A recent study examined the optimal timing of B-
mode and Doppler ultrasound evaluation of uterine
receptivity in IVF populations. Different variables were
studied, including endometrial thickness, endometrial
morphology, uterine artery PI, the presence or absence
of a protodiastolic notch, the presence of end-diastolic
blood flow, and endometrial and subendometrial blood
flow distribution patterns. Themost effective combination
for evaluating uterine receptivity was the presence or
absence of end-diastolic blood flow in the uterine arteries,
endometrial morphology and endometrial thickness.
The best sensitivity and specificity were obtained on
the day of hCG administration (81.1% and 81.3%,
respectively)29.
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 612–619.
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Table 1 Summary of published data on the role of uterine artery Doppler and endometrial and subendometrial vascularity in predicting
outcome in in-vitro fertilization (IVF) and recurrent pregnancy loss
Reference
Number of
patients Population studied Mode Variables Findings
Goswamy et al.25 (1988) 16 Spontaneous ovarian
cycles
TA Uterine artery PI, RI Direct correlation with
hormone assays
Goswamy et al.24 (1988) 153 Spontaneous ovarian
cycles, then IVF
TA Uterine artery flow velocity
waveforms
Decreased uterine perfusion
response may be a cause of
infertility
Steer et al. (1992)26 82 IVF TV Uterine artery PI No implantation with PI>3
Steer et al. (1995)27 86 GnRH cycle, then embryo
transfer cycle
TV Uterine artery PI PI lower in successful than
unsuccessful cycles
Serafini et al. (1994)23 96 Ovulation induction for
IVF, GIFT
TV Uterine artery PI, RI Higher conception rate with
low impedance
Coulam et al. (1994)28 405 IVF natural and donor
cycles and IUI
TV Uterine artery PI PI of >3.3 predicted 88% of
non-conception cycles
Friedler et al. (1996)20 495 Review of three studies TV Uterine artery PI PI of 3 or 3.3: high NPV
(88–100%) and sensitivity
(96–100%) for conception
Habara et al. (2002)41 121 RPL and controls TV Uterine artery PI High impedance with RPL,
especially with antinuclear
antibodies
Raine-Fenning et al.
(2004)35
48 Normal cycles in
subfertility and control
TV Endometrial and
subendometrial VI and VFI
Vascularity indices reduced in
unexplained subfertility
Alca´zar (2006)30 725 Review of five IVF studies TV Endometrial and
subendometrial VI and VFI
Conflicting results
Ng (2006)39 451 First IVF cycle TV Endometrial and
subendometrial VI and VFI
No difference in endometrial
or subendometrial
vascularity in pregnant and
non-pregnant cycles
Ng et al. (2007)40 161 IVF and frozen embryo
cycles
TV Endometrial and
subendometrial VI and VFI
Subendometrial and
endometrial vascularity
higher in pregnant versus
non-pregnant cycles
Lazzarin et al. (2007)42 230 RPL and control TV Uterine artery PI Higher PI in unexplained
RPL, uterine abnormalities
and antiphospholipid
antibodies syndrome
Dechaud et al. (2008)29 124 IVF or ICSI TV Uterine artery PI,
paradiastolic notch,
end-diastolic flow,
endometrial and
subendometrial flow
pattern
End-diastolic blood flow with
endometrial morphology
and endometrial thickness
gave sensitivity and
specificity of 81%, PPVof
68% and NPV of 89%
Chen et al. (2011)43 134 RPL and control TV Endometrial and
subendometrial VI, FI and
VFI
Low VI, FI and VFI in
unexplained RPL
FI, flow index; GIFT, gamete intrafallopian transfer; GnRH, gonadotropin-releasing hormone; ICSI, intracytoplasmic sperm injection; IUI,
intrauterine insemination; NPV, negative predictive value; PI, pulsatility index; PPV, positive predictive value; RI, resistance index; RPL,
recurrent pregnancy loss; TA, transabdominal; TV, transvaginal; VFI, vascularization flow index; VI, vascularization index.
THREE-DIMENSIONAL ENDOMETRIAL
VASCULARITY
3D ultrasound has been shown to have a low intra- and
interobserver variability in assessing endometrial volume,
with Virtual Organ Computer-aided AnaLysis being the
most reproducible technique. Endometrial vascularity can
be assessed also using 3D power Doppler30.
Using B-mode and color Doppler imaging, the cyclical
changes in uterine size, echogenicity and vascularity have
been studied throughout the menstrual cycle in relation
to a positive urinary luteinizing hormone test and in rela-
tion to the first day of menses. Endometrial thickness
was found to increase up to days 3 and 4 of the cycle,
after which it remains relatively constant. This was asso-
ciated with a gradual decrease in the uterine arterial PI
throughout the cycle, which significantly increased at the
time of next menses31. These cyclical changes have been
further studied using 3D ultrasonography. Endometrial
volume increases in the follicular phase and plateaus in
the luteal phase32. Vascularity of the endometrial and
subendometrial regions increases from the mid-follicular
phase and peaks 3 days prior to ovulation before decreas-
ing again over the next 5 days and then increasing until the
next cycle33,34. Raine-Fenning et al. further showed that
endometrial and subendometrial vascularity indices were
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 612–619.
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significantly lower in women with unexplained subfertil-
ity during the mid and late follicular phase, irrespective
of estradiol and progesterone levels35. The subendome-
trial region was defined as a 5-mm shell around the
defined endometrial contour35,36. As would be expected
from endometrial thickness data, 3D measurements of
endometrial volume have showed a high NPV for implan-
tation failure. However, there have been conflicting results
among investigators regarding differences in endometrial
volume, as well as endometrial and subendometrial vascu-
larity between conception and non-conception cycles30,37.
Several factors have been cited as possible explanations for
these conflicting results, e.g. different ultrasound examina-
tion and analysis techniques, variations in the resolution of
equipment and different treatment protocols, especially in
the fertility groups20. However, endometrial and suben-
dometrial 3D power Doppler indices have been shown
to have acceptable reproducibility in evaluating physio-
logical and pathological changes of the endometrium38.
While Doppler studies of the uterine arteries have sug-
gested a mechanism whereby uterine vascularity impacts
on implantation, 3D Doppler studies of the endometrium
have not supported this concept. Currently we do not
know whether compromising endometrial vascularity
leads to implantation failure. To illustrate this point, Ng
et al.39 examined endometrial vascularity in 451 IVF treat-
ment cycles that resulted in 94 clinical pregnancies. No
significant differences in blood flow were seen in pregnant
versus non-pregnant cycles. The authors concluded that
measurements on endometrial and subendometrial blood
flow are not good predictors of pregnancy. The same
authors subsequently examined a further 161 patients
and found increased vascularity in cycles destined to lead
to a live birth compared to a miscarriage40.
A few studies have tested the hypothesis that changes
in endometrial vascularity play an essential role in recur-
rent miscarriage (Table 1). Higher uterine artery PI was
reported in women with recurrent pregnancy loss (RPL),
especially in those with antinuclear antibodies, than in
controls41. Findings were similar in women with unex-
plained RPL or uterine congenital abnormalities and in
women with antiphospholipid antibodies syndrome42.
Most recently the endometrial and subendometrial vas-
cularity in cases of unexplained RPL were reported to be
lower in women with RPL than in controls. This assess-
ment took place 7 days post ovulation43. It is of interest
to observe the same patterns of endometrial vascularity
in patients with RPL and failed assisted reproduction,
suggesting that endometrial vascularity does play a role
in endometrial receptivity and pregnancy maintenance.
UTERINE JUNCTIONAL ZONE
The JZ, or endometrial–myometrial junction (EMJ), is the
transitional zone, sandwiched between the endometrium
and the outer myometrium. Unlike most human tissues
with a mucosa, the endometrium does not contain a
submucosal layer. This layer usually exists to protect
against mucosal invasion into adjacent tissue44. Brosens
et al. postulated in 1995 that the JZ differs from the outer
myometrium not only structurally but also functionally.
Furthermore, they proposed that irregular thickening of
the JZ is the magnetic resonance (MR) criterion for
diagnosis of diffuse adenomyosis13. An increased diameter
of the posterior JZ of the uterus onMR imaging correlated
with invasion of the basal endometrium into the inner
myometrium from as early as the third decade of life45.
The JZ is thought to play an important role in
regulating uterine function and hence fertility46. Video-
vaginosonography studies have shown that propagated
myometrial contractions in the non-pregnant uterus
originate only from the JZ and that the frequency and
orientation of these contraction waves are dependent on
the phase of themenstrual cycle47. These innermyometrial
contractions vary in orientation, amplitude and frequency
throughout the menstrual cycle, and are thought to be
influenced by estradiol and progesterone. In the follicular
phase of the cycle, these contractions are from the cervix
towards the fundus and their amplitude and frequency
increase significantly as ovulation approaches. Following
ovulation a decrease in contractility under the influence
of progesterone is observed44. There is evidence that
this pattern of contractions facilitates sperm transport48,
aids implantation of the developing blastocyst, improves
the supply of oxygen and nutrients to the decidua49
and, in addition, contributes to menstrual shedding50,51.
On the other hand, alteration of the JZ interface, and
hence contractility, is proposed to have an integral
role in diverse reproductive disorders50. Indeed, high-
frequency uterine contractility in women undergoing IVF
treatment on the day of embryo transfer has been shown
to negatively affect the outcome, possibly by expelling
embryos from the uterine cavity52. It has been suggested
that aberrant uterine peristaltic activity at the EMJ
may cause local microtraumas that enable invasion of
endometrial glands and stroma53,54. While this proposed
model of adenomyosis remains speculative, electron
microscopy studies demonstrated that smooth muscle
cells from uteri with adenomyosis are ultrastructurally
different from myocytes of disease-free uteri55,56.
High-resolution MRI has been used to monitor changes
in endometrial and JZ morphometry during the normal
menstrual cycle. This analysis demonstrated that both
endometrial and JZ volumes increase significantly towards
ovulation. While the endometrial volume decreases
significantly post ovulation, the JZ appears to be
less regular during the luteal phase of the cycle57.
These findings support the hypothesis that the JZ and
endometrium constitute a functional unit13.
Changes in the JZ during pregnancy were first observed
incidentally on MR scans carried out 7 days post ovula-
tion in what turned out to be a conception cycle. Even this
early in the pregnancy, a low-signal intensity mass at the
site of implantation has been visualized, with changes in
the regularity of the adjacent JZ58. These uterine changes
are not observed in cases of ectopic pregnancy59. It was
therefore postulated that these MRI features are the result
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 612–619.
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of a change in local blood flow in the area underly-
ing the implantation site, in response to the presence of
implantation factors60,61. The impact of the JZ structure
on the likelihood of pregnancy after IVF treatment was
recently evaluated in a prospective study. The uterus was
imaged prior to IVF treatment and the average and max-
imal JZ thickness values were measured on T2-weighted
sequences. Strikingly, the implantation failure rate was as
high as 95.8% in women with an average or maximal JZ
of 7 and 10 mm, respectively, compared to 37.5% in other
patients (P< 0.0001). This strong association between an
abnormally thickened JZ and IVF failure was independent
of the cause of infertility or the age of the patient62.
3D transvaginal ultrasonography now enables reliable
assessment and visualization of the JZ. As on T2-weighted
MR images (Figure 1), the JZ on ultrasound appears
as a hypoechogenic zone underlying the endometrium
(Figures 2 and 3). 3D reconstruction of coronal sections
of the uterine cavity has made it possible to assess minor
changes in the lateral and fundal aspects of the JZ, which
are impossible to delineate using standard 2D ultrasound.
In addition, processing modalities such as volume contrast
imaging further enhance visualization of the hypoechoic
JZ in comparison to that using 2D imaging44,63. Thus, 3D
technology has made it possible to accurately assess and
grade changes in the JZ architecture such as thickening,
disruption and protrusion of the endometrium into the
inner myometrium.
ULTRASOUND ASSESSMENT OF
PERI-IMPLANTATION EVENTS
Although there is considerable interest in visualizing the
JZ for the diagnosis of adenomyosis44, no studies have
been reported to date on potential changes in JZ structure
or morphology associated with early implantation events.
Based on the observations outlined above, it appears
reasonable to speculate that the JZ is exquisitely sensitive
to pregnancy-associated hormonal and embryonic signals.
Figure 1 The uterine junctional zone appearing as a low-signal area
between the endometrium and the myometrium on a pelvic
magnetic resonance image.
If so, failure of the JZ to remodel in early pregnancy may
be predictive of subsequent failure or even obstetrical
complications such as preterm labor11.
Figure 2 Three-dimensional rendered view of the uterus in the
coronal plane showing the junctional zone as a hypoechoic area
surrounding the endometrium.
Figure 3 Three-dimensional view of the uterus in the coronal plane
showing a regular junctional zone.
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Figure 4 Transvaginal ultrasound post-implantation showing hyperechoic ring around the conceptus that protrudes into the endometrial
lumen (a, b), with the dots delineating this protrusion (b). The pregnancy was viable at 12 weeks.
Unlike MRI, ultrasonography is not contraindicated in
early pregnancy. As outlined above, 3D ultrasonography
appears to be more accurate than is conventional 2D
imaging in characterizing changes in the JZ. Increased
ultrasound resolution also means that it has become
possible to visualize the probable site of implantation.
Early implantation sites are usually characterized by the
presence of a hyperechoic ring around the conceptus
that protrudes into the endometrial lumen (Figure 4).
This appearance on ultrasound fits well with the emerging
concept that the implanting embryo is rapidly and actively
encapsulated by migratory decidual cells64. It remains to
be seen whether the absence of decidual protrusion or
encapsulation detected on ultrasound could serve as an
indirect marker of inadequate decidualization, and thus
predict subsequent pregnancy loss.
SUMMARY
There is a growing body of evidence supporting the
notion that defects in the implantation process create
an adverse ripple effect during the subsequent course of
pregnancy, ultimately culminating in either pregnancy
loss or obstetrical disorders associated with impaired
placentation such as pre-eclampsia, placental abruption
and fetal growth restriction9,65,66. As outlined in this
review, high-resolution ultrasonography has the potential
to provide new insights into the implantation process and
to functionally assess the quality of the maternal decidual
response and associated, but as yet ill-defined, changes in
the JZ. If this notion is correct, it should in turn be possible
to predict pregnancy complications at the implantation
stage and to design tailored interventions that would
genuinely prevent these subsequent complications.
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ABSTRACT
Objectives There is significant variation in cut-off values
for mean gestational sac diameter (MSD) and embryo
crown–rump length (CRL) used to define miscarriage,
values suggested in the literature ranging from 13 to
25 mm for MSD and from 3 to 8 mm for CRL. We aimed
to define the false-positive rate (FPR) for the diagnosis
of miscarriage associated with different CRL and MSD
measurements with or without a yolk sac in a large study
population of patients attending early pregnancy clinics.
We also aimed to define cut-off values for CRL and MSD
that, on the basis of a single measurement, can definitively
diagnose amiscarriage and so exclude possible inadvertent
termination of pregnancy.
Methods This was an observational cross-sectional study.
Data were collected prospectively according to a
predefined protocol. Intrauterine pregnancy of uncertain
viability (IPUV) was defined as an empty gestational sac
or sac with a yolk sac but no embryo seen with MSD
<20 or < 30 mm or an embryo with an absent heartbeat
and CRL <6 mm or <8 mm. We recruited to the study
1060 consecutive women with IPUV. The endpoint was
presence or absence of a viable pregnancy at the time
of first-trimester screening ultrasonography between 11
and 14 weeks. The sensitivity, specificity, positive and
negative predictive values were calculated for potential
cut-off values to define miscarriage fromMSD 8 to 30 mm
with or without a yolk sac and from CRL 3 to 8 mm.
Results Of the 1060 women with a diagnosis of IPUV,
473 remained viable and 587 were non-viable by the time
of the 11–14-week scan. In the absence of both embryo
and yolk sac, the FPR for miscarriage was 4.4% when an
MSD cut-off of 16 mm was used and 0.5% for a cut-off
of 20 mm. There were no false-positive test results for
miscarriage when a cut-off of MSD ≥21 mm was used. If
a yolk sac was present but an embryo was not, the FPR for
miscarriage was 2.6% for an MSD cut-off of 16 mm and
0.4% for a cut-off of 20 mm, with no false-positive results
when a cut-off of MSD ≥ 21 mm was used. When an
embryo was visible with an absent heartbeat, using a CRL
cut-off of 4 mm the FPR for miscarriage was 8.3%, and
for a CRL cut-off of 5 mm it was also 8.3%. There were
no false-positive results using a CRL cut-off of ≥5.3 mm.
Conclusions These data show that some current defini-
tions used to diagnose miscarriage are potentially unsafe.
Current national guidelines should be reviewed to avoid
inadvertent termination of wanted pregnancies. An MSD
cut-off of> 25 mm and a CRL cut-off of>7 mm could be
introduced to minimize the risk of a false-positive diagno-
sis of miscarriage. Copyright © 2011 ISUOG. Published
by John Wiley & Sons, Ltd.
INTRODUCTION
The current criteria used to diagnose miscarriage vary.
For example, in the UK an empty gestational sac,
visualized using transvaginal ultrasound, with a mean
gestational sac diameter (MSD) of ≥20 mm may be
classified as a miscarriage according to the Royal College
of Obstetricians and Gynaecologists’ (RCOG) guideline
for the management of early pregnancy loss1. An empty
gestational sac of <20 mm is defined as an intrauterine
pregnancy of uncertain viability (IPUV) and in order to
confirm or refute viability, a repeat scan at a minimal
interval of 1 week is advised. This guidance, though not
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explicit, implies that an empty gestational sac of>20 mm
may be classified as a miscarriage. No comment is given
regarding criteria that should be used at any repeat scan
to define miscarriage. The same guideline suggests an
embryo with a crown–rump length (CRL) ≥6 mm and
no fetal heartbeat may also be classified as a miscarriage.
This guidance is classed as Grade IV, which is defined
by the RCOG as being ‘obtained from expert committee
reports or opinions and/or clinical experience of respected
authorities’ and so is not evidence-based. Following a
previous public enquiry in the UK, cut-off values for
MSD of 20 mm and for CRL of 10 mm were proposed,
but never on the basis of a single scan and only after a
repeat scan had been carried out at least 7 days later2.
In contrast, the American College of Radiology (ACR)
guidelines define a miscarriage on the basis of an empty
gestational sac with a MSD ≥16 mm or, if present, an
embryo with a CRL measuring ≥5 mm and no heartbeat.
This guidance is based on two small studies from the late
1980s3,4. Other studies have concluded that an empty
gestational sac with a MSD of ≥25 mm or a MSD
of ≥20 mm with a yolk sac present can be used as a
safe approach to diagnose miscarriage5. A CRL cut-off
value of ≥4 mm with no cardiac activity has also been
suggested6. A review article has proposed a CRL cut-off
of ≥5 mm and an appropriate cut-off value for MSD
of ≥13 mm with or without a yolk sac7. Against this
background, it is concerning that Elson et al.8 reported
two pregnancies with empty gestational sacs measuring
18 and 20 mm that were found to be viable after further
follow-up. The authors point out that: ‘ultrasound is an
operator-dependent method and it is conceivable that an
inexperienced operator may fail to detect an embryo in a
relatively large sac due to a poor examination technique’.
In the study by Pexsters et al. in this issue of the
Journal9, there was clinically significant interobserver
variation inMSDmeasurements taken by two experienced
examiners. The implications of this finding for the use
of cut-off values for MSD to define miscarriage are
important. Great care must be taken around whatever
decision boundary is used if a mistake is not to be made.
The variation both in the literature and in national
guidelines, regarding the definitions used to make such
a fundamental decision as the viability of a human
embryo, is concerning, especially as any error may be
associated with inadvertent termination of pregnancy. In
this multicenter observational study, we aimed to establish
the false-positive rate (FPR) for miscarriage for different
cut-off values of MSD with and without a yolk sac and
CRL. We further aimed to define cut-off values for both
MSD and CRL that can be used confidently to classify a
pregnancy as non-viable.
PATIENTS AND METHODS
This was a multicenter observational study. Data were
collected prospectively from three London hospitals
within the Imperial group between September 2010 and
March 2011. Additionally, recruitment at St George’s
took place prospectively between January and October
2006 as part of a study to develop scoring systems to
predict miscarriage10. For Queen Charlottes and Chelsea
Hospital, of 406 women initially recruited nine were
excluded as measurements of MSD and CRL were
missing, leaving 397 in the analysis. For St George’s
Hospital, of 540 initially recruited 80 were excluded as
viability data were missing and one case was excluded
due to there being no MSD available, leaving 459 in
the analysis. For Chelsea and Westminster Hospital, 22
of 108 women were excluded for absent viability data or
missingMSDmeasurements, leaving 86 cases. None of the
118 cases from St Mary’s Hospital was excluded. In total,
1060 eligible women were recruited into the study. The
breakdown of cases from each unit are shown in Table 1.
Indications for ultrasonography included lower abdom-
inal pain, vaginal bleeding, poor obstetric history and
estimation of gestational age. Women classified with
IPUV were eligible for inclusion unless they were clin-
ically unstable or subsequently underwent termination of
pregnancy. In three hospitals, IPUV was defined using
transvaginal ultrasound according to the RCOG Green-
Top guidelines1 as an intrauterine sac of <20 mm MSD
with no obvious yolk sac or embryo, or an embryo with
a CRL of < 6 mm with no fetal heart activity. At Queen
Charlottes and Chelsea Hospital, the definition of IPUV
was extended to include an intrauterine sac of < 30 mm
MSD or an embryo of CRL <8 mm. The cut-off val-
ues used reflected the clinical practice in the four units;
however, the higher values used at Queen Charlottes and
Chelsea Hospital enabled assessment of the performance
of cut-off values greater than those most widely used. In
order to establish immediate viability, scans were repeated
7–14 days later. The final outcome of the study was via-
bility of the pregnancy at 11–14 weeks, at the time of the
routine nuchal translucency scan.
All women underwent sonographic assessment with a
Voluson E8 (GE Medical Systems, Zipf, Austria), Aloka
SSD 5000 (Aloka, Tokyo, Japan) or Samsung Medison
AccuvixXG (SamsungMedison, Seoul, Korea) ultrasound
machine, equipped with a 6–12-MHz transvaginal
transducer for B-mode imaging. All examinations were
performed by gynecologists or nurses with training
and experience relating to the use of ultrasound in
early pregnancy and were performed in dedicated early
pregnancy assessment units. Standardized assessments of
sonographic variables included: measurement of CRL in
the sagittal plane; measurement of sac diameter in three
orthogonal planes i.e. MSD; determination of presence of
a yolk sac; and detection of embryonic cardiac activity.
Demographic variables recorded included date of last
menstrual period or known date of conception after
infertility treatment, the woman’s age and gestational
age at presentation. Symptoms recorded included vaginal
bleeding with or without clots and pain.
The study was registered as an audit of the performance
of cut-off values used to diagnose miscarriage. For
a defined subset of patients recruited at St George’s
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 497–502.
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Hospital, ethical committee approval was obtained in
January 200610.
Statistical analysis
For the four centers separately as well as for the combined
set, we calculated the sensitivity, specificity and positive
and negative predictive values for MSD with or without
yolk sac from 8 to 30 mm, and for CRL from 3 to
8 mm. For each cut-off value, the 95% confidence interval
for specificity of detection of viable pregnancies was
calculated with the Wilson score method11. Analyses
were performed inMatlab R2010b forMac (MathWorks,
Matrix House, Cambridge, UK).
RESULTS
Among the 1060 included women with a diagnosis of
IPUV at initial scan, 473 (44.6%) cases remained viable
at the 11–14-week scan and 587 (55.4%) cases were
non-viable by this time (Table 1). When the yolk sac
and embryo were not visualized on ultrasound, the use
of an MSD cut-off of 16 mm to diagnose miscarriage
was associated with a FPR (viable pregnancy) of 4.4%.
This FPR fell to 0.5% with an MSD cut-off of 20 mm.
There were no misdiagnosed cases when an MSD cut-off
of ≥21 mm was used (Table 2). When the yolk sac was
visualized but an embryo was not, the FPR was 2.6% for
anMSD cut-off of 16 mm and it was 0.4% for a cut-off of
20 mm, with no false-positive cases when the MSD was
≥21 mm (Table 3). When an embryo was visible with
absent heartbeat, the FPR for miscarriage was 8.3% using
a CRL cut-off of 4 mm and using a CRL cut-off of 5 mm.
There were no false-positive results for a CRL ≥5.3 mm
(Table 4). FPRs and optimal cut-off values were similar
for the four units individually (Tables S1–S12).
If a cut-off of 16 mm for MSD had been used for those
462 women with an empty gestational sac, 38 of 279
Table 1 Data overview for women with intrauterine pregnancy of uncertain viability from four London teaching hospitals included in the
study
Hospital/Parameter n Viable pregnancy (n (%)) Non-viable pregnancy (n (%))
Queen Charlottes and Chelsea Hospital
MSD, no YS, no CRL 140 45 (32.1) 95 (67.9)
MSD, YS, no CRL 165 86 (52.1) 79 (47.9)
CRL 92 15 (16.3) 77 (83.7)
St Mary’s Hospital
MSD, no YS, no CRL 33 13 (39.4) 20 (60.6)
MSD, YS, no CRL 63 48 (76.2) 15 (23.8)
CRL 22 3 (13.6) 19 (86.4)
St George’s Hospital
MSD, no YS, no CRL 267 117 (43.8) 150 (56.2)
MSD, YS, no CRL 156 104 (66.7) 52 (33.3)
CRL 36 2 (5.6) 34 (94.4)
Chelsea and Westminster Hospital
MSD, no YS, no CRL 22 8 (36.4) 14 (63.6)
MSD, YS, no CRL 35 28 (80) 7 (20)
CRL 29 4 (13.8) 25 (86.2)
All centers
MSD, no YS, no CRL 462 183 (39.6) 279 (60.4)
MSD, YS, no CRL 419 266 (63.5) 153 (36.5)
CRL 179 24 (13.4) 155 (86.6)
Total 1060 473 (44.6) 587 (55.4)
CRL, embryo crown–rump length; MSD, mean gestational sac diameter; YS, yolk sac.
Table 2 Performance in all centers of different cut-off values of mean gestational sac diameter (MSD) in absence of both yolk sac and
embryo for prediction of non-viable pregnancy at 11–14 weeks (n = 462)
MSD (mm) Sensitivity (% (n)) Specificity (% (n)) 95% CI for specificity PPV NPV
8 49.1 (137/279) 63.9 (117/183) 56.8–70.5 0.67 0.45
10 35.8 (100/279) 80.3 (147/183) 74.0–85.4 0.74 0.45
12 26.5 (74/279) 88.0 (161/183) 82.5–91.9 0.77 0.44
14 17.6 (49/279) 92.9 (170/183) 88.2–95.8 0.79 0.43
16 13.6 (38/279) 95.6 (175/183) 91.6–97.8 0.83 0.42
18 6.5 (18/279) 98.9 (181/183) 96.1–99.7 0.90 0.41
20 2.9 (8/279) 99.5 (182/183) 97.0–99.9 0.89 0.40
21 2.9 (8/279) 100 (183/183) 97.9–100 1 0.40
NPV, negative predictive value; PPV, positive predictive value.
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Table 3 Performance in all centers of different cut-off values of mean gestational sac diameter (MSD) in presence of yolk sac but absence of
embryo for prediction of non-viable pregnancy at 11–14 weeks (n = 419)
MSD (mm) Sensitivity (% (n)) Specificity (% (n)) 95% CI for specificity PPV NPV
8 69.9 (107/153) 35.7 (95/266) 30.2–41.6 0.38 0.67
10 47.7 (73/153) 59.8 (159/266) 53.8–65.5 0.41 0.67
12 36.6 (56/153) 77.8 (207/266) 72.5–82.4 0.49 0.68
14 27.5 (42/153) 91.7 (244/266) 87.8–94.5 0.66 0.69
16 20.9 (32/153) 97.4 (259/266) 94.7–98.7 0.82 0.68
18 13.7 (21/153) 98.1 (261/266) 95.7–99.2 0.81 0.66
20 9.8 (15/153) 99.6 (265/266) 97.9–99.9 0.94 0.66
21 9.2 (14/153) 100 (266/266) 98.6–100 1 0.66
NPV, negative predictive value; PPV, positive predictive value.
Table 4 Performance in all centers of different cut-off values of crown–rump length (CRL) in absence of fetal heart activity for prediction of
non-viable pregnancy at 11–14 weeks (n = 179)
CRL (mm) Sensitivity (% (n)) Specificity (% (n)) 95% CI for specificity PPV NPV
3.0 71.6 (111/155) 75.0 (18/24) 55.1–88.0 0.95 0.29
3.2 67.1 (104/155) 83.3 (20/24) 64.2–93.3 0.96 0.28
3.4 63.9 (99/155) 87.5 (21/24) 69.0–95.7 0.97 0.27
3.6 61.9 (96/155) 87.5 (21/24) 69.0–95.7 0.97 0.26
3.8 56.8 (88/155) 87.5 (21/24) 69.0–95.7 0.97 0.24
4.0 49.7 (77/155) 91.7 (22/24) 74.2–97.7 0.97 0.22
4.2 41.9 (65/155) 91.7 (22/24) 74.2–97.7 0.97 0.20
4.4 37.4 (58/155) 91.7 (22/24) 74.2–97.7 0.97 0.18
4.6 34.2 (53/155) 91.7 (22/24) 74.2–97.7 0.96 0.18
4.8 29.7 (46/155) 91.7 (22/24) 74.2–97.7 0.96 0.17
5.0 22.6 (35/155) 91.7 (22/24) 74.2–97.7 0.95 0.15
5.2 20.0 (31/155) 91.7 (22/24) 74.2–97.7 0.94 0.15
5.3 16.8 (26/155) 100 (24/24) 86.2–100 1 0.16
NPV, negative predictive value; PPV, positive predictive value.
(13.6%) miscarriages would have been foreseen at the
first scan, whilst eight of 183 (4.4%) viable pregnancies
would have been terminated if these women with IPUV
had gone forward to surgical or medical evacuation of
the pregnancy. When a yolk sac was visible, 32 of 153
(20.9%) miscarriages and seven of 266 (2.6%) viable
pregnancies had an MSD of ≥16 mm.
DISCUSSION
To our knowledge this is the largest study that has
been carried out to assess the criteria currently used
to define miscarriage. Our data support those of a pre-
vious retrospective case review study by Rowling et al.
in Radiology12, in which five (8%) of 59 patients with
no embryo visible and with an MSD of ≥16 mm were
subsequently observed to develop live embryos.
A strength of our study is that the data were col-
lected prospectively according to a defined protocol.
Furthermore, the study took place in four different early
pregnancy units with different patient populations, so
the results are unlikely to be a reflection of an individ-
ual unit’s or clinician’s practice and so are likely to be
generally applicable. In this context, it is notable that the
optimal cut-off values and FPR formiscarriage was similar
in all four units. In addition, the ultrasound scans were all
carried out using high-quality equipment, and by practi-
tioners with an interest in the diagnosis and management
of early pregnancy complications. It is therefore likely
that the quality of any ultrasound examination performed
was relatively good. The results therefore may reflect the
‘best case’ scenario, with more false-positive results for
miscarriage occurring with less experienced operators or
with poor equipment. Using viability at 11–14 weeks as
the primary outcome measure is also more clinically use-
ful, as around 14% of first-trimester pregnancies with
visualized cardiac activity subsequently miscarry13, while
the miscarriage rate after 12 weeks is very much lower
and has been reported to be as low as 0.5%14. This has
allowed us to demonstrate that empty sacs with an MSD
equal to or greater than those currently used to define
miscarriage may remain viable and are not a definitive
marker of impending pregnancy failure. It does not seem
likely that the different cut-off values for MSD and CRL
used to define IPUV in our study centers will have affected
the results as there were no viable pregnancies observed
above the minimum thresholds of 20 mm for MSD or
6 mm for CRL. A weakness of the study is that, despite
the large number of cases included, there were still a rel-
atively small number of cases at or around the critical
decision boundaries used to define miscarriage.
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 497–502.
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Unpublished data of a recent survey conducted by
the association of early pregnancy units in the UK
illustrates the potential size of the problem (Kirk et al.,
unpubl. data). This survey suggested that at least 500 000
women attend such units each year. The prevalence of
IPUV with an empty gestational sac of < 20 mm in a
recent publication of all women attending such an early
pregnancy unit was 16%10. If we apply a cut-off of
16 mm for MSD in the absence of a yolk sac to define
miscarriage, this could lead to 3520 viable pregnancies
in the UK each year being classified as a miscarriage and
potentially undergoing termination. To put this number in
context, there are approximately 4000 stillbirths reported
in the UK annually15. Applying a cut-off for MSD of
20 mm could lead to 400 viable pregnancies potentially
being misclassified, compared with approximately 300
‘cot deaths’ reported in the UK each year16. These
numbers are significant and relate to pregnancies that
would be highly likely to reach term14. The use of
expectant management or non-intervention to manage
miscarriage may counterbalance the risk of misdiagnosis
in some cases, but does not detract from the need for
definitive clear guidance.
A study in this issue of the Journal, reporting the inter-
and intraobserver variability of MSD and CRL measure-
ments reveals, for MSD, the limits of agreement to be
±18.78%9. So, an MSD measurement of 20 mm by one
examiner may translate to a measurement of anywhere
between 16.8 and 24.5 mm for a second examiner, while
a CRL measurement of 6 mm translates to a range for a
second examiner of between 5.4 mm and 6.7 mm. This
suggests that safe cut-off values to define miscarriage may
have to be significantly increased to exclude any errors.
These data suggest that decisions to intervene and allow
the potential termination of a viable pregnancy are being
taken based on inappropriate guidance.
In many developed countries, women can now be
managed expectantly without the need for medical
treatment or surgery.Waiting 7–10 days in order to repeat
a scan is highly unlikely to lead to physical harm. The
anxiety associated with being uncertain about the status
of a pregnancy is very significant, but should be balanced
against the possibility of inadvertent termination which is
surely the worst possible outcome for any woman.
Taking inter- and intraobserver variation of measure-
ments into account, an empty MSD cut-off of 25 mm, an
MSD cut-off with a yolk sac present of 25 mm and a CRL
cut-off of 7.0 mm could be introduced and, based on the
available evidence, would be associated with a minimal
risk of a false-positive diagnosis of miscarriage. Empha-
sis should be placed on the need to repeat scans when
measurements are around the decision boundaries. There
should be clarity regarding what might be expected on a
repeat scan. In a further paper in this Journal17, we have
shown that it is possible for there to be no growth in MSD
over at least 10 days and the pregnancy still to be viable.
We found no viable pregnancies when a repeat scan found
that the gestational sac was still empty with no yolk sac
or embryo present. As current guidance is based on such
limited evidence, these changes in approach would seem
prudent pending the publication of larger prospective
studies containing greater numbers of patients around the
decision boundaries. The data in this report and others
suggest that national guidelines should be reviewed or
applied with caution if pregnant women are to be confi-
dent that when they are informed that they have suffered
a miscarriage, there is no chance of an error.
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ABSTRACT
Objectives To assess intra- and interobserver agreement
of routinely performed measurements – crown–rump
length (CRL) and mean gestational sac diameter
(MSD) – for assessing the likelihood of miscarriage
in the first trimester of pregnancy using transvaginal
sonography.
Methods A cross-sectional study of CRL and gesta-
tional sac measurements in first-trimester pregnancies
was conducted in a fetal medicine referral center with
a predominantly Caucasian population. Gestational age
ranged from 6 to 9 weeks. All patients underwent
a transvaginal ultrasound examination using a high-
resolution ultrasound machine. Two measurements of
CRL and measurements of three diameters of the gesta-
tional sac were obtained by two observers. Agreement
within and between observers for CRL and between
observers for MSD was analyzed using 95% prediction
intervals, Bland–Altman plots with 95% limits of agree-
ment and the intraclass correlation coefficient (ICC).
Results In total 54 patients were included in the study,
with measurements obtained by both observers in 44
of these. Intra- and interobserver ICCs were high for
CRL measurements, with values of 0.992 and 0.993
for intraobserver agreement and 0.993 for interobserver
agreement. For the MSD, the interobserver ICC was
0.952. Limits of agreement were ±8.91 and ±11.37%
for intraobserver agreement of CRL and ±14.64% for
interobserver agreement of CRL. For MSD, the inter-
observer limits of agreement were±18.78%. For anMSD
measurement of 20 mm by the first observer, the predic-
tion interval for the second observer was 16.8–24.5 mm.
For a CRL measurement of 6 mm, the prediction interval
for the second observer was 5.4–6.7 mm.
Conclusion For dating purposes, there is reasonable
reproducibility of CRL measurements using transvaginal
ultrasonography at 6–9 weeks’ gestation. When diagnos-
ing miscarriage based on measurements of CRL care must
be taken for values close to any decision boundary. The
higher interobserver variability that we observed for MSD
has implications for the diagnosis of miscarriage based on
this measurement in the absence of a visible embryo or
yolk sac. Copyright © 2011 ISUOG. Published by John
Wiley & Sons, Ltd.
INTRODUCTION
Threshold measurements for the diagnosis of viability or
non-viability of a pregnancy by transvaginal sonography
have been described and incorporated into management
guidelines1. The current guidelines of the Royal College
of Obstetricians and Gynaecologists define a missed
miscarriage or early fetal demise based on ultrasound
criteria as the visualization of an embryo with a length
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of ≥6 mm with no visible cardiac activity1. Similarly an
empty sac is defined as one having a mean gestational sac
diameter (MSD) of ≥20 mm without a visible embryo
or yolk sac. Given the significance of the decisions being
made on the basis of these measurements it is essential
that both intra- and interobserver variability are taken
into consideration.
The reproducibility of first-trimester crown–rump
length (CRL) measurements was described in an early
report with static image scanners for transabdominal
sonography2, after the Robinson and Hadlock curves for
dating had been constructed using similar equipment3–5.
The reproducibility of fetal biometry in the second and
third trimesters of pregnancy with transabdominal 3.5-
MHz linear and curvilinear probes has been established6.
More recently, a good level of reproducibility for mea-
surements taken between 9 and 14 weeks’ gestation
(CRL, biparietal diameter, abdominal circumference and
femur length) has been described using transabdominal
ultrasonography7. However, ultrasound imaging technol-
ogy has evolved rapidly over recent years, allowing better
delineation of landmarks in the early first trimester. More-
over, as new reference CRL dating curves are constructed
with predominantly transvaginal ultrasound, the repro-
ducibility of CRL measurements at earlier gestations has
become more relevant7,8.
The primary aim of this study was to evaluate
agreement in CRL measurements taken by the same
observer (intraobserver agreement) and in measurements
of CRL and MSD taken by different observers (interob-
server agreement) between 6 and 9 weeks’ gestation with
transvaginal sonography, using modern ultrasound equip-
ment. As a secondary goal, we aimed to investigate the
implications for accurately determining gestational age
based on CRL before 9 weeks and to show whether the
level of reproducibility of these measurements has impli-
cations for making a diagnosis of miscarriage based on
current cut-off levels.
METHODS
We conducted a cross-sectional study on the landmarks of
single viable embryos at different gestational ages between
6 and 9 weeks, in a referral center for fetal medicine with a
predominantly Caucasian population, between 2008 and
2009. Patients presenting with an intrauterine pregnancy
at between 6 and 9 weeks were included and were asked
to consent to participate in the study once viability had
been confirmed; patients were excluded if viability could
not be confirmed.
All women underwent an ultrasound assessment using
a Voluson E8 (GE Medical Systems, Zipf, Austria)
machine with a 6–12-MHz transvaginal transducer for
B-mode imaging. The date of the last menstrual period
or known date of conception after infertility treatment
was recorded. During the same visit patients were
scanned consecutively by two observers (Observer A
and Observer B), who were blinded to each other’s
measurements. The measurements of the first observer
were always removed from the machine before the second
observer entered the examination room.
CRL was measured to the nearest mm from the
outer ends of the embryo (greatest length), as described
previously8. To assess intraobserver agreement of the
CRLmeasurements, the CRL was measured twice by each
observer. The probe was moved away from the uterus and
the ovaries were examined in between measurements of
the fetus. Measurements of the gestational sac were taken
in three orthogonal planes from the inner borders of the
sac9, and the MSD was calculated.
All ultrasound assessments were carried out by the
same two gynecologists with specialist training in obstetric
and gynecological sonography. Ethics committee approval
was obtained at the University Hospitals Leuven and the
patients gave informed consent.
Statistical analysis
Statistical analysis was performed using SAS 9.2 (SAS
Institute Inc., Cary, NC, USA) and Matlab 7.4 (The
MathWorks Inc., Natick, MA, USA).
Scatterplots of paired sets ofmeasurementswere created
with the line of equality plotted in order to visualize the
data and assess potential systematic biases between the
measurements. The paired t-test with an alpha level of
0.05 was used to check for systematic bias by testing
whether the average difference between measurements
was different from zero. If so, this would indicate that
one set of measurements was on average higher than the
other.
In cases of no systematic bias, 95% prediction intervals
for the measurement of a second observer given the
measurement of the first were obtained by randomly
permuting both measurements to avoid one of the
observers being systematically chosen as the first observer.
This was repeated 1000 times, and each time the 95%
prediction intervals for the regression of the difference
between the two measurements divided by their mean
(i.e. the proportional difference, expressed in %) against
the first measurement were back transformed to obtain
95% prediction intervals for the second measurement
with respect to the first. These prediction intervals were
averaged to obtain the final prediction intervals. For
CRL, this analysis was only performed using the first
measurement obtained by each observer.
To assess the strength of the absolute agreement
within and between observers, the intraclass correlation
coefficient (ICC) was used based on a two-way random
effects analysis-of-variance model10. High agreement is
evidenced by a high ICC (close to 1).
The difference between pairs of measurements was
plotted against their mean in a Bland–Altman plot11,12.
The average difference between measurements was
calculated, together with the 95% limits of agreement
(LOA), which are defined as the average difference
(which is assumed to be zero in case of no consistent
bias) ± 1.96 SD12. The normality assumption and the
assumptions of constant mean and variance for the
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 510–515.
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LOA were checked. For all comparisons, the assumption
of constant variance was violated as the magnitude
of the difference increased with the mean, such that
the LOA become invalid. We therefore used the
proportional difference rather than the difference itself in
the Bland–Altman plots. The lack of agreement between
measurements or observers becomes relevant only when
the LOAs are wider than what is clinically acceptable.
RESULTS
A total of 54 patients who underwent a first-trimester
transvaginal ultrasound scan were included in the study.
All pregnancies were examined by Observer A, and 44 of
these were also examined by Observer B. Interobserver
agreement of CRL and MSD was assessed in the subset
of 44 patients with measurements performed by both
observers. Maternal age ranged from 25 to 41 years.
The largest proportion of scans (64%) was performed
in women aged 30–35 years. The majority of patients
were Caucasian (52/54). There was one patient of Afro-
Caribbean origin and one of Asian origin, who were both
included in the group of 44 patients in which interobserver
variability was investigated. Measurements of all variables
were possible in all women, but in one case the MSD data
obtained by the second observer could not be retrieved.
Gestational age ranged from 40 to 68 days. Descriptive
statistics for the CRL and MSD measurements obtained
by each observer are presented in Table 1.
Figures 1 and 2 show scatterplots of pairs of measure-
ments and 95% prediction intervals for CRL and MSD
within and between observers. All points lie randomly
around the line of equality in each graph, therefore there
seems to be no systematic bias. The paired t-test confirmed
that the observed bias was not significantly different from
0 for all four comparisons. The data points are close to the
line of equality for CRL, which reflects a good agreement
of the measurements within and between observers, while
interobserver agreement for MSD is lower.
Based on the 95% prediction intervals that were
generated, given a CRL of 6 mm as measured by one
observer, the measurement for the second observer is
likely to range from 5.4 to 6.7 mm (Table 2). Similarly,
Table 1 Descriptive statistics for measurements of crown–rump
length (CRL) and mean gestational sac diameter (MSD) obtained
by Observer A and Observer B
Parameter n
Mean (range)
(mm) SD (mm)
CRL
Observer A first 54 15.2 (1.3–30.6) 8.5
Observer A second 54 15.4 (1.3–31.2) 8.7
Observer B first 44 16.6 (3.4–32.7) 8.5
Observer B second 44 16.4 (3.2–30.6) 8.3
MSD
Observer A 43 29.6 (9.6–47.0) 9.3
Observer B 43 29.1 (10.5–46.9) 8.6
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Figure 1 Scatterplots of first vs. second crown–rump length (CRL)
measurements for Observer A (a) and Observer B (b) showing
intraobserver variation in measurements. The line of equality and
95% prediction intervals are shown.
given an MSD of 20 mm as measured by one observer,
the measurement for the second observer is likely to range
between 16.8 and 24.5 mm (Table 3).
Bland–Altman plots with 95% LOAs (± 1.96 SD)
for intraobserver agreement of CRL measurements
for both observers and interobserver agreement for
measurements of CRL and MSD are presented in Figures 3
and 4. All average proportional differences between
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 510–515.
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Figure 2 Scatterplots of Observer A vs. Observer B for the first
crown–rump length (CRL) measurement (a) and the mean
gestational sac diameter (MSD) (b) obtained by each observer,
showing interobserver variation in measurements. The line of
equality and 95% prediction intervals are shown.
measurements were close to 0, indicating that there
was no systematic bias in the measurements within or
between observers (all t-tests were non-significant, as
mentioned earlier). The mean intraobserver difference
for CRL measurements was −1.15% and ±0.41%
Table 2 Prediction intervals (PI) for crown–rump length (CRL)
measurement by second observer given a CRL value measured by
first observer
CRL as measured by
first observer (mm)
95% PI for CRL as measured
by second observer (mm)
5 4.5–5.6
6 5.4–6.7
7 6.3–7.9
10 8.9–11.2
20 17.9–22.4
30 26.7–33.5
PIs were derived using only the first CRL measurement of each
observer.
Table 3 Prediction intervals (PI) for mean gestational sac diameter
(MSD) measurement by second observer given an MSD value
measured by first observer
MSD as measured by
first observer (mm)
95% PI for MSD as measured
by second observer (mm)
10 8.5–12.6
15 12.7–18.6
16 13.5–19.8
17 14.3–21.0
18 15.1–22.2
19 16.0–23.4
20 16.8–24.5
21 17.6–25.7
22 18.4–26.9
23 19.2–28.0
24 20.0–29.2
25 20.9–30.4
30 24.9–36.1
40 32.5–47.6
for Observers A and B, respectively, and the mean
interobserver difference was +0.25% for CRL and
+0.93% for MSD. For intraobserver agreement of CRL
the 95% LOAs were ± 11.37 and ±8.91% for Observers
A and B, respectively (Figure 3), and they were ±14.64%
for interobserver agreement of CRL (Figure 4a). The
interobserver 95% LOAs for measurement of MSD were
±18.78% (Figure 4b).
Intraobserver ICC for CRL measurement was 0.993
and 0.992 for Observers A and B, respectively, and the
interobserver ICC was 0.993. The interobserver ICC for
MSD was 0.952.
DISCUSSION
We have shown that measurements of CRL in early
pregnancy before 9 weeks’ gestation are associated
with high intra- and interobserver ICCs, and that the
interobserver agreement for CRL measurements is better
than that for MSD measurements. The measurements of
MSD that are specifically used when making a diagnosis
of miscarriage were found to be less reproducible between
two observers when performed in the same gestational
age range.
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 510–515.
514 Pexsters et al.
30
20
10
0
−10
−20
−30
5 10 15 20 25 30
Pr
op
or
tio
na
l d
iff
er
en
ce
 in
 C
R
L 
(%
)
30(a)
(b)
20
10
0
−10
−20
−30
Pr
op
or
tio
na
l d
iff
er
en
ce
 in
 C
R
L 
(%
)
Mean of first and second CRL measurements
of Observer B (mm)
5 10 15 20 25 30
Mean of first and second CRL measurements
of Observer A (mm)
Figure 3 Bland–Altman plots with 95% limits of agreement of
intraobserver agreement of crown–rump length (CRL)
measurements for Observer A (a) and Observer B (b).
A strength of this study is that it is the first to report
on intra- and interobserver agreement of landmarks in
the early first trimester of pregnancy between 6 and
9 weeks’ gestation with transvaginal ultrasound. Our
study was performed with modern ultrasound equipment,
whose high image resolution allowed the best possible
delineation of the embryo and gestational structures
available to date.
However, we acknowledge that this study has
limitations. The population studied was relatively small,
especially for very early gestations where the CRL is
below 10 mm (7 weeks). It appears that the smallest CRL
measurements are closest to the line of equality, and that
the reproducibility at 6 or 7 weeks could possibly be better
than it is later in the early first trimester (8 weeks). At
these very early stages intra- and interobserver differences
in CRL measurements amount to tenths of millimeters,
which would be unlikely to result in a difference of more
than 2 days when dating a pregnancy8. It seems clear that
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Figure 4 Bland–Altman plots with 95% limits of agreement of
interobserver agreement of crown–rump length (CRL)
measurements (a) and mean gestational sac diameter (MSD) (b). In
(a) both the first (×) and second (•) CRL measurements of each
observer are shown.
CRL measurements below 8 weeks are more uniformly
made, since the embryo is straight. From 8 weeks
onwards, measurement differences are possible owing to
the curvature of the embryo. Possible measurement errors
then range from + or −2 mm in an embryo of 20 mm
and from + or −3 mm in an embryo of 30 mm, which
corresponds to a difference in dating of 2 or 3 days, which
is important when considering possible consequences
of inaccurate dating later in pregnancy8. However, in
relation to making a diagnosis of early miscarriage, even
a difference in CRL measurement of as little as 1 mm can
have an impact on clinical decision-making.
The issue of intra- and interobserver variability of mea-
surements in the first trimester of pregnancy has not
been explored widely in the literature to date. Never-
theless a recent paper showed the influence of ethnicity
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 510–515.
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and maternal age on the rate of change of CRL and
MSD13, while another study showed that the requirement
to re-date an early pregnancy may be predictive of later
growth restriction14. It seems likely that the accuracy
of early CRL measurements will become of increasing
importance. In order to improve the accuracy of dat-
ing from 5+ 3 weeks onwards, we constructed a new
reference CRL size curve based on a large number of
pregnancies, which showed meaningful differences of sev-
eral millimeters from the classically used Robinson and
Hadlock curves, especially at very early gestations8. This
study highlighted the fact that research to investigate the
intra- and interobserver variability of CRL measurements
using transvaginal ultrasound was necessary.
A key issue regarding the reproducibility of embryo
and gestational sac size measurements relates to the def-
initions used for miscarriage. A miscarriage is defined
as an embryo with a CRL ≥6 mm with no visible car-
diac activity or an MSD of ≥20 mm where no yolk sac
or embryo can be seen1. Accordingly significant inter-
observer variability may be associated with a misdiagno-
sis of miscarriage and lead to inadvertent termination of
pregnancy. If we consider the 95% prediction intervals
from our data, a measured MSD value of 20 mm by the
first observer corresponds to a range of 16.8–24.5 mm
for the second observer. This is clinically important. Simi-
larly, for a measured CRL of 6 mm, the second observer’s
measurement ranges from 5.4 to 6.7 mm.
Our data show that the variability of CRL mea-
surements – both for a single observer and between
observers – is smaller than the interobserver variability
in MSD measurements. However although small, these
differences may have significant clinical consequences. It
is clear that whatever single cut-off value may be used
to define a miscarriage, great care must be taken when
measurements approach the decision boundary. In gen-
eral little harm is associated with repeating a scan at a
later date when deciding about the potential viability of a
pregnancy. In the future we suggest that for any proposed
cut-off value for CRL or MSD to define miscarriage, pos-
sible variations in measurement accuracy are taken into
account before diagnosing it on the basis of one scan.
Hence in the UK, an MSD of 20 mm to define miscarriage
would become 25 mm to take into account possible mea-
surement error. In this way the risk of terminating wanted
viable embryos should be minimized.
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ABSTRACT
Objectives We studied changes in mean gestational sac
diameter (MSD) and embryonic crown–rump length
(CRL) in intrauterine pregnancies of uncertain viability
(IPUVs). We aimed to establish cut-off values for MSD
and CRL growth that could be definitively associated
with either viability or miscarriage, and to establish the
relationship between growth in MSD and appearance of
embryonic structures in the gestational sac.
Methods One thousand and sixty consecutive IPUVs
were recruited prospectively from four London University
hospitals: 462 with no yolk sac or embryo, 419 with a
yolk sac but no embryo, and 179 with an embryo but
no heartbeat visible. IPUV was defined as an empty
gestational sac with or without a yolk sac but no
embryo seen with MSD <20 or < 30 mm (depending
on center) or an embryo with no heartbeat and CRL
< 6 mm or <8 mm (depending on center). Scans were
repeated 7–14 days later. The endpoint was viability
at first-trimester screening ultrasonography between 11
and 14 weeks. Change in MSD and CRL between the
first and second scans of each pregnancy was compared
with respect to viability and appearance of embryonic
structures using the two-sample t-test.
Results The study included 359 pregnancies in which a
gestational sac with or without embryo was identified
at the follow-up scan 7–14 days later. Of these, 192
were viable and 167 non-viable at the 11–14-week scan.
MSD growth was significantly higher in viable than
non-viable pregnancies (mean 1.003 vs. 0.503 mm/day;
P < 0.001, 95% CI of difference 0.403–0.596). A
difference in CRL growth was found between the
two groups (mean 0.673 vs. 0.148 mm/day; P < 0.001,
95% CI of difference 0.345–0.703). MSD growth
of 0.6 mm/day was associated with a specificity for
diagnosing miscarriage of 90.1%, a sensitivity of 61.7%
and 19 false-positive test results. A cut-off of CRL growth
rate of 0.2 mm/day gave a sensitivity of 76.3% and there
were no false-positive test results for miscarriage. On
repeat scan the failure of either a yolk sac or embryo to
be visualized was always associated with miscarriage.
Conclusion There is an overlap in MSD growth rates
between viable and non-viable IPUV. No cut-off exists
for MSD growth below which a viable pregnancy could
be safely excluded. A cut-off value for CRL growth
of 0.2 mm/day was always associated with miscarriage.
These data suggest that criteria to diagnose miscarriage
based on growth in MSD and CRL are potentially
unsafe. However, finding an empty gestational sac on
two scans more than 7 days apart is highly likely to
indicate miscarriage, irrespective of growth. Copyright ©
2011 ISUOG. Published by John Wiley & Sons, Ltd.
INTRODUCTION
The current criteria used to define miscarriage are not
uniform. In the UK an empty gestational sac visualized on
transvaginal ultrasound with a mean sac diameter (MSD)
of ≥ 20 mm is defined as a miscarriage, whereas in the
USA the cut-off for MSD is > 16 mm1,2. When there
is an empty sac below these thresholds, the pregnancy
is classified as an intrauterine pregnancy of uncertain
viability (IPUV). Current protocols for the management
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of IPUV are unclear. For example the Royal College
of Obstetricians and Gynaecologists’ guidelines advise a
repeat scan at a minimum interval of 1 week in order
to confirm viability1. This and other protocols do not
define how the ultrasound findings are expected to change
over that period of time. In clinical practice this lack
of clarity may on the one hand lead to inappropriate
intervention or on the other to unnecessarily protracted
follow-up.
It has previously been thought that the embryo
and its associated structures except for the yolk sac
grow at a similar consistent velocity3, with both
crown–rump length (CRL) and MSD increasing at a rate
of approximately 1 mm per day. However, more recent
studies have shown that MSD and CRL grow at variable
rates. A smaller than expected first-trimester embryo has
been strongly linked with subsequent miscarriage4. A
further study showed that a CRL below the 50th centile
on the 28th day of gestation was associated with an
early pregnancy loss rate of 19.4%, compared with only
3.3% when the CRL was above the 50th centile5. In one
study of women who suffered miscarriage the mean CRL
was significantly smaller than in those whose pregnancy
remained viable. In this study, the initial CRL for embryos
that subsequently miscarried was below the expected
mean for gestational age in all women, while in 61%
the CRL was at least 2 SD below the mean6. Data on
twin pregnancies have shown that subsequent loss of
a single fetus is associated with a discrepancy in the
CRLs of the embryos; when the discrepancy was > 60%
there were no cases of both twins remaining viable7.
These studies all assessed differences in embryonic size
in relation to expected size for gestation; they did not
assess longitudinal changes or growth in CRL or MSD.
More recently it has been shown that serial measurements
analyzed using functional linear discriminant analysis can
better discriminate between viable pregnancies and those
that subsequently fail8, and that embryo growth is not
fixed but is influenced by factors such as maternal age and
ethnicity9.
Growth in MSD is also variable. The only study that
looked at gestational sac growth prospectively concluded
that growth of less than 0.6 mm/day is associated with
miscarriage10, but this paper did not suggest that a
definitive diagnosis of miscarriage be based on the finding
of sub-optimal growth rates. The utility of using a relative
lack of gestational sac growth to define miscarriage has
not been explored.
In the present study we aimed to establish growth-rate
ranges for both the gestational sac (expressed as changes
in MSD) and the embryo (expressed as changes in CRL)
in IPUV subsequently shown to be viable or non-viable.
We aimed to establish if cut-off values for MSD and CRL
growth that could definitively predict a miscarriage could
be defined. For gestational sac growth we further set out
to investigate whether failure of a yolk sac or embryo to
be visible on serial scans is a predictor of miscarriage.
In this way currently accepted approaches to defining
miscarriage could be tested.
METHODS
This was amulticenter observational study of womenwith
a diagnosis of IPUV carried out in three London teaching
hospitals between September 2010 and March 2011 and
in a fourth, St George’s, between January and October
2006. For Queen Charlottes and Chelsea Hospital, nine
of 406 women recruited were excluded as measurements
of MSD were missing, so 397 remained in the analysis.
At St George’s Hospital 80 of 540 initially recruited were
excluded because of an absence of viability data and one
case was excluded due to an absent MSD value, leaving
459 in the analysis. For Chelsea and Westminster Hos-
pital 22 of 108 women were excluded for an absence of
viability data or missing MSD measurements, leaving 86
cases. None of the 118 cases from St Mary’s Hospital was
excluded.
Data from St George’s Hospital have been used previ-
ously in a different analysis related to developing scoring
systems to predict miscarriage11, and examining safe cut-
off values for MSD and CRL to define miscarriage12.
Indications for ultrasonography included pelvic pain,
vaginal bleeding, poor obstetric history and estimation
of gestational age.
Women classified as having IPUV were eligible for
inclusion unless they were clinically unstable or if they
subsequently chose to terminate their pregnancy. In three
hospitals, IPUVwas defined using transvaginal ultrasound
as an intrauterine sac with an MSD of < 20 mm with no
visible yolk sac or embryo, or an embryo with a CRL of
< 6 mm with no fetal heart activity. At Queen Charlottes
and Chelsea Hospital the definition of IPUV was extended
to include an MSD of <30 mm or an embryo of CRL
< 8 mm. In order to establish immediate viability, scans
were repeated 7–14 days later (second scan). The final
outcome of the study was viability of the pregnancy at
11–14 weeks’ gestation at the time of the routine nuchal
translucency scan. Of the 1060 eligible women recruited,
359 pregnancies had a gestational sac with or without
embryo at the second scan and were included in the final
study population. The distribution of cases between each
of the centers is illustrated in Table 1.
All women underwent an ultrasound scan with a 6–12-
MHz transvaginal transducer for B-mode imaging, using
a Voluson E8 (GEMedical Systems, Zipf, Austria), Aloka
SSD 5000 (Aloka, Tokyo, Japan) or Samsung Medison
Accuvix XG (Samsung Medison, Seoul, Korea) machine.
Demographic variables recorded included the date of the
last menstrual period or known date of conception after
infertility treatment, the woman’s age and gestational age
at presentation. Sonographic variables recorded included
measurements of CRL in the sagittal plane and sac
diameter in three orthogonal planes i.e.MSD, the presence
of a yolk sac and the detection of embryonic cardiac
activity. In many cases the gestational sac did not contain
a visible embryo. Therefore, the number of cases with
a measured CRL was smaller than those with measured
MSD. All gestational sac measurements were performed
in a gestational-age range of 35 to 84 days.
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 503–509.
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Table 1 Number of women with intrauterine pregnancy of uncertain viability from four London teaching hospitals included in the study
with at least two scans during the first trimester
Hospital/Parameter n Viable pregnancy (n (%)) Non-viable pregnancy (n (%))
Queen Charlottes and Chelsea Hospital
MSD 196 109 (55.6) 87 (44.4)
CRL 30 11 (36.7) 19 (63.3)
St Mary’s Hospital
MSD 62 45 (72.6) 17 (27.4)
CRL 7 2 (28.6) 5 (71.4)
St George’s Hospital
MSD 37 3 (8.1) 34 (91.9)
CRL 1 0 (0.0) 1 (100)
Chelsea and Westminster Hospital
MSD 64 35 (54.7) 29 (45.3)
CRL 16 3 (18.7) 13 (81.3)
All centers
MSD 359* 192 (53.5) 167 (46.5)
Sac empty at both scans 47 0 (0.0) 47 (100.0)
Sac empty at first scan only 76 50 (65.8) 26 (34.2)
Sac non-empty at both scans 218 142 (65.1) 76 (34.9)
CRL 54 16 (29.6) 38 (70.4)
Mean gestational sac diameter (MSD) measurements were available in all women included, but crown–rump length (CRL) measurements
were only available in a subset. *There were 18 non-viable cases in which the sac was non-empty at first scan and empty at second scan.
These were not included in the analysis.
All ultrasound assessments were carried out by gyne-
cologists or nurses with training and experience relating
to the use of ultrasound in early pregnancy and were
performed in dedicated early-pregnancy assessment units.
The study was registered as an audit of the performance of
cut-off values used to diagnose miscarriage. For a defined
subset of patients recruited at St George’s Hospital, ethical
committee approval was obtained in January 200611.
Statistical analysis
Growth in CRL and MSD and the difference in growth
according to diagnosis and appearance of embryonic
structures were studied. Growth was considered inde-
pendently of gestational age, in order to include all cases,
regardless of availability of the date of the last menstrual
period. Growth in CRL and MSD between the first and
second scans of each pregnancy was expressed in mm/day
for viable vs. non-viable pregnancies separately and for
pregnancies with or without a certain embryonic struc-
ture. The two-sample t-test was applied with the null
hypothesis that viable and non-viable pregnancies follow
the same distribution for growth rate with equal mean.
Analyses were performed in Matlab R2011a for Mac
(MathWorks, Matrix House, Cambridge, UK).
RESULTS
Of 359 women included in the study, 192 cases (53.5%)
were viable at the 11–14-week scan, while 167 cases
(46.5%) had failed by then (Table 1). MSDmeasurements
were available for both the first and second scans in all
women and CRL measurements were recorded in 16
viable and in 38 non-viable pregnancies at both scans.
Overlap in MSD growth rate was seen between
the viable and non-viable groups of IPUV. The MSD
growth rate was significantly higher in the viable
than the non-viable group (mean 1.003± 0.356 vs.
0.503± 0.564 mm/day; P < 0.001, 95% CI of difference,
0.403–0.596). Median growth rate for MSD was
0.965 (25th –75th percentile, 0.803–1.176) mm/day in
the viable compared with 0.460 (25th –75th percentile,
0.170–0.849) mm/day in the non-viable group. Figure 1
illustrates MSD growth according to final outcome. The
interaction betweenMSDmeasurement at first scan, MSD
growth rate and first-trimester outcome can be seen in
Figure 2, which also shows that the majority of MSD
measurements were less than 15 mm at the first scan.
A significant difference in CRL growth was also found
between viable and non-viable pregnancies (mean 0.673±
0.208 vs. 0.148± 0.330 mm/day; P < 0.001, 95% CI of
difference 0.345–0.703), the CRL median growth rates
being 0.661 (25th –75th percentile, 0.5–0.904) mm/day
and 0.068 (25th –75th percentile, −0.022 to 0.2) mm/day
in the viable and non-viable groups, respectively. Limited
overlap was observed in the CRL growth rates between
the viable and non-viable groups. This can be seen in
Figure 3, which shows CRL growth according to final
outcome. The interaction between CRL measurement at
first scan, CRL growth rate and outcome can be seen
in Figure 4, which also shows that the majority of CRL
measurements were less than 3 mm on first scan.
Cut-off values of MSD growth to define miscarriage in
the four units were generated, and the sensitivity, speci-
ficity, accuracy, positive predictive values and negative
predictive values in terms of miscarriage prediction (i.e.
for growth rate less than the cut-off) were calculated
(Table 2). When the cut-off of growth rate for MSD
between two scans was 0.2 mm/day the specificity of a
diagnosis of miscarriage was 99%, with two false-positive
test results, for a sensitivity of 28.7%. An MSD growth
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 503–509.
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Figure 1 Mean gestational sac diameter (MSD) at first and second
scans in pregnancies with viable (blue) and non-viable (red)
outcome at 11–14 weeks’ gestation.
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Figure 2 Scatterplot of change in mean gestational sac diameter
(MSD) between first and second scans against MSD at first scan for
pregnancies with viable (blue) and non-viable (red) outcome at
11–14 weeks’ gestation.
rate cut-off of 0.6 mm/day was associated with a speci-
ficity of 90.1%, a sensitivity of 61.7% and 19 false-
positive test results.
A similar table was generated for CRL growth rates.
Interestingly, at a CRL growth-rate cut-off of 0.2 mm/day,
miscarriage was diagnosed with a specificity of 100% with
no false-positive cases, for a sensitivity of 76.3%. At a
CRL growth-rate cut-off of 0.6 mm/day the specificity
of diagnosis miscarriage was 56.3%, with seven false-
positive cases for a sensitivity of 89.5% (Table 3).
When the gestational sac was empty on both the first
scan and initial follow-up scan, all cases (n = 47) ended
with miscarriage. When gestational sacs described as being
empty on the first scan developed embryonic features by
the time of the initial follow-up scan, 26 cases miscarried
and 50 were viable. Of those sacs with embryonic struc-
tures visible on both scans 76 cases miscarried and 142
were viable (Table 1).
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Figure 3 Crown–rump length (CRL) at first and second scans in
pregnancies with viable (blue) and non-viable (red) outcome at
11–14 weeks’ gestation.
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Figure 4 Scatterplot of change in crown–rump length (CRL)
between first and second scans against CRL at first scan for
pregnancies with viable (blue) and non-viable (red) outcome at
11–14 weeks’ gestation.
In the miscarriage group the appearance of these
embryonic structures had a significant influence on MSD
growth rates. Pregnancies with empty sacs at both scans
and those with non-empty sac at both scans had a mean
growth rate of 0.278 and 0.569 mm/day, respectively
(P = 0.006). Furthermore, empty sacs that developed
embryonic structures on the second scan grew at a higher
rate of 0.827 mm/day. This was also significant when
compared with the growth rate when there was an empty
sac at both scans (P = 0.04) (Table 4). On the other
hand, the appearance of embryonic structures had no
significant influence on MSD growth in the viable cases
(Table 4). The diagnostic value of MSD growth rate when
embryonic structures were present at both scans was
comparable with that observed when the whole dataset
was examined, regardless of the appearance of embryonic
structures (Table 5).
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Table 2 Performance of different cut-off values for changes in mean gestational sac diameter (MSD) for the prediction of non-viable
outcome of pregnancy at 11–14 weeks’ gestation
MSD change
cut-off (mm/day)
Sensitivity
(%)
Specificity
(%)
Accuracy
(%) PPV NPV
True
positive (n)
False
negative (n)
True
negative (n)
False
positive (n)
−2 0 100 53.5 N/A 0.53 0 167 192 0
−1.8 0.6 100 53.8 1 0.54 1 166 192 0
−1.6 0.6 100 53.8 1 0.54 1 166 192 0
−1.4 0.6 100 53.8 1 0.54 1 166 192 0
−1.2 0.6 100 53.8 1 0.54 1 166 192 0
−1.0 0.6 100 53.8 1 0.54 1 166 192 0
−0.8 1.8 100 54.3 1 0.54 3 164 192 0
−0.6 1.8 100 54.3 1 0.54 3 164 192 0
−0.4 3.0 100 54.9 1 0.54 5 162 192 0
−0.2 8.4 100 57.4 1 0.56 14 153 192 0
0 13.2 100 59.6 1 0.57 22 145 192 0
0.2 28.7 99.0 66.3 0.96 0.61 48 119 190 2
0.4 43.1 94.8 70.8 0.88 0.66 72 95 182 10
0.6 61.7 90.1 76.9 0.84 0.73 103 64 173 19
0.8 73.7 75.0 74.4 0.72 0.77 123 44 144 48
1.0 80.8 45.3 61.8 0.56 0.73 135 32 87 105
1.2 88.6 24.0 54.0 0.50 0.71 148 19 46 146
1.4 94.6 10.9 49.9 0.48 0.70 158 9 21 171
1.6 97.6 7.8 49.6 0.48 0.79 163 4 15 177
1.8 98.8 2.6 47.4 0.47 0.71 165 2 5 187
2.0 99.4 1.6 47.1 0.47 0.75 166 1 3 189
2.2 99.4 0.5 46.5 0.46 0.50 166 1 1 191
2.4 99.4 0 46.2 0.46 0 166 1 0 192
2.6 99.4 0 46.2 0.46 0 166 1 0 192
2.8 100 0 46.5 0.47 N/A 167 0 0 192
N/A, not applicable; NPV, negative predictive value; PPV, positive predictive value.
Table 3 Performance of different cut-off values for changes in crown–rump length (CRL) for the prediction of non-viable outcome of
pregnancy at 11–14 weeks’ gestation
CRL change
cut-off (mm/day)
Sensitivity
(%)
Specificity
(%)
Accuracy
(%) PPV NPV
True
positive (n)
False
negative (n)
True
negative (n)
False
positive (n)
−0.6 0 100 29.6 N/A 0.30 0 38 16 0
−0.4 5.3 100 33.3 1 0.31 2 36 16 0
−0.2 5.3 100 33.3 1 0.31 2 36 16 0
0 26.3 100 48.1 1 0.36 10 28 16 0
0.2 76.3 100 83.3 1 0.64 29 9 16 0
0.4 76.3 87.5 79.6 0.94 0.61 29 9 14 2
0.6 89.5 56.3 79.6 0.83 0.69 34 4 9 7
0.8 94.7 31.3 75.9 0.77 0.71 36 2 5 11
1.0 97.4 0 68.5 0.70 0 37 1 0 16
1.2 100 0 70.4 0.70 N/A 38 0 0 16
N/A, not applicable; NPV, negative predictive value; PPV, positive predictive value.
DISCUSSION
We have shown that slow or absent gestational sac
growth is not necessarily associated with miscarriage.
We have also demonstrated that CRL growth can be
very slow in pregnancies that subsequently turn out
to be viable at 11–14 weeks’ gestation. These findings
are a concern when set against many protocols used to
define miscarriage in early pregnancy. Our data further
show that failure to visualize a yolk sac or embryo on
a repeat scan after at least 7 days was associated with
miscarriage.
A recent study reported that 29% of women attending
an inner London early-pregnancy assessment unit were
classified as having an IPUV according to current UK
criteria11. The majority of these had an empty gestational
sac. Current guidelines advise that in such cases a repeat
scan should be arranged 7–10 days later. However these
guidelines do not stipulate what findings on a repeat scan
can definitively be used to define a miscarriage. There is
an inference that if the pregnancy is viable the gestational
sac should grow in the time interval between scans and/or
a yolk sac or embryo should become visible.
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2011; 38: 503–509.
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Table 4 Mean gestational sac diameter growth in relation to
appearance of embryonic structures (n = 341/359)
Outcome at 11–14 weeks
Non-viable Viable
Gestational sac
appearance
Growth rate
(mm/day)
(mean (SD)) P*
Growth rate
(mm/day)
(mean (SD)) P*
Non-empty at
both scans
0.569 (0.573) 1.000 (0.387)
Empty at first
scan only
0.827 (0.460) 0.040 1.010 (0.255) 0.874
Empty at both
scans
0.278 (0.530) 0.006
*Two-sample t-test with respect to non-empty at both scans.
In the current study we have shown a clear overlap
in gestational sac growth rates (expressed as change in
MSD) between viable and non-viable IPUV. Therefore,
we were unable to establish daily or weekly MSD growth
cut-off values below which a diagnosis of miscarriage can
safely be made. The results were different with embryonic
growth rates expressed as change in CRL. Below a CRL
growth rate of 0.2 mm/day pregnancies were associated
with miscarriage with a specificity of 100%. This means
that a CRL that changes by as little as 1.4 mm in a week
can potentially be associated with a viable pregnancy.
These findings are a concern, especially as a recent
study of the inter- and intraobserver variability of MSD
and CRL measurements showed that for MSD, the limits
of agreement were ± 18.78%13. This implies that an
MSD measurement of 20 mm by one examiner may be
measured as anywhere between 16.8 and 24.5 mm for a
second examiner. Furthermore, for a CRL measurement
of 6 mm the range for a second examiner is between 5.4
and 6.7 mm. Applying these figures to MSD and CRL
measurements around the decision boundaries makes it
clear that there can be an absence of gestational sac or
embryonic growth over at least a week and the pregnancy
may still be viable. While the rates of change of MSD
and CRL in viable pregnancies are thought to be always
> 0.6 mm/day3,14, our data show that using this cut-off
in the growth rate to diagnose miscarriage is associated
with significant false-positive rates of 9.9 and 43.7%,
respectively.
The results of our study show that if a gestational
sac is empty on initial scan, failure of a yolk sac or
embryo to be visible on a second scan 7 or more days
later was always associated with miscarriage. As might be
expected there was a significant difference in the growth
rate of gestational sacs that remained empty compared
with those where an embryonic structure was present on
one or both initial scans.
A strength of our study is that as it was prospective
and multicenter, the results are likely to be more generally
applicable. The ultrasound scans were performed using
high-quality equipment by clinicians working in dedicated
acute gynecology and early-pregnancy assessment units.
It is probable that the quality of the scans in this study
is relatively good. More false-positive test results for
miscarriage may occur in less specialist services. Our
use of viability at 11–14 weeks as the primary outcome
measure also obviates the criticism that slow-growing
gestational sacs are always ‘sick sacs’ that are destined
to miscarry even if they do appear viable at some point
in their natural history. Although a large number of
Table 5 Performance of different cut-off values of change in mean gestational sac diameter (MSD) for prediction of non-viable outcome of
pregnancy at 11–14 weeks’ gestation when sac was non-empty at both scans (n = 218)
MSD
change
cut-off
(mm/day)
Sensitivity
(%)
Specificity
(%)
Accuracy
(%) PPV NPV
True
positive
(n)
False
negative
(n)
True
negative
(n)
False
positive
(n)
−0.6 0 100 65.1 N/A 0.65 0 76 142 0
−0.4 1.3 100 65.6 1 0.65 1 75 142 0
−0.2 9.2 100 68.3 1 0.67 7 69 142 0
0 11.8 100 69.3 1 0.68 9 67 142 0
0.2 30.3 98.6 74.8 0.92 0.73 23 53 140 2
0.4 39.5 93.7 74.8 0.77 0.74 30 46 133 9
0.6 56.6 87.3 76.6 0.70 0.79 43 33 124 18
0.8 67.1 71.8 70.2 0.56 0.80 51 25 102 40
1.0 75.0 43.7 54.6 0.42 0.77 57 19 62 80
1.2 86.8 25.4 46.8 0.38 0.78 66 10 36 106
1.4 93.4 12.7 40.8 0.36 0.78 71 5 18 124
1.6 96.1 9.2 39.4 0.36 0.81 73 3 13 129
1.8 98.7 2.8 36.2 0.35 0.80 75 1 4 138
2.0 98.7 2.1 35.8 0.35 0.75 75 1 3 139
2.2 98.7 0.7 34.9 0.35 0.50 75 1 1 141
2.4 98.7 0 34.4 0.35 0 75 1 0 142
2.6 98.7 0 34.4 0.35 0 75 1 0 142
2.8 100 0 34.9 0.35 N/A 76 0 0 142
N/A, not applicable; NPV, negative predictive value; PPV, positive predictive value.
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IPUV were included in the study, there was only a
relatively small number of cases with slow growth that
remained viable. Furthermore only a small number of
IPUVs showed an absence of embryonic structures on
both scans.
Our data suggest that some of the presumptions made
about IPUV, gestational sac growth and viability should
be questioned. We have demonstrated that pregnancies
may be viable despite little or no change in MSD over
quite prolonged periods; however we did observe that an
absence of embryonic structures from a gestational sac
on two separate scans 7–14 days apart was always a sign
of miscarriage. However, the number of cases fulfilling
these criteria in the study was relatively small, and larger
prospective studies are needed to confirm this observation.
The difference in CRL growth between viable and non-
viable pregnancies is significant, but the interobserver
variation inherent in measurement of CRL means that
care must be taken before assuming that a slow-growing
embryo will always miscarry.
Current protocols in the UK and elsewhere make the
assumption that in the event of an IPUV, if a repeat
scan shows no growth in the gestational sac, then this is
definitive evidence of a miscarriage. Similar assumptions
are made about absence of change in CRL. Our data
suggest that great care should be taken before making
a diagnosis of miscarriage in these circumstances, and
guidance should be reviewed to reflect this.
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Correspondence
Re: Limitations of current definitions of
miscarriage using mean gestational sac diameter
and crown–rump length measurements: a
multicenter observational study
In a recent Opinion1, the study by Abdallah et al.2 was
hailed as one of the most significant pieces of research
ever published by this Journal. The study is purported to
provide robust evidence that the diagnosis of miscarriage
could be made on a single ultrasound examination in
a woman who presents with an empty gestational sac
measuring > 25 mm in mean diameter, or an embryo
with crown–rump length > 7 mm and no evidence of
cardiac activity.
Both the authors and the accompanying Opinion failed
to notice, however, that three out of four cases assessed by
the South Glamorgan Health Authority (SGHA) enquiry
in 19953 would have been classified as miscarriages if
these new criteria were to be embraced so enthusias-
tically. It is worth reminding readers that the SGHA
public enquiry was conducted by a group of distinguished
experts, including the past president of the British Insti-
tute of Radiology, a barrister-at-law and the founding
president of the International Society of Ultrasound in
Obstetrics and Gynecology and was published in this
Journal3. The enquiry focused on four cases of misdi-
agnosis of death of an embryo, which occurred in three
different women. The gestational ages of the pregnancies
at time of misdiagnosis were 5, 8, 11 and 12 weeks. The
authors of the report recognized that a variety of fac-
tors may lead to a misdiagnosis of miscarriage, the most
important one being operator error. As a result, they put
forward several recommendations, covering appropriate
policies, guidelines, training, equipment and organiza-
tion of early pregnancy ultrasound services. The authors
implicitly recognized that, whatever ultrasound diagnos-
tic criteria are put in place, misdiagnoses would continue
to occur due to human error. In order to minimize the
risk of mistakes, their main recommendation was that
the diagnosis of early embryonic demise should never be
made in a single visit, only on a follow-up examination.
These recommendations have been widely adopted in
the UK and all students attending theoretical courses
in acute gynecology and early pregnancy ultrasound at
the Royal College of Obstetricians and Gynaecologists
(RCOG) are taught to adopt this approach in their rou-
tine clinical practice. The RCOG clinical guidelines on the
management of early pregnancy loss4, which are referred
to by Abdallah et al.2, do not provide explicit advice on
the criteria with which to diagnose any form of miscar-
riage and in particular there is no suggestion that women
with an empty sac≥ 20 mmor an embryo≥6 mmwith no
heart rate should be offered a termination of pregnancy.
Even with all these apparent safeguards in place, in
the last 6 months I have come across three women
who were referred to us for a second opinion from
three different institutions where an ultrasound diagnosis
of early embryonic demise had been made. All three
cases were entirely consistent with the diagnostic criteria
proposed by Abdallah et al.2 and yet all three women had
normal intrauterine pregnancies between 7 and 11 weeks’
gestation (data on file).
I wish to put on record my belief that the criteria for the
diagnosis of miscarriage reported by Abdallah et al.2 will
be no better or worse than are any previously published
data using a similar methodological approach. The main
criticism remains that the researchers fail to accept that
any diagnostic test, however good it appears when initially
defined, will inevitably produce false-positive and false-
negative findings. Although occasional diagnostic errors
are accepted as being unavoidable inmany areas of clinical
practice, when it comes to the diagnosis of miscarriage,
even a single false diagnosis is unacceptable. To achieve
the seemingly impossible task of avoidingmisclassification
of a viable pregnancy as a miscarriage, every early
pregnancy diagnostic unit has to develop a comprehensive
strategy in an attempt to eradicate diagnostic errors. The
recommendations provided by Hately et al.3 remain the
best guide in efforts to achieve this goal. The overriding
principle for the safe diagnosis of miscarriage in early
pregnancy remains straightforward: never in one visit and
never by one person.
D. Jurkovic
Early Pregnancy Clinical Study Group,
National Reproductive Health Research Network (UK)
(e-mail: jurkovic.davor@googlemail.com)
DOI: 10.1002/uog.11107
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Reply
We thank Dr Jurkovic for his helpful comments with
respect to our recent paper1. We would, however,
recommend that the cases described in the South
Glamorgan Health Authority Inquiry are considered once
again. Based on the information disclosed in the paper
describing the report2, it is unlikely that any of the
cases described would have been diagnosed incorrectly
as miscarriage as a result of the criteria that we proposed
in our paper.
Nevertheless, we are in complete agreement that
appropriate training, demonstrable competence and good-
quality ultrasound equipment are important prerequisites
for making a diagnosis of miscarriage. System error is
nearly always a factor when mistakes are made, and Dr
Jurkovic is absolutely right that a unit must have processes
in place to reduce to a minimum the chances of an error
being made. These issues were highlighted graphically by
the recent review of miscarriage misdiagnosis by the Irish
Health Service Executive3. However, the same argument is
precisely why practitioners require unambiguous guidance
regarding what ultrasound features may be used to define
a miscarriage, whether this is on the basis of a single scan
or after follow-up scans. It is clearly important that such
guidance is evidence-based. Published in the same issue
of the Journal was a systematic review4 that concluded
that the evidence used to derive ultrasound criteria to
define miscarriage was based on a small number of poor-
quality studies and so we can only conclude that previous
guidance cannot be considered to be robust. Our data go
beyond information previously published in the literature
and so do give important information about what is likely
to constitute safe practice1.
Our conclusions are consistent with those of the South
Glamorgan Health Authority Inquiry, although the cut-
offs differ slightly. We too recommend the liberal use of
repeat scans, although the concept of repeating a scan does
not lead in all cases to a clear outcome. We have shown
that an embryo or gestational sac can show minimal or
no growth over several days and still be associated with a
viable pregnancy5. We would recommend that common
sense prevails in later pregnancies where, for example,
clear visualization of an embryo with a crown–rump
length (CRL) of 30 mm and an absent fetal heart beat
should in the hands of an experienced practitioner not
require a repeat scan in 1 week. It is important to strike
a balance between a dogmatic and inflexible insistence
on repeating scans in every case of miscarriage and the
psychological impact of keeping women in a state of
uncertainty. A further consideration is the likelihood of
miscarriage occurring at home for women waiting for a
follow-up scan, which for some women may be extremely
distressing.
Dr Jurkovic refers to the Royal College of Obstetricians
and Gynaecologists (RCOG) Green Top Guidance (2005)
for the management of pregnancies of uncertain viability.
We hope that he would approve the newly revised
interim RCOG guidance based on a precautionary
approach to the diagnosis of miscarriage in the light
of recent publications1,4,5, with a recommendation for
interval rescans and the use of more conservative CRL
and gestational sac measurement cut-off values6. This
new guidance is now the subject of a further large
prospective study that should be available within the
year.
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Re: Limitations of current definitions of
miscarriage using mean gestational sac diameter
and crown–rump length measurements: a
multicenter observational study
We read with great interest the article by Abdallah
et al.1 describing the limitations of current definitions
of miscarriage using mean gestational sac diameter and
crown–rump length measurements. The authors should
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 361–365.
Correspondence 363
be congratulated on bringing our attention back to the
difficulties in the ultrasound diagnosis of early embry-
onic demise. They aimed to define the false-positive rate
for the diagnosis of miscarriage associated with differ-
ent measurements and also to define cut-off values for
single measurements that can definitively diagnose a mis-
carriage. They propose that the diagnosis of miscarriage
could be made on a single ultrasound examination in a
woman who presents with a gestational sac > 25 mm in
mean diameter in the absence of an embryo, or in the
presence of an embryo with crown–rump length > 7 mm
and no cardiac activity.
However, the authors provide conflicting information
about the type of study they conducted. In the abstract
section they state that the patients were recruited
prospectively, at the beginning of the methods section the
study is described as observational and a few paragraphs
later they state that the study was registered as an audit.
One of the difficulties with conducting a truly prospective
observational study aiming to define criteria with which
to diagnose early embryonic demise is that the standard
clinical protocols need to be modified to facilitate open-
ended, expectant management of all women until viability
is proven or there is conclusive evidence of miscarriage.
The criteria to diagnose miscarriage have to be clearly
defined and they need to be based mainly on histological
evidence of retained products in the tissue spontaneously
expelled from the uterus or in surgical specimens following
uterine evacuation for clinical indications. None of these
issues is considered in this study, but they are particularly
important given that the intervention being studied is
the diagnosis of miscarriage. In addition, the inclusion
criteria are not clearly specified, nor are details as to
how the recruited patients were followed up. Only
one participating center had a number of patients lost
to follow-up, suggesting either that the availability of
viability data was an inclusion criterion or that the other
centers had an unusually low attrition rate. Furthermore,
there is a paucity of data on the technique of ultrasound
examination, with no descriptions of the measurements
of the gestational sac, yolk sac or embryo. The presence
or size of the amniotic sac has not been recorded and
there is nothing about the possible use of color Doppler
in cases of diagnostic uncertainty. Not only was patient
recruitment in one center completed 4 years before that
in the rest, but there was also no synchronization of
management protocols among the participating centers.
All this, as well as the way in which data are presented
and the conclusions drawn, carries the hallmarks of a
retrospective study.
Closer analysis of the results shows that the quality
of ultrasound scanning in some of the participating
centers may have been below average. It is worrying that
even the most basic measurements were not recorded in
some women. It is of particular concern that ultrasound
operators failed to identify the presence of embryonic
heart activity in the 13.4% of women with a visible
embryo who were found to have normal pregnancies
on follow-up. All practitioners with an interest in early
pregnancy diagnosis would agree that in very early
pregnancies, around 6 weeks’ gestation, it is often easier to
demonstrate embryonic cardiac pulsations on ultrasound
than it is to visualize the embryo itself. In experienced
hands it is therefore very unusual to see a clear ultrasound
image of a healthy embryo without evidence of cardiac
activity. It is thus likely that in the majority of these
cases the ultrasound operators have confused other
intragestational sac structures with embryos. There is
also a lack of information about the procedures that were
used to verify the accuracy of the ultrasound findings in
women with a presumed diagnosis of miscarriage.
The credibility of their conclusions is further under-
mined by the fact that the recommended cut-off level is
not actually based on the results of this study. The cut-off
is derived by combining observations from this audit with
the results of another study on the interobserver variability
of ultrasound measurements in early pregnancy2. There
are no data given regarding the number of observations at
different sac diameters and crown–rump length measure-
ments, though the authors state in the discussion that there
were ‘a relatively small number of cases at or around the
critical decision boundaries used to define miscarriage’.
The lure of retrospective studies is their tendency to
offer simple answers to complex diagnostic questions.
This was the case with Doppler studies in gynecology;
there were many retrospective studies published, each
offering a new ‘improved’ cut-off level for indices of
impedance in the detection of ovarian cancer. It is there-
fore not surprising that Abdallah et al.1, looking back
at their data set, are offering us a new cut-off level for
gestational sac diameter and crown–rump length, to be
used to discriminate between normal and abnormal preg-
nancy on ultrasound, with minimal risk of misdiagnosis
of miscarriage. Unfortunately, they have not performed
the prospective multicenter observational study needed to
address their aims.
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Reply
We thank Drs Ross and Johns for their comments on our
recent paper1, to which we reply in order.
The chairman of the ethics committee at St George’s
Hospital gave written advice that this non-interventional
observational study did not need formal ethical approval.
The same methodology was considered to constitute
an audit at Imperial College NHS trust. The data
were collected prospectively. Dr Ross does, however,
raise an interesting point. We did not call this a
‘prospective’ study in the title, to accommodate the
mistaken though widely held belief that a study
registered as an audit cannot be labeled ‘prospective’.
Accordingly, this is most appropriately described as
a prospective observational study and, as it was
carried out in four London hospitals, as multicenter.
No intervention and no alternative management was
undertaken in women who were entered prospectively
into the study.
We do not agree that the diagnosis of miscarriage
requires histological confirmation. In routine clinical
practice this occurs in only a proportion of women with a
diagnosis of miscarriage, as a large proportion of women
undergo medical or expectant management with no tissue
being collected for histological examination. Furthermore,
the methodology of the study meant that women were
followed up with a repeat scan after visualization of an
intrauterine gestational sac until a diagnosis ofmiscarriage
was made. This appears to be the same approach as
that taken by Dr Ross and her colleagues in their
recent paper in Human Reproduction in which they use
criteria to define miscarriage that are similar to those
used in our paper2. In defining our outcome we stated:
‘In order to establish immediate viability, scans were
repeated 7–14 days later. The final outcome of the study
was viability of the pregnancy at 11–14 weeks, at the
time of the routine nuchal translucency scan.’ In the
methodology we state: ‘Outcomes at the follow-up visit
were a viable pregnancy with detectable cardiac activity,
non-viable pregnancy or a complete miscarriage before
the follow-up visit.’ Ross and colleagues in September
2011 defined outcome as follows: ‘The final diagnosis
of a viable pregnancy was made at the 11–14 week
scan. Miscarriage was defined as the absence of a
previously visible gestational sac, when the gestational
sac remained without an embryo or embryonic cardiac
activity ceased within the first trimester. Pregnancies
that were viable at the initial follow-up but miscarried
later in the first trimester were therefore counted as
miscarriages’2.
We believe the inclusion criteria, ultrasound techniques
and loss to follow-up data are all described comprehen-
sively in the methods section of the paper.
We are unclear on what basis details of amniotic
sac measurement and color Doppler should have been
recorded for this study. Our study relates to the use of
mean gestational sac diameter (MSD) and crown–rump
length (CRL) measurements to define miscarriage. Whilst
there are studies that describe the ‘empty amnion sign’
we are not aware of any current guidance that uses
Doppler information or amnion measurements3 to make
a diagnosis of miscarriage.
Drs Ross and Johns make some assumptions regarding
the quality of ultrasound scanning carried out in the study.
We would consider the quality of ultrasound in the study
to broadly reflect UK practice; however, we are aware of
the absence of UK data and agreed measures from which
the quality of ultrasound in individual departments can be
judged. The failure to record some ultrasound informa-
tion clearly in the record is regrettable, but we think this is
an honest reflection of what can happen in busy units, and
this missing information is clearly stated in the methods
in order that the reader can draw their own conclusions.
It is of interest that the findings were very similar in all
four units that participated in the study (shown online as
supplementary material). Whilst it is of course possible
that the quality of scanning at all these London units is
below average, it would seem more likely to mean that
our results are likely to be generalizable.
We are not aware of evidence to support the idea
put forward that once an embryo is seen fetal heart
pulsations should always be visible. The fact that clin-
icians find embryos with no heart beat is the reason
why a robust CRL cut-off is necessary before a diagno-
sis of miscarriage can be considered. This may of course
not be considered necessary by those practitioners who
consider themselves ‘expert’ and who have the oppor-
tunity to use high-end equipment on all occasions. This
is not the case in all early pregnancy units or emer-
gency rooms. This is evidenced in the well-known MIST
study by Trinder et al.4 on management of miscarriage,
in which two women with an ultrasound diagnosis of
miscarriage were subsequently found to have viable ongo-
ing pregnancies. Guidance must be applicable to all units
and not just to often better-resourced research-orientated
specialist hospital departments.
Drs Ross and Johns consider that as the cut-off levels
used were different from those subsequently derived, this
undermines the study’s credibility. However, as we had
no preconceptions as to the cut-offs that we might derive
after completion of data collection and analysis, we were
in no position to determine cut-offs prior to the study’s
commencement.
We agree with Drs Ross and Johns that our paper is not
the last word on the ultrasound diagnosis of miscarriage.
However, the paper does give the best indication to date
of the performance of different cut-off levels, and in
particular confidence limits for specificity, for both CRL
and MSD. A prospective study using the revised CRL
and gestational sac measurements is necessary to test the
new recommendations and we are pleased to report that
this multicenter study has already commenced. Regarding
our tentative suggestions to guide clinicians, in the final
paragraph of our paper we state: ‘As current guidance is
based on such limited evidence, these changes in approach
would seem prudent pending the publication of larger
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 361–365.
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prospective studies containing greater numbers of patients
around the decision boundaries. The data in this report
and others suggest that national guidelines should be
reviewed or applied with caution if pregnant women are
to be confident that when they are informed that they
have suffered a miscarriage, there is no chance of an
error.’
We think these conclusions are reasonable and propor-
tionate. In the same issue of the Journal, a systematic
review by Jeve and colleagues5 showed that prior to our
publications any guidance on the ultrasound-based diag-
nosis of miscarriage was based on small, poor-quality
studies; indeed, the Royal College of Obstetricians and
Gynaecologists (RCOG)’s guidance has been categorized
previously as being based on only level-4 evidence (‘expert
opinion’)6. Our paper on interobserver variability demon-
strated clinically significant differences between measure-
ments of MSD and CRL by experienced sonographers7,
and in a further paper we showed that there may be min-
imal changes in both MSD and CRL on repeat scans8.
As a result of the systematic review and the information
provided by our studies, the RCOG recently decided to
issue new guidance on the ultrasound-based diagnosis of
miscarriage with immediate effect pending further data
being available9. As evidenced by the report into the mis-
diagnosis of miscarriage published by the Irish Health
Service Executive10, women do have wanted pregnancies
wrongly classified as miscarriages. Setting conservative,
evidence-based ultrasound criteria seems appropriate for
avoidance of these errors.
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study question: Can we accurately define a group of pregnancies of unknown location (PULs) as low risk in order to safely reduce
follow-up for these pregnancies and allocate resources to pregnancies at an increased risk of being ectopic?
summary answer: Prediction model M4 classified around 70% of PULs as low risk, of which around 97% were later characterized as
failed PULs or intrauterine pregnancies (IUPs), while still classifying 88% of ectopic pregnancies as high risk.
what is known already: Depending on the level of suspicion of ectopic pregnancy (EP), women with a PUL receive a lengthy
follow-up in order to confirm the location and viability of the pregnancy.
study design, size, duration: A multi-centre diagnostic accuracy study of 1962 patients was carried out between 2003 and
2007 for retrospective temporal validation and between 2009 and 2011 for prospective external validation. The reference standard is
the final characterization of PUL as failed pregnancies or IUPs (low risk), or as ectopic pregnancies (high risk). M4 is a multinomial logistic
regression model based on the serum human chorionic gonadotrophin (hCG) levels at presentation and 48 h later.
participants/materials, setting, methods: Temporal validation data from 1341 PULs collected at St George’s Hospital
in London were available, of which 53% were failed, 39% were intrauterine and 8% were ectopic pregnancies. External validation data from
621 PULs collected at four other London-based teaching hospitals were available, of which 63% were failed, 22% were intrauterine and 15%
were ectopic pregnancies.
main results and the role of chance: The EP rate varied between 8 and 16% across the five hospitals. At St George’s,
980 [73.1%, 95% confidence interval (CI): 70.5–75.4] PULs were considered low risk. Of these, 963 were failed PULs or IUPs (98.3%, 95%
CI: 97.2–98.9) and 17 were ectopic pregnancies. At the other four hospitals, 62–75% were considered low risk, with 96–98% of these
turning out to be failed PUL or IUP. Eighty-five percent (95% CI: 76.8–90.2) of the ectopic pregnancies were considered high risk at St
George’s, compared with 80–92% in the other hospitals.
limitations, reasons for caution: Of total, 120 patients had been excluded due to loss to follow-up, and a further 102
patients because of missing hCG levels due to differences in local clinical practice. There are variations in the definition of a PUL used in
different countries.
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wider implications of the findings: The suggested protocol could safely reduce the follow-up in the majority of PUL such that
units could increase the focus on women at a risk of complications. This would lead to a change in the management of the majority of women
with a PUL and a more efficient use of resources. At the end of the manuscript, we provide a link to enable clinicians to use the protocol.
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Introduction
In clinical practice, women classified as having a pregnancy of unknown
location (PUL) often receive a lengthy follow-up in order to confirm
the location and viability of the pregnancy. The management of
PULs varies due to a lack of standardized protocols, and the follow-up
varies in intensity according to the level of suspicion of an ectopic
pregnancy (EP). Women may have multiple blood tests to measure
serum human chorionic gonadotrophin (hCG) and progesterone
levels and undergo numerous transvaginal ultrasound scans (TVS).
They are usually only discharged following a negative pregnancy test
indicating a resolved failed PUL or after visualization of an intrauterine
pregnancy (IUP) or an EP on a subsequent TVS examination. While
this intensive follow-up approach is warranted for an EP, it is not ne-
cessary for a failed PUL or IUP. The latter two groups, representing at
least 70% of the PUL population (Kirk et al., 2009), can be labelled as a
low-risk group. For these women, early discharge or reduced follow-
up can be applied, which would reduce the clinical workload and
improve the patient’s convenience (Kirk et al., 2007).
To rationalize the management of PULs, it is important to reliably
detect pregnancies that can be safely managed with a reduced follow-
up. In the literature, a number of strategies have been described to
predict a low-risk PUL (failed PUL or IUP). However, many of these
strategies were designed to predict either a failed PUL (e.g. Hahlin
et al., 1995; Banerjee et al., 2001) or an IUP (e.g. Kadar et al.,
1981; Romero et al., 1986; Condous et al., 2002), but not both. On
the other hand, various risk prediction models based on multinomial
logistic regression have been developed to predict the three different
PUL outcomes (Condous et al., 2004, 2007a,b; Van Calster et al.,
2009). Prediction model M4 (Condous et al., 2007a) uses the ratio
of the serum hCG level at 48 h with the level at presentation and
the average of the two hCG levels to estimate the risk of a failed
PUL, IUP and EP. Based on these risks, a system was suggested to clas-
sify pregnancies with the aim of achieving a high detection rate (sensi-
tivity) for each outcome. For example, in an interventional trial, this
system reported detection rates of 86% for failed PUL, 86% for IUP
and 73% for EP, such that 27% of patients with an EP would be
selected for early discharge or reduced follow-up (Kirk et al., 2007).
More recently, more sensible management strategies based on risk
rather than on making a certain diagnosis have been considered
(Cordina et al., 2011), the aim being to focus on PULs that are
likely to be EPs while reducing the follow-up for IUPs and failed
PULs. In addition, no extensive temporal or external validation of
M4 has been undertaken, which are crucial steps for the eventual
deployment of any prediction model in clinical practice (Justice
et al., 1999; Altman et al., 2009).
The aim of the present study was to propose a classification system
for PULs based on M4 that is aimed at reliably classifying a group of
PULs as low risk in order that the follow-up for these PULs can be
reduced. The usefulness of this system, and also the performance of
the M4 logistic regression model were temporally and externally vali-
dated using more recent data from the unit where M4 was developed
and data from four other units.
Materials and Methods
Design, setting and participants
This is a multi-centre observational diagnostic accuracy study of women
with a PUL. Temporal validation data collection from London’s
St George’s Hospital (SGH), where M4 was developed, was done accord-
ing to a strictly defined study protocol (Kirk et al., 2007; Condous et al.,
2007a) between July 2003 and February 2007 (Table I). External validation
data from the following four London hospitals were prospectively col-
lected between April 2009 and 2011 (Table I): Queen Charlotte’s and
Chelsea Hospital (QCCH), Imperial College NHS Trust, Chelsea and
Westminster Hospital (CWH), West Middlesex Hospital (WMH) and
St Mary’s Hospital (SMH), Imperial College NHS Trust.
At SGH, women were classified as having a PUL if there was no evi-
dence of an IUP or EP on TVS. The data collected for external validation
incorporated new definitions of PUL contained within a recent consensus
paper (Barnhart et al., 2011) that includes in the PUL population small pos-
sible intrauterine gestation sacs or possible EP where embryonic structures
have not been visualized. According to these criteria, a pregnancy can be
classified as: PUL—probable intrauterine, PUL—probable ectopic or true
PUL (which is consistent with the older definition used at SGH). During
the recruitment period, all women with a PUL were included in the
study unless they were clinically unstable, had an acute abdomen or had
blood in the pouch of Douglas according to the ultrasound images at
the time of the initial TVS examination.
Data collection and reference standard
Those included in the study had their serum hCG level assessed at pres-
entation and were scheduled to have serum hCG levels measured again
48 h later. When the 48 h hCG ratio was ,0.87, a follow-up serum
hCG at Day 7 and urine hCG at Day 14 were organized. Women were
then followed up until the final clinical outcome of the pregnancy was
known—failing PUL, IUP or EP. The exact method and timing of follow-up
was decided on an individual case basis. A failing PUL was diagnosed on
the basis of a spontaneous decrease in the serum hCG level to
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,15 IU/l. An IUP was diagnosed if there was an intrauterine gestational
sac with or without a yolk sac or fetal pole or heterogeneous tissue
within the endometrial cavity suggestive of retained products of concep-
tion on a follow-up TVS. Alternatively, an IUP was diagnosed if histological
evidence of products of conception was confirmed after surgical evacu-
ation. An EP was diagnosed on TVS if no IUP was seen and one of the fol-
lowing was visualized: an inhomogeneous adnexal mass separate from the
ovary (Condous et al., 2007b), an empty extra-uterine gestational sac seen
as a hyperechoic ring (‘bagel sign’) in the adnexal region (Condous et al.,
2005a), or a yolk sac or fetal pole+ cardiac activity in an extra-uterine sac
in the adnexal region. An EP was also diagnosed at laparoscopy or lapar-
otomy and confirmed histologically. As persistent PULs most likely
represent missed EPs that behave in the same way biochemically, persist-
ent PULs were analysed as EPs. Failed PUL and IUPs were considered to
be low-risk PULs, and EPs were considered to be high-risk PULs.
For the external validation data, any interventions carried out were
recorded including medical treatment with methotrexate or surgical
procedures such as the evacuation of retained products of conception,
laparoscopy or laparotomy (leading to salpingectomy, salpingostomy or
oophorectomy).
Rationalizing PUL management using M4
Our aim was to identify low-risk PULs with a high level of confidence, such
that it is safe to select these women for a reduced follow-up.
.............................................................................................................................................................................................
Table I Overview of units and descriptive statistics.
Unit (characteristic) Failing PUL IUP EP
St George’s (n ¼ 1341)
Recruitment period July 2003–February 2007
n (%) 713 (53%) 517 (39%) 111 (8%)
Age 31 (26–36) 30 (24–34) 31 (28–36)
Serum hCG 0 h 221 (60–716) 595 (295–1034) 368 (186–1039)
Serum hCG 48 h 95 (24–321) 1271 (684–2196) 473 (221–1168)
hCG ratio 0.39 (0.28–0.60) 2.20 (1.92–2.47) 1.18 (0.95–1.41)
Queen Charlotte’s and Chelsea (n ¼ 309)
Recruitment period April 2009–July 2011
n (%) 209 (68%) 51 (17%) 49 (16%)
Age 32 (27–36) 30 (25–35) 33 (29–36)
Serum hCG 0 h 420 (158–1663) 471 (259–1243) 545 (222–1034)
Serum hCG 48 h 158 (56–640) 861 (593–2151) 608 (222–1090)
hCG ratio 0.38 (0.26–0.54) 2.15 (1.66–2.68) 1.14 (1.00–1.40)
Chelsea and Westminster (n ¼ 130)
Recruitment period November 2009–June 2010
n (%) 73 (56%) 37 (28%) 20 (15%)
Age 33 (29–37) 29 (23–33) 31 (28–35)
Serum hCG 0 h 606 (224–1279) 467 (255–699) 435 (156–907)
Serum hCG 48 h 207 (98–338) 961 (681–1493) 638 (226–1320)
hCG ratio 0.34 (0.23–0.48) 2.21 (1.83–2.74) 1.26 (0.99–1.61)
West Middlesex (n ¼ 101)
Recruitment period November 2009–June 2010
n (%) 71 (70%) 17 (17%) 13 (13%)
Age 30 (24–35) 28 (26–33) 30 (24–34)
Serum hCG 0 h 766 (296–2705) 1088 (569–3519) 1029 (653–1361)
Serum hCG 48 h 336 (132–868) 1905 (1141–2185) 1186 (801–2085)
hCG ratio 0.41 (0.23–0.56) 1.13 (0.91–2.68) 1.30 (0.94–1.48)
St Mary’s (n ¼ 81)
Recruitment period December 2009–June 2010
n (%) 38 (47%) 33 (41%) 10 (12%)
Age 33 (27–35) 29 (26–37) 32 (29–34)
Serum hCG 0 h 392 (136–1367) 650 (343–1140) 821 (170–1323)
Serum hCG 48 h 131 (49–375) 1401 (579–2038) 977 (325–2120)
hCG ratio 0.35 (0.30–0.56) 1.80 (1.17–2.24) 1.18 (1.01–1.53)
PUL, pregnancy of unknown location; IUP, intrauterine pregnancy; EP, ectopic pregnancy; hCG, human chorionic gonadotrophin.
Descriptive statistics for age and hCG information are presented as the median (interquartile range).
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Misclassification of an EP as low risk is thus considered much more harmful
than misclassification of a low-risk pregnancy as high risk. This suggests the
choice of a low cut-off for the risk that a PUL is an EP, given the direct
relationship between risk cut-off and relative misclassification costs
(Pauker and Kassirer, 1975; Vickers, 2011; Steyerberg et al., 2012). We
considered it sensible to refer PULs for extensive follow-up if their risk
of being EPs was at least 5%. Because the desired risk threshold is
partly subjective, we also present results for a cut-off of 3%. If a PUL
was classified as low risk, we predicted a failed PUL or IUP depending
on which outcome had the highest estimated risk.
The risk of each outcome category was estimated by M4. This model is
based on the hCG ratio (hCG level at 48 h divided by the hCG level at
presentation) and the log of the average hCG level as predictors. The
formula for M4 is provided in Supplemental Information.
Statistical analysis
M4 was applied to each PUL and the estimated risks of failed PULs, IUPs
or EPs were recorded. Performance evaluation consists of two parts:
evaluation of the estimated risks estimated from M4 with respect to dis-
crimination and calibration, and evaluation of PUL triage as high versus
low risk based on a risk cut-off. We focus on the latter as this is clinically
most relevant. It is important to also address discrimination (Van Calster
et al., 2012a, 2012b) and calibration of the estimated risks, but this is
addressed in Supplemental Information. Regarding triage, the main
performance measures are the percentage of low-risk classifications (per-
centage of PULs selected for reduced follow-up), negative predictive value
(the percentage of failed PULs or IUPs among low-risk classifications), sen-
sitivity (the percentage of EPs classified as high risk) and false positive rate
(the percentage of failed PULs or IUPs classified as high risk).
Results were obtained for all five hospitals separately and for the aggre-
gate data of the four external validation hospitals to increase numbers. As
the definition of what constitutes a PUL was different for the prospectively
collected external validation data following a recent consensus statement
(Barnhart et al., 2011), we also obtained results for the aggregate valid-
ation data based on the PUL definition used for developing M4 and for
temporal validation.
All analyses were performed using SAS 9.2 (SAS Institute, Cary,
NC, USA).
Results
A flow chart of this study is presented in Fig. 1. The total number of
PULs was 2184. This includes 1467 PULs from SGH and 717 PULs
from the four external units. Overall, 222 patients were excluded,
120 (5.5%) were lost to follow-up and 102 of the remaining patients
(4.9%) had missing hCG levels because of the following reasons: an
IUP or extra-uterine pregnancy was detected prior to the second
Figure 1 Flowchart of the study.
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blood sample being taken, the patient was only followed up with a
urinary pregnancy test due to a very low initial hCG level or the
patient returned out of hours for the second blood sample. The EP
rate varied between 8 and 16% across the five units. Table I presents
the recruitment periods, the distribution of the reference standard and
descriptive statistics for all units.
Table II presents cross-tabulations of the classification as low or high
risk, and Table III summarizes the performance measures of the clas-
sifications using risk cut-offs of 5 and 3% for the risk of EP. Figure 2
visualizes the high-risk classification conditional on the initial serum
hCG level and the hCG ratio. Focusing on triage using the 5%
cut-off, 980 (73%) of PULs at SGH and 432 (70%) at the external
............................................................................................................
............................................. .............................................
.............................................................................................................................................................................................
Table II Two-by-two cross-tabulations of the prediction of PULs as low or high risk based on the M4 prediction model.
Classifications based on the M4 prediction model
5% cut-off on the risk of EP 3% cut-off on the risk of EP
Unit Final diagnosis Low risk High risk Low risk High risk
SGH Low risk (IUP/failed PUL) 963 267 906 324
High risk (EP) 17 94 14 97
All external Low risk (IUP/failed PUL) 421 108 404 125
High risk (EP) 11 81 9 83
QCCH Low risk (IUP/failed PUL) 211 49 204 56
High risk (EP) 4 45 4 45
CWH Low risk (IUP/failed PUL) 94 16 91 19
High risk (EP) 4 16 2 18
WMH Low risk (IUP/failed PUL) 62 26 58 30
High risk (EP) 1 12 1 12
SMH Low risk (IUP/failed PUL) 54 17 51 20
High risk (EP) 2 8 2 8
SGH, St George’s Hospital; QCCH, Queen Charlotte’s and Chelsea Hospital; CWH, Chelsea and Westminster Hospital; WMH, West Middlesex Hospital; SMH, St Mary’s Hospital;
IUP, intrauterine pregnancy; PUL, pregnancy of unknown location; EP, ectopic pregnancy.
A PUL is classified as high risk if the risk of an EP given by M4 is on or above the cut-off (5 or 3%), and as low risk if the risk of an EP is below the cut-off.
.............................................................................................................................................................................................
Table III Triage performance of the classification of PULs as low or high risk based on the M4 prediction model.
Unit PULs classified
as low risk
Negative predictive value
(failed PULs/IUPs among PULs
classified as low risk)
Sensitivity
(EPs classified
as high risk)
False positive rate
(failed PULs/IUPs
classified as high risk)
5% cut-off on the risk of EP
SGH 73.1% (70.5–75.4) 98.3% (97.2–98.9) 84.7% (76.8–90.2) 21.7% (19.5–24.1)
All external 69.6% (65.8–73.1) 97.5% (95.5–98.6) 88.0% (79.9–93.2) 20.4% (17.2–24.1)
QCCH 69.6% 98.1% 91.8% 18.9%
CWH 75.4% 95.9% 80.0% 14.6%
WMH 62.4% 98.4% 92.3% 29.6%
SMH 69.1% 96.4% 80.0% 23.9%
3% cut-off on the risk of EP
SGH 68.6% (66.1–71.0) 98.5% (97.5–99.1) 87.4% (79.9–92.3) 26.3% (24.0–28.9)
All external 66.5% (62.7–70.1) 97.8% (95.9–98.9) 90.2% (82.4–94.8) 23.6% (20.2–27.4)
QCCH 67.3% 98.1% 91.8% 21.5%
CWH 71.5% 97.9% 90.0% 17.3%
WMH 58.4% 98.3% 92.3% 34.1%
SMH 65.4% 96.2% 80.0% 28.2%
SGH, St George’s Hospital; QCCH, Queen Charlotte’s and Chelsea Hospital; CWH, Chelsea and Westminster Hospital; WMH, West Middlesex Hospital; SMH, St Mary’s Hospital;
IPU, intrauterine pregnancy; PUL, pregnancy of unknown location.
A PUL is classified as high risk if the risk of an EP given by M4 is on or above the cut-off (5% or 3%), and as low risk if the risk of an EP is below the cut-off. Numbers between parentheses
are 95% confidence intervals (CIs). 95% CIs are computed using Wilson’s score method.
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units were considered to be low risk (the percentage for these units
varies between 62 and 75%). The low-risk classification was correct
for 98% of the women at SGH and for 97% of the women at the
four external units (the percentage varies between 96 and 98%). At
SGH 85% of EPs were correctly classified as high risk, while this
was 88% at the external units (the percentage varies between 80
and 92%).
Of the 11 misclassified EPs in the external units (Table IV), 5
resolved without intervention, 3 received methotrexate injections
(despite a declining serum hCG in one) and 3 underwent laparoscopic
surgery. Thus, for 6 cases out of 621 PULs (1.0%) intervention was
deemed necessary. Of all 92 EPs in the external units, 41 received a
surgical intervention of which 3 were misclassified (7%), 37 received
methotrexate of which 3 were misclassified (8%) and 14 did not
receive an intervention of which 5 were misclassified (36%).
The cross-tabulation of the original reference standard (failed PUL,
IUP, and EP) with the classification as low risk-failed PUL, low risk-IUP
or high risk is shown in Supplementary data, Table SII.
Figure 2 Visualization of high-risk classification based on the initial hCG level and the hCG ratio. PULs located inside the ellipsoid line are classified
as high risk. Data from all five units are shown.
.............................................................................................................................................................................................
Table IV The 11 EPs misclassified as low risk at the external validation units.
Unit Initial (hCG) 48 h (hCG) hCG ratio Risk of ectopic (M4) (%) Intervention
Misclassified as IUP
QCCH 78 225 2.88 ,0.1 Expectant management
QCCH 1220 4356 3.57 ,0.1 Salpingotomy
CWH 168 530 3.15 ,0.1 Expectant management
SMH 147 325 2.21 1.1 Methotrexate
WMH 911 2085 2.29 0.5 Laparoscopy
CWH 112 229 2.04 4.0 Expectant management
CWH 829 1674 2.02 4.4 Methotrexate
Misclassified as failed PUL
CWH 62 21 0.34 ,0.1 Expectant management
SMH 170 67 0.39 ,0.1 Methotrexate
QCCH 225 133 0.59 0.8 Expectant management
QCCH 1707 878 0.51 2.6 Laparoscopy
QCCH, Queen Charlotte’s and Chelsea Hospital; CWH, Chelsea and Westminster Hospital; WMH, West Middlesex Hospital; SMH, St Mary’s Hospital; hCG, human chorionic
gonadotrophin; EP, ectopic pregnancy; IUP, intrauterine pregnancy; PUL, pregnancy of unknown location.
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When re-analysing the external validation data using only PULs that
would be classified as PULs using the definitions used at SGH, very
similar results were obtained (Supplementary data, Table SIII).
Discussion
We have shown that the M4 risk prediction model for PULs based on
measurements of serum hCG can be used as a triage tool to signifi-
cantly reduce the number of visits, blood tests and scans in a large
proportion of women attending hospital in early pregnancy with a
PUL. The model still performed well on external validation. The
most important result is that M4-based triage of PULs as low or
high risk using a 5% risk cut-off for EPs managed to select around
70% of PULs for reduced follow-up while still referring at least 85%
of EPs for extensive follow-up. Among the PULs selected for
reduced follow-up, 96–98% were later confirmed as failed PULs
or IUPs.
We can illustrate how the model would be used in practice using
some examples. A 42-year-old woman with a history of two first tri-
mester miscarriages presented with light vaginal bleeding and lower
abdominal pain at 6 weeks of gestation according to her last menstrual
period. TVS revealed an empty uterus with an endometrial thickness
of 8 mm. The serum hCG level was 570 IU/l at presentation and
1467 IU/l 48 h later (hCG ratio 2.57). M4 predicted a low-risk IUP,
for which we would suggest a repeat scan after 1 week. This
woman had a viable IUP. Another woman, aged 29, in her first preg-
nancy presented with a history of light vaginal spotting. TVS revealed
an empty uterus with an endometrial thickness of 5 mm. Both ovaries
appeared normal and no adnexal masses were seen. The hCG level
was 245 IU/l at presentation and 237 IU/l at 48 h (hCG ratio 0.97).
M4 predicted a high risk, and so we would suggest a repeat scan
and hCG assessment after a further 48 h. The woman was later
found to have an inhomogeneous mass in the right adnexa next to
the right ovary, and a laparoscopic right salpingectomy was performed.
Finally, a 26-year-old woman with one previous normal delivery at
term presented with a history of heavy bleeding with clots at 10
weeks of gestation according to her last menstrual period. The
uterus appeared empty on TVS with no adnexal masses seen. The
serum hCG was 2303 IU/l at presentation and 749 IU/l at 48 h
(hCG ratio 0.33). M4 predicted low risk-failed, for which we would
suggest a urinary pregnancy test after 1 week. This pregnancy was
indeed a failed PUL.
The cases classified as low risk would not be discharged completely
but undergo reduced follow-up, for example, a urinary pregnancy test
or scan after 1 week. Patients on a reduced follow-up protocol would
also be given strict instructions to return in the event of a change in
their symptoms. This approach seems reasonable and is likely to
lead to women with an EP returning for review. Nonetheless, classify-
ing EPs as low risk is undesirable, as the risk of tubal rupture should be
minimized and treatment enabled as early in the natural history of the
condition as possible. Reviewing the data from the four external units,
5 of the 11 misclassified EPs resolved without intervention and man-
agement would not have been improved by classifying them as high
risk. For six patients intervention was deemed necessary and lack of
closer follow-up may have led to harm. In most cases, an EP misclas-
sified as an IUP would be identified at the time of a follow-up scan.
Although there were no complications reported in this study among
the EPs falsely classified as low risk, this study was not interventional.
We therefore do not know whether these patients would have come
back to the unit in the event of symptoms or come to harm prior to
follow-up, and we do not know the exact time period until making the
correct diagnosis of EP. To demonstrate this, an interventional trial is
currently ongoing. Of all EPs in the external units, M4-based triage
classified nearly all EPs that received intervention as high risk,
whereas it misclassified one-third of EPs that did not receive interven-
tion. This suggests that triage performs particularly well for EPs that
require surgery or medical treatment.
Two limitations on the performance of M4 are the decreased dis-
crimination performance in one external hospital (WMH) and the
overestimation of the risk of EP in the external units (cf. Supplemental
Information, Table SI). WMH data contained an unusually high number
of non-viable IUPs. This may be due to a tendency to classify women
with evidence of retained products on ultrasound as a PUL due to the
absence of a visible gestation sac. However, triage results for WMH
were not worse than those for other units. Also, given the clinical re-
quirement not to categorize many EPs as low risk, a minor overesti-
mation of the risk of EPs while not ideal, is not a major drawback.
Moreover, it did not negatively affect triage results.
The four hospitals used in this study serve diverse multi-cultural
populations and represent a mix of university units and district
hospitals; the prospective external validation of M4 in these hospitals
supports the view that this approach will have general applicability in
other units.
A similar approach to the management of PULs was proposed using
a single-visit strategy based on the initial serum progesterone and hCG
levels (Condous et al., 2005b). When tested prospectively on a total
of 518 PULs, this approach correctly eliminated 84% of low-risk PULs
from further follow-up but simultaneously misclassified 67% of EPs
(Condous et al., 2005b). Another single-visit strategy was described
in a recent prospective interventional study in which a single measure-
ment of serum progesterone ,10 nm/l at presentation was used to
discharge women with a PUL (Cordina et al., 2011). Using this ap-
proach, Cordina and colleagues classified 37% of their PUL population
as low risk. Fifteen (6.6%) out of 227 discharged women returned to
the unit because of worsening symptoms and 4 (1.7%) needed surgical
intervention of which 2 of the 5 were discharged EPs. While the single
progesterone approach has the advantage of giving a result on the
basis of one blood test, using M4 enables significantly more women
to be classified as low risk. It is important to emphasize that the
Cordina study is interventional, and so while M4 may have theoretical
advantages, an interventional study is needed to enable us to compare
these approaches to PUL triage appropriately.
Undoubtedly, the management of PUL takes up a significant amount
of time and resources in units caring for women with early pregnancy
complications. By far, the majority of PULs are low risk and the
number of blood tests and visits to hospital for review represent a sig-
nificant burden both on patients and clinicians. We have shown that
the M4 prediction model with a risk cut-off of 5% on the risk of EP
could be used to reduce follow-up in over 70% of PULs. This would
make more time available to concentrate on women at a high risk
of complications and potentially better use of resources. The good
performance of M4 when validated externally suggests that the use
of this approach prospectively would lead to a change in the manage-
ment of the majority of women with a PUL and a more efficient use of
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resources. The M4-based protocol can be accessed and used at http
://homes.esat.kuleuven.be/~biomed/M4PUL/M4triage.htm.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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ABSTRACT
Objective To determine the impact of ovulation and
implantation timing on first-trimester crown–rump length
(CRL) and the derived gestational age (GA).
Method One hundred and forty-three women who were
trying to conceive were recruited prospectively. The
timing of ovulation and implantation and the ovulation
to implantation (O–I) interval were established in 101
pregnancies using home urinary tests for luteinizing
hormone and human chorionic gonadotropin. In 71
ongoing pregnancies, GA determined by measurement
of fetal CRL at 10–14 weeks’ gestation was compared
with GA based on ovulation and implantation day. First-
trimester growth was determined by serial ultrasound
scans at 6–7, 8–9 and 10–14 weeks.
Results The median ovulation and implantation days
were 16 and 27, respectively, with an O–I interval
of 11 days. GA estimated from CRL at 10–14 weeks
was on average 1.3 days greater than that derived from
ovulation timing. CRL Z-score was inversely related to
O–I interval (ρ=−0.431, P= 0.0009). There was no
significant relationship between CRL growth rate and the
difference between observed CRL and expected CRL
based on GA from last menstrual period (ρ= 0.224,
P= 0.08).
Conclusions Early implantation leads to a larger CRL
and late implantation to a smaller CRL at 10–14 weeks,
independent of CRL growth rate. Implantation timing
is a major determinant of fetal size at 10–14 weeks
and largely explains the variation in estimates of GA in
the first trimester derived from embryonic or fetal CRL.
Copyright © 2012 ISUOG. Published by John Wiley &
Sons, Ltd.
Correspondence to: Mr C. C. Lees, Box 228, Fetal Medicine Department, Rosie Hospital, Hills Road, Cambridge, CB2 0QQ, UK
(e-mail: christoph.lees@addenbrookes.nhs.uk)
Accepted: 17 July 2012
INTRODUCTION
Assessment of gestational age (GA) forms the basis for
interpreting early pregnancy ultrasound scans, diagnosing
fetal growth restriction and making critical decisions
regarding pregnancy management; GA at delivery is itself
a determinant of perinatal outcome1. Early pregnancy
ultrasound appearances can vary even with certain
menstrual or in-vitro fertilization (IVF) dates: a healthy
ongoing pregnancy might appear to be of uncertain
viability, leading to a false diagnosis of miscarriage and
even termination of a potentially viable early pregnancy2.
The Royal College of Obstetricians and Gynaecologists’
guidance in relation to the diagnosis of miscarriage has
recently been updated to reflect these uncertainties3.
GA is routinely determined by measuring the fetal
crown–rump length (CRL) at 10–14 weeks using
ultrasound4,5. The CRL charts in general use were con-
structed from observed first-trimester CRL measurements
in relation to GA calculated from the last menstrual period
(LMP) in women with regular menstrual cycles, assum-
ing that ovulation occurs mid-cycle6–8. However, only
10% of women with a regular 28-day menstrual cycle
ovulate on day 149,10, and the median ovulation day in
women with regular cycles is day 1611,12. The ovulation
to implantation (O–I) interval in a natural conception
varies by up to 6 days13. The impact of ovulation and
implantation timing on apparent embryonic or fetal size
and GA assessment has never been determined.
A relationship between a small first-trimester embryonic
measurement and low birth weight has been shown in
IVF pregnancies and spontaneous conception14–16. In
these studies a single CRL measurement was used to
define fetal growth restriction and no account was taken
of variation in implantation timing and first-trimester
growth, as opposed to size14–16.
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. ORIGINAL PAPER
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The development of a urinary luteinizing hormone
(LH) testing kit has enabled reliable prediction of
ovulation17. Similarly, a highly sensitive urinary human
chorionic gonadotropin (hCG) testing kit detects
implantation13,18,19. It is now possible to establish the
timing of both ovulation and implantation to a high
degree of accuracy using home urinary testing kits in
women trying to conceive.
We prospectively observed ovulation timing, implanta-
tion timing and O–I interval in women trying to conceive
naturally and investigated the effect of these observations
on embryonic and fetal growth and size, and the estima-
tion of GA derived from first-trimester CRLmeasurement.
METHODS
One hundred and forty-three women who were trying
to conceive were recruited prospectively via open
advertisement in the hospital, GP surgeries, newspapers,
pre-school groups or by invitation letter. This was part
of a larger study on cardiovascular changes in pregnancy.
All women were healthy non-smokers and not known to
have diabetes, thrombophilia or fertility problems. The
study received ethical approval from the local research
ethics committee, and written consent was obtained at the
time of recruitment.
Age, ethnicity, LMP, detailed menstrual history,
obstetric and cardiovascular history, height, weight and
body mass index were recorded at recruitment. The
women started using digital urinary home ovulation and
pregnancy test kits at least a month after stopping con-
traception. They were asked to perform daily ovulation
tests from the 6th day of their menstrual period until
the urinary LH surge was detected and then carry out
daily pregnancy tests from 8 days after the LH surge
until their next period or until they had three consecutive
positive pregnancy tests. They continued testing in every
menstrual cycle until they became pregnant or for up to
6 to 12 months if no clinical pregnancy occurred. The
test kits were provided free of charge by Swiss Precision
Diagnostics, GmbH (Bedford, UK).
A rise in urinary LH predicts ovulation at amean of 20 h
from the initial rise17. We therefore calculated the ‘LH
surge+ 1 day’ to define the day of ovulation, as previously
described11,17. The day of the first positive pregnancy
test using sensitive digital urine pregnancy test kits was
reported as the ‘implantation day’ in a similar way to
previously described13. TheO–I interval was calculated as
the time interval between the presumed day of ovulation as
indicated by the urinary LH test kits and the first positive
pregnancy test. The urinary tests had been previously
validated against urinary assays for detection of LH surge
and hCG by Swiss Precision Diagnostics, GmbH20.
Ultrasound scans were performed at 6–7, 8–9 and
10–14 weeks’ gestation from LMP in all women with
a regular 28-day cycle, and where this was not the case
they were scheduled from the date of the LH surge. CRL
was measured transvaginally at 6–7 and 8–9 weeks by
placing the calipers at the outer side of the crown and
rump of the embryo or fetus in a longitudinal, midsagittal
section21,22. Of three CRL measurements taken, the one
that most closely conformed to the standard described
above was used for analysis. Fetal CRL at 10–14 weeks
was imaged transabdominally in a midsagittal plane with
the genital tubercle and the fetal spine longitudinally in
view and the maximum CRL was measured16,22. GA
for pregnancies viable at 10–14 weeks was assigned
according to the observed CRL measurement, and only
women with ongoing pregnancies at 10–14 weeks were
included in the study. GA adjusted for ovulation timing
(GAOV) was derived by subtracting 14 days from the
predicted ovulation date (LH + 1) to derive the effective
LMP, as is the convention for pregnancy dating. GA
adjusted for implantation timing (GAIMP) was derived by
adding the difference between the observed implantation
day and the median implantation day (which in this study
was day 27) if the observed implantation day was earlier
than day 27. Similarly, we subtracted the difference if the
observed implantation day was later than day 27.
Statistical analysis was performed using the MedCalc
software for windows (MedCalc Software bvba, Version
11.6, Mariakerke, Belgium) and Statistical Package for
Social Sciences (SPSS Version 18.0.0, 2009, SPSS Inc.,
Chicago, IL, USA). The data were checked for normality
of distribution and are expressed as mean ± SD and
median (interquartile range (IQR)) or median (range), as
appropriate. The timing of ovulation and implantation
and the O–I interval in ongoing pregnancies at 10 weeks,
pregnancies that miscarried at less than 6 weeks and
pregnancies that miscarried after 6 weeks were compared
using the Kruskal–Wallis test. Bland–Altman plots were
constructed to compare the differences between GA
predicted by CRL measurement (GACRL) and that based
on LMP (GALMP), adjusted for ovulation (GAOV) and
adjusted for implantation (GAIMP). Pairwise differences
were plotted against the mean GA in each case23.
95% limits of agreement (LoA) were calculated for the
differences between the GA estimated from a single CRL
measurement and that estimated from LMP (GALMP),
GAOV and GAIMP.
CRL growth rate (mm/day) was calculated by dividing
change in CRL by change in GA. An average was taken of
the growth rate between scans 1 and 2 and that between
scans 2 and 324. CRL Z-score at the 10–14-week scan
was calculated as: (measured CRL at the 10–14-week
scan − expected CRL based on GAOV)/SD, with respect
to the Robinson and Fleming curve6. The relationship
between implantation day, O–I interval and first-trimester
growth was investigated. Associations between pairs of
continuous variables were evaluated using Spearman’s
correlation coefficient (ρ).
RESULTS
One hundred and one women became pregnant while
enrolled in the study (Figure 1). The median time taken
to conceive from when they started trying was 5 (IQR,
2–7) months and this constituted a median of two cycles
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 40: 630–635.
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Early pregnancy loss (n = 29):
Miscarriage at < 6 weeks (n = 13)
Miscarriage at > 6 weeks (n = 12)
Ectopic pregnancy (n = 4)
Data analyzed of women with
complete information on O–I interval
(n = 56)
Missing ovulation and/or implantation data (n = 15):
Amenorrhea so did not start using LH kit (n = 1)*
Did not use LH test as per protocol or did not detect
    LH surge (n = 12)*
Did not use pregnancy test as per protocol (n = 13)*
Women attempting
to conceive recruited to study
(n = 143)
Lost to follow-up
(n = 1)
Pregnancy
(n = 101)
Pregnancy ongoing after 10
weeks
(n = 71)
Figure 1 Recruitment flowchart for the study.*Categories are not mutually exclusive. LH, luteinizing hormone; O–I, ovulation to
implantation.
Table 1 Characteristics of study participants with ongoing
pregnancy after 10 weeks
Characteristic Participants (n=71)
Age (years) 32 (29–35)
Ethnicity
White 65 (91.5)
Black 2 (2.8)
Asian 2 (2.8)
Other 2 (2.8)
Parity
Nulliparous 37 (52)
Parous 34 (48)
Data shown as median (interquartile range) or n (%).
(IQR, 1–5) after entry to the study. One woman was
lost to follow-up and 29 suffered early pregnancy loss,
thus there were 71 women with an ongoing pregnancy
after 10 weeks (Figure 1); their characteristics are given
in Table 1. The median ovulation day, implantation day
and O–I interval in all pregnancies are given in Table 2.
The median O–I interval and median implantation days
were 14 and 31 days, respectively, in pregnancies that
miscarried at < 6 weeks (n= 13), compared with 11 and
27 days in ongoing pregnancies and 11 and 25 days in
those that miscarried at > 6 weeks (n=12) (P < 0.001
for O–I interval; P= 0.004 for implantation day).
We compared the differences between GACRL and
GALMP, GACRL and GAOV and that between GACRL and
GA adjusted for median implantation of 27 days (GAIMP)
using Bland–Altman plots. The mean difference between
GACRL and GALMP was −0.8 days (95% LoA, –11.8 to
10.1 days) (Figure 2a), that between GACRL and GAOV
was 1.3 days (95% LoA, –3.8 to 6.4 days) (Figure 2b)
and that between GACRL and GAIMP was 0.4 days (95%
LoA, –4.0 to 4.9 days) (Figure 2c).
CRL Z-score at the 10–14-week scan (with expected
CRL based on GAOV and with respect to the Robinson and
Fleming curve) showed a negative linear relationship with
the O–I interval (ρ=−0.431, P= 0.0009; Figure 3a).
The difference between GACRL and GAOV showed a
similar negative linear relationship with O–I interval
(ρ=−0.430, P= 0.0009; Figure 3b).
There was no significant relationship between CRL
growth rate and the difference between observed and
expected CRL based on GALMP (ρ= 0.224, P= 0.08) or
between CRL growth rate and O–I interval (ρ= 0.122,
P=0.371). However, there was a significant relationship
between CRL growth rate and the difference between
observed and expected CRL based on GAOV (ρ= 0.308,
P=0.017) and that between observed and expected CRL
based on GAIMP (ρ= 0.459, P= 0.001).
DISCUSSION
The major novel finding of this study was that fetal
size at 10–14 weeks’ gestation is mainly a composite of
ovulation and implantation timing. There was an 11-day
range in O–I interval that translated directly to fetal size
for a given gestation. In other words, at 10–14 weeks an
early implanting embryo (short O–I interval) was larger
than expected and a later implanting embryo (long O–I
interval) was smaller than expected, by almost exactly
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 40: 630–635.
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Table 2 Summary of menstrual cycle data in all pregnancies
Pregnancy ongoing
at > 10 weeks (n=71)
Miscarriage at
< 6 weeks (n=13)
Miscarriage at
> 6 weeks (n=12) P
Ovulation day 16 (11–39) (n=59)* 15 (14–23) 14 (12–20) 0.2
Menstrual cycle length 28 (21–60) (n=69)* 30 (27–47) 28 (25–35) 0.2
Implantation day 27 (23–44) (n=58)* 31 (26–37) 25 (23–32) 0.004†
Ovulation to implantation
interval
11 (9–20) (n=56)* 14 (11–17) 11 (9–13) < 0.001†
Data are shown as median (range) days. *Number for which complete information was available. †P < 0.05, Kruskal–Wallis test.
the number of days of variance about the median O–I
interval, independent of first-trimester CRL growth rate.
Moreover, first-trimester fetal growth was not influenced
by O–I interval.
This is the first study to prospectively investigate
the impact of biological variation in ovulation and
implantation timing on GA assessment in natural
conception. The Robinson and Fleming CRL charts were
derived from CRL measurements plotted against GA
deduced from LMP in women with regular menstrual
cycles, and remain to this day the standard method of
assigning GA in the first trimester6. However, these charts
do not account for a woman’s ovulation day. As this is
reported to occur later than day 14 of the menstrual cycle
in most women9,10, such charts are likely to lead to a
systematic overestimation of postimplantation GA. This
has been hypothesized though not shown by others4; that
ovulation occurs at a median of 16 days after LMP is
the most plausible explanation for the observed 1.3 days
overestimation from GACRL compared with GAOV.
We found an 11-day range of implantation timing
in viable pregnancies. Interestingly, a late-implanting
embryo was smaller in size at 10–14 weeks. It has pre-
viously been shown that first-trimester fetal size predicts
subsequent birth weight. This is based on studies in which
a single first-trimester CRL measurement was deemed to
be small in relation to the expected size based on known
conception timing in a cohort of assisted-conception
pregnancies14 or known ovulation timing in pregnancies
conceived naturally15,16. Although the possibility of GA
misclassification based on implantation timing was raised
in these studies16, they were unable to take into account
implantation timing. Further, first-trimester growth was
extrapolated from a single CRL measurement, though in
fact it was size that was being measured14–16. Our find-
ings could underlie the observed variation in first-trimester
fetal size, and also explain why embryos with larger than
expected CRL are more likely to be large at term15.
We did not find a significant relationship between
first-trimester growth rate and CRL Z-score based on
LMP at 10–14 weeks. The CRL growth rate is, however,
related to the difference between observed and expected
CRL adjusted for ovulation and implantation timing. Put
simply, first-trimester CRL is a composite of two variables:
(1) when the embryo implants and (2) its subsequent
growth rate. Thus, the contribution of implantation
timing may explain the discrepancy in fetal size at 10–14
weeks seen in previous studies14,15, rather than this
being principally due to first-trimester intrauterine growth
restriction. This alternative explanation is supported by
studies showing no relationship between first-trimester
growth or first-trimester CRL and birth weight24,25.
The 95% LoA of differences between GACRL and
GALMP reduced from 21.9 days to 10.2 days by
adjusting for ovulation and to 8.9 days by adjusting
for implantation day. This implies that the precision
in dating a pregnancy by CRL improves greatly when
taking into account ovulation, and improves even further
when taking into account implantation date. Thus, CRL
charts derived from a knowledge of implantation day are
likely to be considerably more accurate than those derived
from gestation assumed from LMP. A potential criticism
may be made of the assumption that implantation day is
equivalent to the day of first detectable hCG using urinary
testing kits and that of missing implantation earlier than
day 8 using our urinary testing protocol. A large study
of O–I interval in human pregnancy reported the day
of first detection of hCG using sensitive urine assays as
the ‘implantation day’13. Although earliest implantation
was observed on day 6 from the time of ovulation in that
study, this was not observed in our study, as no participant
who performed urinary testing as per the protocol had
a positive hCG at the time of the first test on day 8.
We observed that delayed implantation is associated with
pregnancy loss before 6 weeks, as previously reported13.
We show that the hitherto unexplored contribution
of ovulation and implantation timing is important in
determining fetal size, and hence in influencing estimation
of GA. Reliable information on implantation timing is
more important than is certain LMP or known ovulation
date in natural conception and in IVF pregnancies. In IVF
pregnancies GA is often estimated from the egg collection
date, adjusting for day 14 ovulation. This is based on the
assumption that median ovulation timing is day 14, and
that implantation timing is either constant or has no effect
on embryonic size.
Variation in implantation timing may however explain
the variability of embryonic or fetal ultrasound appear-
ances compared with those expected from known LMP
or IVF dates. Furthermore, it might explain the recent
observation that isolated measurements of mean sac
diameter or embryo size are unreliable when establishing
a diagnosis of miscarriage early in pregnancy2. Where
there is late implantation, even though the LMP and
probable conception date may be known, a perfectly
healthy early fetus might appear to be significantly smaller
Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 40: 630–635.
634 Mahendru et al.
80 85 90 95 100 105
−25
−20
−15
−10
−5
0
5
10
15(a)
(b)
(c)
Average of GACRL and GALMP (days)
G
A
C
R
L  
– 
G
A
LM
P  
(d
ay
s)
Mean
−0.8
−1.96 SD
−11.8
+1.96 SD
10.1
75 80 85 90 95 100 105
−6
−4
−2
0
2
4
6
8
Average of GACRL and GAOV (days)
G
A
C
R
L  
– 
G
A
O
V
 (d
ay
s)
Mean
1.3
−1.96 SD
−3.8
+1.96 SD
6.4
75 80 85 90 95 100
−15
−10
−5
0
5
10
15
Average of GACRL and GAIMP (days)
G
A
C
R
L  
– 
G
A
IM
P  
(d
ay
s)
Mean
0.4
−1.96 SD
−4.0
+1.96 SD
4.9
Figure 2 Bland–Altman plots showing comparison of gestational
age (GA) estimated from crown–rump length measurement at
10–14 weeks’ gestation (GACRL) with: (a) GA based on last
menstrual period (GALMP), (b) GA adjusted by ovulation day
(GAOV) and (c) GA adjusted in each pregnancy to a median
implantation day of 27 days (GAIMP). The bold line represents the
mean difference with 95% CI ( ) and dashed lines ( )
represent 95% limits of agreement (± 1.96 SD).
than expected, or embryonic structures may not be visible
on ultrasound scan, giving a false impression of a preg-
nancy of unknown viability. Moreover, we challenge the
assumption that small first-trimester CRL equates to fetal
growth restriction. We do not discount a contribution of
fetal growth rate in explaining observed fetal size differ-
ences from expected CRL. However, these measurements
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Figure 3 Scatterplots of crown–rump length (CRL) Z-score at
10–14 weeks (a) and difference between gestational age (GA)
according to CRL (GACRL) and GA derived from ovulation timing
(GAOV) (b) against the ovulation–implantation (O–I) interval. The
smaller the O–I interval, the greater the CRL Z-score (ρ=−0.431,
P= 0.0009) and the greater the difference between GACRL and
GAOV (ρ=−0.430, P=0.0009). Regression lines are shown.
are predominantly explained by variability in implan-
tation timing, the influence of which on embryonic and
fetal size has not previously been considered.
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For NHS research sites only, management permission for research (“R&D approval”) should 
be obtained from the relevant care organisation(s) in accordance with NHS research 
governance arrangements.  Guidance on applying for NHS permission for research is 
available in the Integrated Research Application System or at http://www.rdforum.nhs.uk.  
Where the only involvement of the NHS organisation is as a Participant Identification 
Centre, management permission for research is not required but the R&D office should be 
notified of the study. Guidance should be sought from the R&D office where necessary.
Sponsors are not required to notify the Committee of approvals from host organisations.
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
 
Document   Version   Date   
 Covering Letter  08 February 2010 
 REC application  08 February 2010 
 Protocol 1 08 February 2010 
 Investigator CV  08 February 2010 
 Participant Consent Form 1 08 February 2010 
 Summary CV for student (Dr Yazan Abdallah)    
 Summary CV for Jan Brosens (Academic Supervisor)    
 Response to Request for Further Information    
 Participant Information Sheet: non pregnant participants 3 06 May 2010 
 Participant Information Sheet: pregnant participants 3 06 May 2010 
 Letter of invitation to participant 3 06 May 2010 
 
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
After ethical review
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website.
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:
• Notifying substantial amendments
• Adding new sites and investigators
• Progress and safety reports
• Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
10/H0709/19 Please quote this number on all correspondence
Yours sincerely
Dr Jan Downer
Chair
Email: alison.okane@nwlh.nhs.uk
Enclosures: “After ethical review – guidance for researchers” 
Copy to: Michelle Quaye
R&D Office
1st floor, Hammersmith House
Du Cane Rd
London
W12 0HS.
 
Addendum to GTG No 25 (Oct 2006): The Management of Early Pregnancy Loss  
  
Recent research suggests that given inter-observer variability in ultrasound measurements 
and the greater variation in early embryonic growth than has hitherto been assumed, a more 
conservative approach to the diagnosis of early pregnancy loss is warranted.  
 
The studies from Imperial College London, Queen Mary, University of London and the 
Katholieke Universiteit Leuven, Belgium published in the November 2011 issue of 
Ultrasound in Obstetrics and Gynaecology concluded that current definitions used to 
diagnose miscarriage could lead to an incorrect diagnosis and they call for clearer evidence-
based guidance on detecting miscarriage through ultrasound scans.   
  
Having carefully considered these papers, we recommend adoption of the following interim 
guidance with immediate effect: 
  
1. Ultrasound diagnosis of miscarriage should only be considered with a mean 
gestation sac diameter >/= 25mm (with no obvious yolk sac), or with a fetal pole with 
crown rump length >/=7mm (the latter without evidence of fetal heart activity) 
 
2. A transvaginal ultrasound scan should be performed in all cases 
 
3. Where there is any doubt about the diagnosis and/or a woman requests a repeat 
scan, this should be performed at an interval of at least one week from the initial scan 
before medical or surgical measures are undertaken for uterine evacuation. No 
growth in gestation sac size or CRL is strongly suggestive of a non-viable pregnancy 
in the absence of embryonic structures. 
 
These revised values for 'mean gestation sac diameter' and 'crown rump length' do not imply 
that previously used values were wrong, nor that diagnosis of miscarriage in the past has 
been unsafe, This interim guidance suggests a more cautious approach is warranted, 
pending more definitive data becoming available. It extends the criteria included in the 
RCOG Green Top Guideline No 25, which recommended a conservative approach with 
mean gestation sac diameter <20mm or fetal CRL <6mm.  
  
Christoph Lees MRCOG on behalf of the RCOG Ultrasound Advisory Group 
Kim Hinshaw FRCOG Lead author, Green Top Guideline No. 25 
Philip Owen FRCOG Chair, RCOG Guidelines Committee 
David Richmond FRCOG RCOG Vice President (Standards)  
  
19th October 2011 
  
Notes 
 
The Ultrasound Advisory Group has representation from the Society and College of Radiographers, 
International Society of Ultrasound in Obstetrics and Gynecology, British Maternal-Fetal Medicine 
Society, British Medical Ultrasound Society and Royal College of Radiologists. This guidance is 
endorsed by BMUS, and by the Council of the Society and College of Radiographers. 
 
To view a copy of the RCOG clinical guideline The Management of Early Pregnancy Loss, click on the 
title above or here.   
